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baCkGround
Chronic kidney disease (CKD) is an important and sizeable health issue. The global 
prevalence of CKD is estimated to be between 11 and 13%.(1) In the Netherlands, 
the CKD prevalence is estimated at 12% of the population.(2) The current and most 
widely used definition of CKD was composed by the Kidney Disease: Improving Global 
Outcomes (KDIGO) in 2012. Their CKD criteria are displayed in Table 1.(3)
Table 1. The 2012 KDIGO CKD criteria
Ckd criteria (one or more of the following for > 3 months)
Kidney damage Albuminuria (AER≥30 mg/24 hours; ACR ≥3 mg/mmol)
Urine sediment abnormalities
Electrolyte and other abnormalities due to tubular disorders
Abnormalities detected by histology
Structural abnormalities detected by imaging
History of kidney transplantation
Decreased GFR GFR <60 ml/min/1.73 m2
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate. Reference: Kidney Disease: 
Improving Global Outcomes CWG. KDIGO clinical practice guideline for the evaluation and management 
of chronic kidney disease. Kidney Int Suppl. 2013(3):S1 - 150.
Patients with CKD are at increased risk for progression to end stage renal disease (ESRD) 
and are even more prone to suffer cardiovascular events.(4)
These cardiovascular and renal risks increase as CKD becomes more severe. The sever-
ity is estimated using the patient’s eGFR and albuminuria results. The standard equation 
used to calculate eGFR was the four variable Modification of Diet and Renal Disease 
(MDRD) study equation.(5) The more accurate chronic kidney disease epidemiological 
collaboration (CKD-EPI) equation was published in 2009.(6) A shift from the MDRD to 
the CKD-EPI equation could have implications for the cardiovascular risk management 
in patients who are reclassified out of CKD when using the CKD-EPI equation instead of 
the MDRD equation for eGFR reporting. The 2012 CKD classification and prognostica-
tion scheme by the KDIGO group is shown in figure 1.(3)
Adequate and timely treatment of CKD can help attenuate risk of cardiovascular compli-
cations and slow the progression of renal function decline.(7) This includes monitoring 
renal function and albuminuria status, as a UK study showed that prolonged failure to 
monitor these parameters was associated with increased cardiovascular events, ESRD 
and mortality in people with diabetes.(8)
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The vast majority of patients with CKD is treated in primary care, and when necessary 
co-managed with the nephrologist. This gives the GP a key role in the care for patients 
with CKD.
In order for GPs to provide high quality care for their CKD population it is important to 
first establish who has CKD: this is done mostly by case finding through renal function 
and albuminuria assessment in high risk patients, e.g. patients with diabetes or cardio-
vascular disease. Next, decreased renal function is registered as a separate entity on the 
episode list in the electronic medical record (EMR) with International Classification of 
Primary Care (ICPC) code for impaired renal function.
International studies noted deficiencies in the quality of care (QoC) for CKD patients 
in primary care: especially with regard to CKD documentation, screening for metabolic 
complications and achievement of blood pressure targets.(9, 10) However, the quality of 
primary care CKD management in the Netherlands was not assessed before. Exploration 
of the QoC in primary care CKD management could provide insight in determinants of 
high quality care and generate hypotheses for improvement plans.
In the Netherlands the Dutch interdisciplinary CKD guideline provides recommenda-
tions on which health care setting best suits the patient’s needs: management in primary 
care, management in primary care with input from a nephrologist through consultation, 
or referral to secondary care.(11) A qualitative study from Australia showed that nearly 
90% of GPs preferred to manage patients with CKD in primary care with specialist as-
figure 1. The 2012 KDIGO categories for prognosis of CKD by GFR and albuminuria
Reference: Kidney Disease: Improving Global Outcomes CWG. KDIGO clinical practice guideline for the 
evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013(3):S1 - 150.
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sistance.(12) However, the process of consultation is not always straightforward. Tradi-
tional consultation by telephone or e-mail comes with several obstacles such as difficulty 
to find a time slot for both GP and nephrologist to confer, lack of documentation and 
issues regarding data security. In other specialties, mainly in the field of dermatology, 
electronic consultation options were successfully developed to provide an alternative 
way of consultation.(13) In our attempt to overcome these obstacles in the field of 
nephrology we developed an e-consultation intervention, telenephrology, to facilitate 
communication between GPs and nephrologists.
aiM of The Thesis
This thesis aims to describe quality of primary care CKD management in the Netherlands 
and explores in what way the e-consultation platform telenephrology can contribute to 
primary care CKD management.
Major research questions
1. What is the quality of care, expressed as guideline adherence and CKD registration, 
in routine general practice for all stages of CKD?
2. What are the associations between quality of care and patient and practice charac-
teristics?
3. What is the feasibility of telenephrology?
4. Does telenephrology lead to a lower in-person referral rate and a higher consultation 
rate compared to usual care?
5. Is telenephrology associated with higher quality of care and lower costs?
6. Which patient and practice characteristics are associated with non-adherence to 
guideline advice regarding referral and consultation?
7. What is the quality of care in patients who are not co-managed by a nephrolo-
gist despite guideline advice, and what patient characteristics are associated with 
adequate monitoring in this group?
8. Does GP education on CKD management and providing practices with a list of their 
CKD population improve quality of care compared to routine usual care?
9. What is the cardiovascular risk profile of patients who no longer fulfil CKD stage 3 
criteria when using the CKD-EPI formula for eGFR reporting?
Chapter 1
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ouTline of The Thesis
Chapter 2 describes the QoC in routine general practice for patients with CKD in terms 
of guideline adherence and CKD documentation in the patient´s EMR.
Chapter 3 explores the feasibility of the e-consultation platform telenephrology.
Chapter 4 presents the cluster randomised controlled trial on the effect of telenephrology 
on referral and consultation rates, QoC, costs and GPs’ experiences with telenephrology.
Chapter 5 focuses on CKD patients who are not co-managed by a nephrologist despite 
guideline advice. We assess QoC for this group and identify patient factors associated 
with adequate monitoring.
Chapter 6 describes the effect of GP education and practice feedback on QoC in terms 
of guideline adherence and CKD documentation in patient’s EMR.
In chapter 7 we determine the cardiovascular risk profile of patients who are reclassified 
out of CKD when using the CKD-EPI equation instead of the MDRD equation for eGFR 
reporting.
Chapter 8 contains the summary and general discussion.
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absTraCT
background: Early detection and appropriate management of Chronic Kidney Disease 
(CKD) in primary care are essential to reduce morbidity and mortality.
aim: To assess the quality of care (QoC) of CKD in primary healthcare in relation to 
patient and practice characteristics in order to tailor improvement strategies.
design and setting: Retrospective study using data between 2008-2011 from 47 
general practices (207,469 patients of whom 162,562 adults).
Method: CKD management of patients under care of their general practitioner (GP) 
was qualified using indicators derived from the Dutch interdisciplinary CKD-guideline 
for primary care and nephrology and included [1] monitoring of renal function, albumin-
uria, blood pressure and glucose, [2] monitoring of metabolic parameters, and alongside 
the guideline: [3] recognition of CKD. The outcome indicator was [4] achieving blood 
pressure targets. Multilevel logistic regression analysis was applied to identify associated 
patient and practice characteristics.
results: Kidney function or albuminuria data were available for 59,728 adult patients. 
9288 patients had CKD, of whom 8794 were under GP care. Monitoring of disease pro-
gression was complete in 42% of CKD-patients, monitoring of metabolic parameters in 
2%, and blood pressure target was reached in 43.1%. GPs documented CKD in 31.4% 
of CKD-patients. High QoC was strongly associated with diabetes, and to a lesser extent 
with hypertension and male sex.
Conclusion: Room for improvement was found in all aspects of CKD management. As 
QoC was higher in patients who received structured diabetes care, future CKD care may 
profit from more structured primary care management e.g. according to the chronic 
care model.
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inTroduCTion
General practitioners (GPs) play a key role in the complex care of patients with Chronic 
Kidney Disease (CKD). The K/DOQI guidelines (USA) and the National Institute for Health 
and Clinical Excellence (NICE) CKD guideline (UK) provide GPs with recommendations 
on good CKD management, including monitoring of disease progression and strictly 
controlling cardiovascular risk factors.(1, 2) The Dutch interdisciplinary CKD-guideline 
for primary care and nephrology is similar to these guidelines, but incorporates age in its 
recommendations (Web-appendix table 1).(3)
Studies have shown that high standard CKD management attenuates and delays 
adverse outcomes such as progression to end stage renal failure and cardiovascular 
events.(4, 5) However, literature also notes deficiencies in the quality of care (QoC).(6, 
7) The high prevalence of co-morbidity challenges the GP to balance guideline advices 
to the patients individual needs.(8)
Our study aimed to analyze QoC in routine general practice for all stages of CKD, in 
relation to patient and practice characteristics. We hypothesized that our study would 
reveal predictors of high QoC.
MaTerial and MeThods
Recruitment of participants
This retrospective study used baseline patient data of general practices that participated 
in a cluster randomized controlled trial on the effect of web-consultation between GP 
and nephrologist on in-person referrals: the CONTACT study (Consultation Of Nephrol-
ogy by Telenephrology Allows optimal Chronic kidney disease Treatment in primary 
care, Netherlands Trial Registration code 2368). The CONTACT study recruited general 
practices during a CKD management course for GPs. Forty seven non-academic general 
practices signed up for participation. Data between 2008-2011 were analyzed from their 
registered populations’ electronic medical records (EMRs) (n=207,469). We included all 
patients aged 18 years or older who met the CKD criteria: eGFR<60 ml/min/1.73m2 or 
albuminuria. Patients under secondary renal care were excluded from analysis.
Classification of patients
The interdisciplinary CKD-guideline for primary care and nephrology provides guidance 
for the GP in selecting the best suited health care setting for patients with CKD, based 
on eGFR, albuminuria and age. These settings are: treatment in primary care, consulta-
tion of a nephrologist without referral, and referral to secondary care. The guideline 
provides specific monitoring criteria for each group. We applied this classification to our 
Chapter 2
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cohort, resulting in a primary care-, a consultation- and a referral-group. For the primary 
care-group this implied monitoring of disease progression, while the consultation and 
the referral-groups additionally required monitoring of metabolic parameters (Web-
appendix table 1). We used laboratory reported MDRD calculated eGFR values and in 
congruence with the guideline, we defined microalbuminuria as an urinary albumin to 
creatinine ratio (ACR) of 2.5–25 mg/mmol in men and 3.5–35 mg/mmol in women. 
Higher ratios reflected macroalbuminuria. If an ACR was unavailable, we used urine 
albumin concentration with cut-off values >20–200 mg/l for microalbuminuria and 
>200 mg/l for macroalbuminuria. Patient age was set on the latest eGFR date.
Process and outcome indicators (Table 2)
We derived indicators from the interdisciplinary CKD-guideline for primary care and 
nephrology.(3) Included process indicators were: [1] monitoring of disease progression 
(assessment of eGFR or serum creatinine, albuminuria, glucose, and blood pressure); [2] 
monitoring of metabolic parameters (assessment of hemoglobin, calcium, phosphate, 
parathyroid hormone (PTH), serum albumin, and potassium), and alongside the guide-
line; [3] recognition of CKD in patients with an eGFR <60 ml/min/1.73m2 (separate 
entity on the EMR episode list with International Classification of Primary Care (ICPC) 
code U99.1 for renal impairment). The outcome indicator was [4] achievement of blood 
pressure targets, for which the mean of the two latest measurements had to be <140/90 
mmHg. Additionally, we analyzed blood pressures <130/80 mmHg to allow comparison 
with existing literature.
Table 1. Classification of adult patients with available renal function using the interdisciplinary CKD-
guideline for primary care and nephrology.
albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients ≥ 65 years (n = 19.887)
eGFR ≥ 60 7.696 5.467 893 74
eGFR 45 – 60 2.085 1.632 411 52
eGFR 30 – 45 620 442 195 46
eGFR < 30 179 44 33 18
Patients < 65 years (n = 39.841)
eGFR ≥ 60 28.927 8.350 693 59
eGFR 45 – 60 869 620 70 16
eGFR 30 – 45 102 55 22 7
eGFR < 30 33 4 6 8
Classification of patients based on renal function, albuminuria and age. ‘primary care group’ n=5.714: 
treatment in primary care. ‘consultation group’ n=2.816: consultation of a nephrologist without referral. 
‘referral group’ n=758: referral to secondary care. eGFR in ml/min/1.73m2
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Patient and practice characteristics
We extracted patient demographic and clinical data concerning co-morbidities and 
medication from the EMRs (Table 3). Patient age was categorized in ranges 18-45, 
45-60, 60-75, and over 75 years. Co-morbidities were defined by ICPC codes as a 
history of diabetes (T90), hypertension (K86,K87) and cardiovascular disease (K74-
K77,K89,K90,K92).(9) We selected drug prescriptions issued during 2010 for medica-
tion shown in table 3 using Anatomical Therapeutic Chemical (ATC) codes.(10)
Practice characteristics included type (solo-,duo- or group-practice), vocational train-
ing, location (urban or rural based on the Statistics Netherlands’ Key figures postcode 
areas database of 2004), and General Practice Information System (Web-appendix table 
2).
Table 3. Patient characteristics based on data from 2008 – 2011 for patients under GP care.
Patient characteristic Groups
Overall
(n=8794)
Primary care
(n=5710)
Consultation
(n=2780)
Referral
(n=304)
Demographics (SD)
Age in years 71.4 (11.9) 73.6 (10.2) 66.7 (13.3) 72.3 (14.0)
Male sex 40.0% 42.7% 33.6% 47.0%
Co morbidity
Diabetes 32.9% 36.0% 24.5% 52.6%
Hypertension 56.2% 57.8% 53.5% 52.0%
Cardiovascular disease 35.6% 36.1% 32.4% 53.6%
Laboratory (SD) [n]
Creatinine in µmol/l 103.9(25.9) 
[n=8792]
95.6 (18.5) 
[n=5709]
117.4 (23.7) 
[n=2779]
136.7 (61.6) 
[n=304]
eGFR in ml/min/1.73m2 52.6 (8.1) 
[n=8794]
55.4 (4.9) 
[n=5710]
47.7 (9.0) 
[n=2780]
43.0 (15.1) 
[n=304]
Fasting glucose in mmol/l 6.5 (1.8) [n=6938] 6.6 (1.9) [n=4689] 6.2 (1.6) [n=1998] 7.0 (2.3) [n=251]
Hemoglobin in g/dl 13.50 (1.56) 
[n=2085]
12.78 (1.96) 
[n=227]
Calcium in mmol/l 2.33 (0.12) 
[n=445]
2.32 (0.14) [n=72]
Phosphate in mmol/l 1.03 (0.18) 
[n=341]
1.15 (0.20) [n=46]
PTH in pmol/l 7.51 (4.70) 
[n=138]
7.34 (5.42) [n=13]
Albumin in g/l 38.8 (4.4) [n=271] 38.6(4.6) [n=57]
Potassium in mmol/l 4.3 (0.45) 
[n=2238]
4.4 (0.56) [n=270]
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Data analysis
CKD stage prevalence was calculated using the registered population aged 18 years 
and over as denominator. We used descriptive statistics to assess adherence to process 
and outcome indicators and to evaluate GPs’ recognition of CKD. The guideline advices 
annual monitoring, but in routine general practice the monitoring could take place 
outside this 12 month timeframe. We took this into account and extended the period 
to 15 months prior to data extraction on March 1, 2011. Because of the hierarchical 
structure of our data (patients nested within practices) the analyses were based on the 
multilevel logistic regression model (PROC GLIMMIX in SAS). To identify patient and 
Table 3. Patient characteristics based on data from 2008 – 2011 for patients under GP care. (continued)
Patient characteristic Groups
Overall
(n=8794)
Primary care
(n=5710)
Consultation
(n=2780)
Referral
(n=304)
Urine [(first and third quartile) n]
Albumin urine in mg/l 15.0 (3.4–51.0) 
[n=2928]
20.0 (5.0-53.0) 
[n=2049]
6.0 (2.9-18.0) 
[n=721]
210.6 (84.3–
480.2) [n=158]
Albumin/creatinine ratio 2.5 (0.9-6.1) 
[n=5022]
3.2 (0.9-6.4) 
[n=3557]
0.9 (0.8-2.3) 
[n=1254]
37.7 (14.8-58.2) 
[n=211]
Physical examination [(SD) n]
Diastolic blood pressure 
in mm Hg
78.8 (9.7) 
[n=7291]
78.6 (9.5) 
[n=4889]
79.1 (9.9) 
[n=2147]
78.6 (11.3) 
[n=255]
Systolic blood pressure in 
mm Hg
142.7 (17.7) 
[n=7290]
143.8 (17.4) 
[n=4889]
139.8 (17.5) 
[n=2146]
145.1 (21.6) 
[n=255]
Medication prescribed in 2010
Renin angiotensin 
blockers
55.9% 56.4% 53.7% 67.4%
B-blockers 46.3% 46.5% 45.4% 52.0%
Diuretics 41.4% 40.8% 41.8% 49.3%
Calcium antagonist 21.6% 21.4% 20.6% 32.9%
Statins 47.0% 48.8% 42.6% 52.3%
Vitamin D 3.7% 2.2% 6.1% 9.5%
Erythropoietin 0.3% 0.1% 0.5% 1.3%
Blood glucose lowering 
drugs
25.0% 27.3% 18.5% 40.1%
Antithrombotics 46.6% 48.3% 42.1% 57.6%
NSAIDs 21.3% 21.1% 22.3% 17.8%
‘primary care group’: treatment in primary care. ‘consultation group’: consultation of a nephrologist 
without referral. ‘referral group’: referral to secondary care.
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practice characteristics associated with high quality care, we performed a model with 
a random intercept and all other variables were fixed. The type of General Practice 
Information System was considered a confounder, since it could affect the quality of 
data recording. We started with a full model including all independent variables and 
excluded statistically non-significant variables one by one in a backward procedure. We 
considered a P-value <0.05 statistically significant. Descriptive analysis was conducted 
using SPSS version 20.0 (IBM PASW statistics 20) and multilevel logistic regression analy-
sis was conducted using SAS V9.2.
resulTs
Practice population
The 47 practices served a population of 207,469 people of whom 162,562 were aged 
18 or older. Data on renal function (n=59,728) or albuminuria (n=19,217) were present 
for 59,728 adult patients (31%). More data were available for elderly: 71% of the 
population over 65 years had a renal function assessment. Diabetes was recorded in 
10,623 patients (6.5% of the population), hypertension in 23,647 (14.5%), and cardio-
vascular disease in 12,938 (8.0%).
Study population
9288 patients met the criteria for CKD, resulting in a known adult prevalence of CKD 
in our study of 5.7%. K/DOQI stages 1–2 accounted for 1.06% (n=1719) and stages 
3–5 for 4.66% (n=7569). Of these, 494 patients received secondary renal care and were 
excluded from analysis. In the cohort of 8794 patients treated by their GP, the guideline 
recommended treatment in primary care in 64.9%, consultation of a nephrologist in 
31.6% and referral in 3.5% of patients. Table 3 provides detailed characteristics.
Process and outcome indicators
GPs completely followed the guideline in 42% (95% CI 41%-43%) of their CKD 
patients for monitoring disease progression and in 2.4% (95% CI 1.9%-2.9%) for 
monitoring metabolic parameters. Blood pressure was below 140/90 mmHg in 43.1% 
(95% CI 41.8%-44.3%) and below 130/80 mmHg in 16.4% (95% CI 15.5%-17.3%) 
of patients in whom a blood pressure measurement was available (n=6325). All patients 
considered, the achievement of blood pressure targets amounted 31.0% and 11.8% 
respectively. GPs recognized decreased eGFR in 31.4% (95% CI 30%-32%) by using 
ICPC code U99.1 for impaired renal function. Table 2 provides further details on quality 
indicators.
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Associated patient and practice characteristics
A history of diabetes (OR 10.97; 95% CI 9.75–12.34) or hypertension (OR 2.45; 95% 
CI 2.19–2.73), and male gender were associated with better monitoring of disease 
progression (Table 4a). A history of cardiovascular disease was negatively correlated with 
monitoring of disease progression. Cardiovascular disease and highest age were posi-
tively associated with monitoring of metabolic parameters (Table 4b). Factors associated 
with recognition of CKD were a history of cardiovascular disease, hypertension, female 
sex and highest age. Blood pressure outcome target <140/90 mmHg was positively 
associated with a history of cardiovascular disease, and had a negative correlation with 
highest age.
Table 4a. Significant results of multilevel logistic regression model on the association between patient 
and practicecharacteristics and QoC.
Variable
Monitoring disease progression
eGFR albumin urine fasting glucose blood pressure complete
Patient characteristics
Age (18 – 45 years as reference)
45 – 60 years
1.46
(1.04 – 2.05)
0.99
(0.71 – 1.40)
1.61
(1.16 – 2.25)
1.82
(1.29 – 2.58)
1.15
(0.79 – 1.68)
60 – 75 years
1.99
(1.43 – 2.76)
1.03
(0.74 – 1.24)
2.09
(1.52 – 2.87)
2.59
(1.85 – 3.61)
1.43
(0.99 – 2.05)
>75 years
2.47
(1.77 – 3.43)
0.81
(0.58 – 1.12)
1.58
(1.15 – 2.18)
2.90
(2.08 – 4.04)
1.20
(0.83 – 1.72)
Male sex
1.28
(1.16 - 1.42)
1.26
(1.13 - 1.40)
Diabetes
2.98
(2.58 – 3.45)
9.33
(8.34 - 10.44)
7.07
(6.22 – 8.04)
4.14
(3.62 – 4.74)
10.97
(9.75 – 12.34)
Hypertension
1.84
(1.64 - 2.07)
2.15
(1.94 - 2.38)
2.42
(2.19 - 2.68)
4.00
(3.58 - 4.48)
2.45
(2.19 - 2.73)
Cardiovascular disease
0.87
(0.76 – 0.98)
0.77
(0.69 - 0.86)
0.82
(0.73 - 0.91)
0.76
(0.68 - 0.86)
Practice characteristics
Urban location
0.57
(0.37 - 0.88)
0.52
(0.29 - 0.93)
Results are shown as odds ratios with 95% confidence intervals in parenthesis. Outcomes on practice 
type and vocational training practice were not significant.
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disCussion
Summary
Our results show room for improvement in all aspects of CKD management, yet most 
clinical relevance lies in the achievement of blood pressure targets (43% <140/90 
mmHg). A history of diabetes was strongly associated with high QoC.
Prevalence and recognition
In the Netherlands, the estimated community prevalence of CKD is 10.4%, with 5.1% 
in CKD stages 1-2, and 5.3% in stages 3-5.(11) For our data, this implies that respec-
tively 21% and 88% of expected CKD patients could have been ascertained in primary 
care with the available laboratory results. However, recognized decreased eGFR was 
lower: only 31.4% of potentially identifiable patients. Recognition is important, as it is 
associated with better quality of care.(12)
Strengths and limitations
A key strength of our study is the utilization of routine general practice data, which 
provides a realistic view on quality of care. Our study represents a large proportion of 
the (potential) CKD population in primary care, as data on renal function were available 
for most patients over 65 years. To accurately report on QoC in routine general practice, 
we focused on patients under care of their GP.
Several limitations should be considered. We applied the guideline classification based 
on single creatinine and albuminuria assessments whereas at least two and three mea-
surements are advised. This might have led to less accurate classification, but is in line 
with other CKD studies. The practices’ intrinsic motivation to participate in the CONTACT 
trial might have led to a selection bias with possible overestimation of QoC. Conversely 
QoC might be underestimated due to analysis of data routinely recorded in the EMR. It 
is not unlikely that blood pressure was measured, but was not registered. Furthermore, 
GPs had little time to implement the guideline within our studied timeframe (January 
1,2010 to March 1,2011) considering its introduction in November 2009.
Comparison with existing literature
Our results on monitoring of disease progression are in line with previous studies. 
Research on CKD stages 3-4 conducted within multi-specialty group practices, housing 
both GPs and nephrologists, found a comparable eGFR assessment rate (86%), and a 
slightly lower albuminuria testing rate (30%).(6) Also, impressive results are shown in 
the United Kingdom, where they recorded an 82% albuminuria testing rate in CKD 
stages 3-5.(13) Of possible influence is the pay for performance system: the Quality 
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and Outcomes Framework (QOF). In the Netherlands, GPs are not given incentives to 
manage CKD, but for diabetes management local financial incentives exist.(14)
Outcomes on metabolic parameter monitoring were relatively low in our study. The 
earlier mentioned multi-specialty group study reported two- to threefold more moni-
toring of hemoglobin, calcium and PTH.(6) Nephrologists’ presence close to GPs may 
account for these differences.
The overall level of CKD recognition is not exceptional in our study, as other studies 
report electronic documentation of CKD between 4-38%.(6, 7, 12, 15) However, results 
from the QOF show that improvement is possible, as their recorded recognition was 
72%.(16, 17) Low recognition may well be related to hurdles that doctors experience in 
assigning a CKD diagnosis.(18)
Blood pressure targets were equally met in most other studies, an Italian study re-
ported blood pressures <140/90 mmHg in 45% of CKD patients; other reports mention 
blood pressures <130/80 mmHg in 13% to 54% of patients depending on the included 
CKD stages.(12, 19, 20) The QOF shows strong results with blood pressures <140/85 
mmHg in 72% of the CKD population.(13)
Research shows that patient factors associated with high QoC are concurrent diabe-
tes, hypertension or coronary artery disease, age >75 years, and male sex.(6, 20-22) Our 
findings are comparable, except that cardiovascular disease was negatively associated 
with monitoring of disease progression. Possibly, monitoring was left at the discretion 
of a cardiologist.
Results derived from the QOF show that vocational training practices, group practices 
and practices in less socially deprived areas were associated with a higher QoC in gen-
eral.(23, 24)
Implications for research and/or practice
In CKD stages 1 and 2 we found a high QoC for monitoring of disease progression. 
We hypothesize that the high prevalence of diabetes in these patients (62%), and their 
treatment supported by an evidence-based primary care-generated diabetes guideline 
is key to their renal function and albuminuria assessments.(25, 26) This guideline has 
been developed in, by and for general practice, with the objective to translate disease-
specific recommendations into a framework of person-centered care over time. Since its 
introduction in 1989, the guideline has been revised and updated to scientific progress 
but also following practice-based experiences in its implementation.(27) Our findings 
suggest that embedding of CKD care in a support model and organisation comparable 
to diabetes, would stand the best chance to improve QoC in general practice.(28) This 
should not be a new single disease model, but should support GP-based CKD care 
and preferably be integrated in existing support models for chronic care to prevent 
fragmentation.(29)
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Feedback on laboratory results and GP education to increase CKD recognition can assist 
GPs to better identify CKD patients.(12) Periodic reviewing of EMRs, with or without the 
support of nephrologists, could be a component of support models.(30) Introduction of 
a pay for performance system for CKD management has shown favorable results in the 
UK.(17) Quality improvement strategies should focus on better recognition, systematic 
monitoring of disease progression including albuminuria, and blood pressure targets.
addiTional inforMaTion
Funding
The Dutch Kidney Foundation funded the study. Amgen provided an additional non-
conditional grant.
Ethical approval
Ethical approval was not required according to the accredited Medical Research Ethics 
Committee Arnhem/Nijmegen registration number 2010/187. This study was performed 
according to the Code of Conduct for Health Research which has been approved by the 
Data Protection Authorities for conformity with the applicable Dutch privacy legislation.
Competing interests
The Department of Primary and Community Care received a non-conditional grant from 
Amgen.
Jack Wetzels received research grants from Amgen, Genzyme and Pfizer for the Mas-
terplan study.
All other authors have no conflicting interests.
Acknowledgements
The Dutch Kidney Foundation
Participating practices
Lea Peters, research assistant
Reinier Akkermans, statistician
29
Quality of chronic kidney disease management in primary care
2
referenCes
 1. National Kidney Foudation. K/DOQI Guidelines[internet]. New York; 2002 [accessed 2012]. Avail-
able from http://www.kidney.org/professionals/KDOQI/guidelines_commentaries.cfm.
 2. National Collaborating Centre for Chronic Conditions Chronic Kidney Disease. National Clinical 
Guideline for Early Identification and Management in Adults in Primary and Secondary Care.
London: Royal College of Physicians; 2008.available from http://www.nice.org.uk/nicemedia/pdf/
CG073NICEGuideline.pdf (15 November 2012 date last accessed).
 3. De Grauw WJC KH, Bilo HJG, Faber EF, Flikweert S, Gaillard CAJM, et al. Landelijke transmurale 
afspraak chronische nierschade. Huisarts Wet. 2009; 52: 586 - 97.
 4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. The New England journal of medicine. 2004; 
351(13): 1296-305.
 5. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Associa-
tion of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular 
mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731): 
2073-81.
 6. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of 
chronic kidney disease. Journal of general internal medicine. 2011; 26(4): 386-92.
 7. Stevens PE, O’Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic 
kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007; 
72(1): 92-9.
 8. Luijks HD, Loeffen MJ, Lagro-Janssen AL, van Weel C, Lucassen PL, Schermer TR. GPs’ consider-
ations in multimorbidity management: a qualitative study. The British journal of general practice: 
the journal of the Royal College of General Practitioners. 2012; 62(600): e503-10.
 9. Wonca International Classification Committee. ICPC-2: International Classification of Primary 
Care. 2nd edn. Prepared by the International Classification Committee of WONCA (WICC). 
Oxford, UK: Oxford University Press, 1998.
 10. WHO Collaborating Centre for Drug Statistics Methodology (2006) Guidelines for ATC classifica-
tion and DDD assignment 2007, Oslo.
 11. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target 
for therapy. Kidney international Supplement. 2005(98): S25-9.
 12. Ravera M, Noberasco G, Weiss U, Re M, Gallina AM, Filippi A, et al. CKD awareness and blood 
pressure control in the primary care hypertensive population. Am J Kidney Dis. 2011; 57(1): 71-7.
 13. Stevens PE, de Lusignan S, Farmer CK, Tomson CR. Engaging primary care in CKD initiatives: the 
UK experience. Nephrol Dial Transplant. 2012; 27 Suppl 3: iii5-iii11.
 14. Struijs JN, Baan CA. Integrating care through bundled payments--lessons from The Netherlands. 
The New England journal of medicine. 2011; 364(11): 990-1.
 15. de Lusignan S, Chan T, Stevens P, O’Donoghue D, Hague N, Dzregah B, et al. Identifying patients 
with chronic kidney disease from general practice computer records. Family practice. 2005; 22(3): 
234-41.
 16. Centre TNI. Quality and Outcomes Framework Achievement Data 2010/11. 2012.
 17. The quality and outcomes framework. Available from: http://www.ic.nhs.uk/statistics-and-data-
collections/audits-and-performance/the-quality-and-outcomes-framework (12November 2012, 
date last accessed).
Chapter 2
30
 18. Blakeman T, Protheroe J, Chew-Graham C, Rogers A, Kennedy A. Understanding the manage-
ment of early-stage chronic kidney disease in primary care: a qualitative study. The British journal 
of general practice : the journal of the Royal College of General Practitioners. 2012; 62(597): 
233-42.
 19. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in 
chronic kidney disease: overall burden and rates of treatment and control. Archives of internal 
medicine. 2006; 166(17): 1884-91.
 20. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. Am 
J Kidney Dis. 2007; 49(5): 634-41.
 21. de Lusignan S, Nitsch D, Belsey J, Kumarapeli P, Vamos EP, Majeed A, et al. Disparities in testing 
for renal function in UK primary care: cross-sectional study. Family practice. 2011; 28(6): 638-46.
 22. Akbari A, Swedko PJ, Clark HD, Hogg W, Lemelin J, Magner P, et al. Detection of chronic kidney 
disease with laboratory reporting of estimated glomerular filtration rate and an educational 
program. Archives of internal medicine. 2004; 164(16): 1788-92.
 23. Ashworth M, Armstrong D. The relationship between general practice characteristics and quality 
of care: a national survey of quality indicators used in the UK Quality and Outcomes Framework, 
2004-5. BMC family practice. 2006; 7: 68.
 24. Ashworth M, Schofield P, Seed P, Durbaba S, Kordowicz M, Jones R. Identifying poorly perform-
ing general practices in England: a longitudinal study using data from the quality and outcomes 
framework. Journal of health services research &amp; policy. 2011; 16(1): 21-7.
 25. Dhoul N, de Lusignan S, Dmitrieva O, Stevens P, O’Donoghue D. Quality achievement and dis-
ease prevalence in primary care predicts regional variation in renal replacement therapy (RRT) 
incidence: an ecological study. Nephrol Dial Transplant. 2012; 27(2): 739-46.
 26. Rutten GEHM GWd, Nijpels G, Houweling ST, Van de Laar FA, Bilo HJ, et al. NHG-Standaard 
Diabetes mellitus type 2. 2013.
 27. van Doorn-Klomberg AL, Braspenning JC, Wolters RJ, Bouma M, de Grauw WJ, Wensing M. Or-
ganizational determinants of high-quality routine diabetes care. Scandinavian journal of primary 
health care. 2014; 32(3): 124-31.
 28. van Hateren KJ, Drion I, Kleefstra N, Groenier KH, Houweling ST, van der Meer K, et al. A pro-
spective observational study of quality of diabetes care in a shared care setting: trends and age 
differences (ZODIAC-19). BMJ open. 2012; 2(4).
 29. van Weel C, Carelli F, Gerada C. Reforming primary care: innovation or destruction? The British 
journal of general practice : the journal of the Royal College of General Practitioners. 2012; 
62(594): 43-4.
 30. Rayner HC, Hollingworth L, Higgins R, Dodds S. Systematic kidney disease management in a 
population with diabetes mellitus: turning the tide of kidney failure. BMJ quality &amp; safety. 
2011; 20(10): 903-10.
31
Quality of chronic kidney disease management in primary care
2
Web-aPPendiCes
W
eb
-a
p
p
en
d
ix
 t
ab
le
 1
. C
K
D
 m
an
ag
em
en
t 
re
co
m
m
en
da
tio
ns
 p
ro
vi
de
d 
by
 t
he
 in
te
rd
is
ci
pl
in
ar
y 
C
K
D
-g
ui
de
lin
e 
fo
r 
pr
im
ar
y 
ca
re
 a
nd
 n
ep
hr
ol
og
y.
A
nn
ua
l m
on
ito
rin
g 
of
 d
is
ea
se
 p
ro
gr
es
si
on
A
nn
ua
l m
on
ito
rin
g 
of
 m
et
ab
ol
ic
 p
ar
am
et
er
s
eG
FR
al
bu
m
in
 u
rin
e
fa
st
in
g 
gl
uc
os
e
bl
oo
d 
pr
es
su
re
he
m
og
lo
bi
n
ca
lc
iu
m
ph
os
ph
at
e
PT
H
se
ru
m
 a
lb
um
in
po
ta
ss
iu
m
Pa
ti
en
ts
 ≥
 6
5 
ye
ar
s
eG
FR
 ≥
 6
0 
an
d
m
ic
ro
al
bu
m
in
ur
ia
•
•
•
•
eG
FR
 4
5 
– 
60
 a
nd
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
eG
FR
 3
0 
– 
45
 a
nd
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
•
•
•
•
•
•
eG
FR
 <
 3
0 
an
d
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
•
•
•
•
•
•
eG
FR
 a
ny
 a
nd
 m
ac
ro
al
bu
m
in
ur
ia
•
•
•
•
•
•
•
•
•
•
Pa
ti
en
ts
 <
 6
5 
ye
ar
s
eG
FR
 ≥
 6
0 
an
d
m
ic
ro
al
bu
m
in
ur
ia
•
•
•
•
eG
FR
 4
5 
– 
60
 a
nd
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
•
•
•
•
•
•
eG
FR
 3
0 
– 
45
 a
nd
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
•
•
•
•
•
•
eG
FR
 <
 3
0 
an
d
no
rm
o-
 o
r 
m
ic
ro
-a
lb
um
in
ur
ia
•
•
•
•
•
•
•
•
•
•
eG
FR
 a
ny
 a
nd
 m
ac
ro
al
bu
m
in
ur
ia
•
•
•
•
•
•
•
•
•
•
‘p
rim
ar
y 
ca
re
 g
ro
up
’: 
tr
ea
tm
en
t i
n 
pr
im
ar
y 
ca
re
. ‘
co
ns
ul
ta
tio
n 
gr
ou
p’
: c
on
su
lta
tio
n 
of
 a
 n
ep
hr
ol
og
is
t w
ith
ou
t r
ef
er
ra
l. 
‘r
ef
er
ra
l g
ro
up
’: 
re
fe
rr
al
 to
 s
ec
on
da
ry
 
ca
re
. e
G
FR
 in
 m
l/m
in
/1
.7
3m
2
Chapter 2
32 33
Quality of chronic kidney disease management in primary care
2
Web-appendix table 2. Practice characteristics
Practice type n
Solo practice 6
Duo practice 16
Group practice 25
Vocational training practice 30
Rural location 15
General Practice
Information System
Medicom 25
Micro-HIS 6
MIRA 6
Promedico ASP 8
Promedico VDF 2
Web-appendix table 3a. Classification of included CDK patients with diabetes under care of their GP 
using the interdisciplinary CKD-guideline for primary care and nephrology.
albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients ≥ 65 years (n = 2.164)
eGFR ≥ 60 559 44
eGFR 45 – 60 133 690 253 27
eGFR 30 – 45 76 214 127 14
eGFR < 30 6 9 10 2
Patients < 65 years (n = 729)
eGFR ≥ 60 418 22
eGFR 45 – 60 46 186 31 4
eGFR 30 – 45 5 8 6 2
eGFR < 30 1 0 0 0
Classification of patients based on renal function, albuminuria and age. ‘primary care group’ n=2.053: 
treatment in primary care. ‘consultation group’ n=680: consultation of a nephrologist without referral. 
‘referral group’ n=160: referral to secondary care. eGFR in ml/min/1.73m2
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absTraCT
Purpose: A Web-based consultation system (telenephrology) enables family physicians 
to consult a nephrologist about a patient with chronic kidney disease. Relevant data are 
exported from the patient’s electronic file to a protected digital environment from which 
advice can be formulated by the nephrologist. The primary purpose of this study was to 
assess the potential of telenephrology to reduce in-person referrals.
Methods: In an observational, prospective study, we analyzed telenephrology consulta-
tions by 28 family practices and 5 nephrology departments in the Netherlands between 
May 2009 and August 2011. The primary outcome was the potential reduction of 
in-person referrals, measured as the difference between the number of intended refer-
rals as stated by the family physician and the number of referrals requested by the 
nephrologist. The secondary outcome was the usability of the system, expressed as time 
invested, the implementation in daily work hours, and the response time. Furthermore, 
we evaluated the questions asked.
results: One hundred twenty-two new consultations were included in the study. In 
the absence of telenephrology, 43 patients (35.3%) would have been referred by their 
family physicians, whereas the nephrologist considered referral necessary in only 17 
patients (13.9%) (P <.001). The family physician would have treated 79 patients in 
primary care. The nephrologist deemed referral necessary for 10 of these patients. Time 
investment per consultation amounted to less than 10 minutes. Consultations were 
mainly performed during office hours. Response time was 1.6 days (95% CI, 1.2–1.9 
days). Most questions concerned estimated glomerular filtration rate, proteinuria, and 
blood pressure.
Conclusion: A Web-based consultation system might reduce the number of referrals 
and is usable. Telenephrology may contribute to an effective use of health facilities by 
allowing patients to be treated in primary care with remote support by a nephrologist.
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inTroduCTion
In 2002 the National Kidney Foundation released the Kidney Disease Outcomes Quality 
Initiative guideline for the evaluation and treatment of patients with chronic kidney dis-
ease,1 which has been instrumental in improving the care of patients with this disease. 
According to the guideline definition the prevalence of chronic kidney disease in the 
United States has increased from 10% in 1994 to 13% in 20042; in Western Europe it 
is only slightly less prevalent.3,4 The widely implemented default laboratory reporting of 
estimated glomerular filtration rate (GFR) has raised the awareness of chronic kidney 
disease in primary and secondary health care and, together with increased prevalence, 
has increased the economic burden on the health care system.5–7
Cost-effective management of patients with chronic kidney disease requires that care 
should be given in a primary care setting where possible and in a secondary care setting 
where necessary. In the United Kingdom, the National Institute for Clinical Excellence 
guidelines on chronic kidney disease provide family physicians with tools to decide which 
health care setting—primary or secondary—is best suited for providing the patient’s 
required care.8 In the Netherlands, the interdisciplinary guideline for primary care and 
nephrology on chronic kidney disease serves the same purpose.9 To facilitate good care 
in a primary care setting, the advice of a nephrologist may be helpful and would limit 
referrals for only those that need an in-person referral.
Consultation between a family physician and a nephrologist is traditionally performed 
by telephone or e-mail. The first may be inconvenient because a lot of detailed informa-
tion has to be communicated, a report of the consultation is lacking, and a time slot that 
suits both physicians has to be found.10,11 The latter is impractical because all relevant 
data must be transferred from the medical record to the e-mail message, and most 
e-mail services are not sufficiently protected. Studies have reported electronic consulting 
where nephrologists had full access to the electronic health record of the patient.12,13 
Access issues may raise privacy concerns, however, as more information is available to 
the nephrologist than is necessary for the consultation.
To overcome these shortcomings, the Radboud University Nijmegen Medical Centre 
(RUNMC) Department of Primary and Community Care and Department of Nephrology 
have devised a Web-based consultation system: telenephrology. Family physicians upload 
defined data that are relevant to chronic kidney disease. These data are automatically 
extracted from the patient’s electronic health record to a secured digital environment. 
Family physicians and nephrologists can use the system independently and at a con-
venient time. The nephrologist gives treatment advice to the physician based on the 
patient’s information, and by so doing, the need for referral may be reduced.
We describe an observational study and analyze the use of telenephrology by family 
physicians and nephrologists. The primary objective was to assess the potential of tele-
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nephrology to affect referral rates. A secondary objective was to examine the usability 
of telenephrology by judging time investment, implementation in daily work, and the 
nephrologist’s response time. Finally, we explored the areas of patient care about which 
physicians were likely to consult through telenephrology.
MeThods
The content of telenephrology was developed in the RUNMC by the Department of Pri-
mary and Community Care and the Department of Nephrology. TeleMC, a company in 
telemedicine applications, was responsible for the technical development of the system. 
Telenephrology was introduced in 2009 in the RUNMC and 5 family practices. In 2011 it 
was expanded to a total of 28 family practices and 5 hospitals with nephrology care. In 
this observational prospective study we describe and analyze Web-based consultations 
between May 2009 and August 2011 by 42 family physicians and 5 nurse practitioners 
in 28 family practices and 14 nephrologists from 5 participating hospitals. Nurse prac-
titioners worked on behalf of the family physicians. We included all new consultations. 
If the consultation resulted in a recommendation for additional (diagnostic) testing, we 
also used the follow-up consultations to establish the outcome of the process. Data 
extraction was conducted by TeleMC for the patients’ age, sex, estimated GFR values, 
and albuminuria. TeleMC further provided the times of consultation and time invest-
ments of the clinicians and physicians, as well as the nephrologists’ response times. Data 
categorization was performed by two of the authors (V.A.G., N.D.S).
The usual referral process consisted of a face-to-face consultation between patient 
and nephrologist. The primary care clinician wrote either a paper or electronic referral 
letter to inform the nephrologist and to request an appointment for the patient. In ad-
dition to these regular referrals, a clinician could telephone the nephrologist for advice. 
The clinicians in our study had the choice to either refer the patient in the usual way or 
to consult a nephrologist by telenephrology and then, based on the advice given, decide 
how and where to manage the patient.
The clinician could enter the telenephrology system directly from the patient’s file in 
the electronic health record by logging on with a user name and password. Essential 
patient data on medical history, medication, laboratory results, and blood pressure were 
automatically extracted from the patient’s electronic health record and displayed in an 
orderly manner. If the clinician judged part of the displayed information not to be ap-
plicable, for example privacy-sensitive information, that information could be removed. 
Mandatory information consisted of the actual question(s), whether the patient would 
have been referred if telenephrology were not available, and time investment per con-
sultation.
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The nephrologist, who was notified by e-mail or text message that a consultation had 
arrived, logged onto the website and, based upon the patients’ information, advised 
the clinician how to treat the patient in primary care, whether to refer, or whether to 
refer if additional diagnostic information met conditions specified by the nephrologist. 
The nephrologist could request additional information and defer management advice 
until this information was available. Subsequently, the patient’s primary care clinician 
was informed in a similar manner when a reply, which was automatically noted in the 
electronic health record of the patient, arrived. The clinician could then adjust patient 
care or refer the patient according to the nephrologist’s advice. Requested additional 
information could be provided in a follow-up consultation when new results had ar-
rived. At that time, the clinician could ask for clarification or pose additional questions. 
A consultation about the same patient but addressing a new topic was considered 
a new consultation. An example of a telenephrology consultation can be viewed in 
Supplemental Appendix 1, available online at http://annfammed.org/content/11/2/151/
suppl/DC1.
For the analysis, we compared the clinicians’ referral decisions had there not been the 
possibility of telenephrology with the nephrologists’ referral advice, which was consid-
ered the reference standard. The nephrologists’ advice to refer was collected from their 
entries in the online program. When the nephrologist had requested additional informa-
tion, the entry was taken from the follow-up consultation after receiving these data. We 
asked the clinicians at every consultation whether the patient would have been referred 
to the nephrologist had telenephrology not been available and, after the nephrolo-
gists’ responses, whether they would follow the referral advice given. We compared 
the referral rates for chronic kidney disease with the recommendations as advocated 
by the Dutch interdisciplinary guideline for primary care and nephrology. To determine 
outcome significance between the clinicians’ intention to refer and the nephrologists’ 
referral advice, we conducted a McNemar’s test to compare paired proportions using 
PASW 18.0 (SPSS Inc).
To assess usability we investigated time investment, implementation in daily work 
hours, and nephrologists’ response time. Time investment was reported by the clini-
cians and physicians. Implementation in daily work hours was defined by the time slot 
during which the consultation took place (6:00–8:00, 8:00–17:00, 17:00– 19:00, or 
19:00–6:00), which enabled us to evaluate use during office hours, just before and after 
office hours, and at a later time during the day. The response time of the nephrologist 
was calculated in days.
For analysis of the questions asked, we firstly analyzed the individual questions with 
the intention to find categories and subcategories. We subsequently allocated the ques-
tions to these subcategories. Each consultation could contain 1 or more questions.
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To assess the satisfaction of the clinicians with the system, we sent an online question-
naire in 2011 to the 5 practices that had used telenephrology during the pilot phase in 
the previous year.
Ethics approval was not required according to the accredited Medical Research Ethics 
Committee Arnhem/Nijmegen (ABR NL16590.091.07).
resulTs
Between May 2009 and August 2011, 125 recorded new consultations were performed 
by 42 family physicians and 5 nurse practitioners from 28 family practices. Three 
consultations were excluded because the clinicians used the system to get information 
on patients that had already been referred. The final 122 consultations included 116 
patients. In 24 patients a total of 52 follow-up consultations were performed. Clinical 
characteristics of the patients are displayed in Table 1.
Referral
We compared the primary care clinicians’ intention to refer with the final referral advice 
of the nephrologists (Table 2). The clinicians intended to refer 43 patients. The nephrolo-
gists concluded that referral was not necessary and care could be delivered in primary 
care in 36 of these patients (84% reduction).
The opposite was seen in 10 patients, who according to the clinicians could be treated 
in primary care. The nephrologists advised referral for the following reasons: relatively 
young age (n = 3), comorbidity (n = 1) proteinuria (n = 2), rapid decline in renal function 
(n = 2), and unspecified reason (n = 2). The clinicians agreed with all the referral advice 
given, which meant a net referral reduction from 43 to 17 (60.5%) referrals.
For comparison we also applied the recommendation given by the Dutch interdisci-
plinary guideline on for primary care and nephrology. Explanation of the guideline and 
comparison results are given in online-only Supplemental Appendixes 2 and 3, available 
at http://annfammed.org/content/11/2/151/suppl/DC1.
Usability
Time investment per consultation amounted to 9 minutes for primary care clinicians and 
nephrologists. Seventy-three percent of the clinicians’ use of telenephrology was be-
tween 8:00 and 17:00. Sixty-one percent of the consultations were answered between 
8:00 and 17:00.
The nephrologists’ average response time was 1.6 days (95% CI, 1.2–1.9 days); 43% 
(n = 52) of all consultations were answered on the day of submission, and 84% (n = 
102) were answered within 3 days. The full results are given in Table 1.
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Nine clinicians answered the questionnaire. They all judged the amount and content 
of information that was sent by telenephrology to be appropriate. Ease of use was 
judged as reasonable (2 clinicians) to good (7 clinicians). Four of the clinicians found it 
reasonably easy and 5 found it easy to fit the use of telenephrology within daily practice 
work. Eight of 9 users said that their knowledge of nephrology had increased by the 
use of telenephrology. The 2 nephrologists found the data supplied was sufficient to 
get a good understanding of the patient’s case. In the future they would prefer the data 
to be presented graphically. The nephrologists could see a learning curve in the way 
physicians asked questions.
Consultation Content
The result of the categorization of question topics is displayed in Table 3. The nephrolo-
gist addressed the question in a broader context and provided advice not specifically 
asked for in 35% (n = 43) of the answers. This advice mainly considered medication 
safety in relation to renal function and advice to check the patient for mineral and 
bone disorders (secondary hyperparathyroidism and issues associated with calcium, 
phosphorus, vitamin D) or for anemia.
Table 1. Patient characteristics and time investment in telenephrology consultations
Characteristics distribution
new consultations (n = 122)
Age (range), y 73.6 (34 – 96)
Sex, % (No.)
Male 40 (49)
Female 60 (73)
Estimated GFR (range), mL/min/1.73 m2 46 (22 – 128)
Albuminuria
Normoalbuminuria, % (No.) 49 (48)
Microalbuminuria, % (No.) 38 (38)
Macroalbuminuria, % (No.) 13 (13)
Time of consultation, family physician, % (No.)
06:00 – 08:00 1 (1)
08:00 – 17:00 73 (89)
17:00 – 19:00 17 (21)
19:00 – 06:00 9 (11)
Time of consultation, nephrologist, % (No.)
06:00 – 08:00 1 (1)
08:00 – 17:00 61 (74)
17:00 – 19:00 25 (31)
19:00 – 06:00 13 (16)
Time investment, family physician, No. (95% CI), min 9:27 (8:29 - 10:25)
Time investment, nephrologist, No. (95% CI), min 8:45 (8:04 - 9:27)
Days until response, No. (95% CI) 1.6 (1.2 - 1.9)
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Table 1. Patient characteristics and time investment in telenephrology consultations (continued)
Characteristics distribution
follow-up consultations (n=52)
Time investment, family physician, No. (95% CI), min 6:43 (5:48 - 7:38)
Time investment, nephrologist, No. (95% CI), min 6:47 (5:55 - 7:40)
GFR = glomerular filtration rate.
Notes: Consultations performed by 42 family physicians and 5 nurse practitioners in 28 family practices, 
between May 2009 and August 2011.
Table 2. Intended referral by primary care clinicians and referral advice from nephrologists
Nephrologist
advises referral
No. (%)
advises primary care
No. (%)
Total
No. (%)
Primary care clinician
Intends to refer  7 (5.7) 36 (29.5)  43 (35.3)
Wants to treat in 
primary care
10 (8.2) 69 (56.6)  79 (64.8)
Total 17 (13.9) 105 (86.1) 122 (100.0)
Note: McNemar’s test comparing family physician’s intention to refer and the nephrologist’s referral 
advice: p<0.001.
Table 3: Categorization and distribution of the primary care clinicians’ questions
Question by group Subject No.
Intrinsic kidney disease,
60% (n = 124)
Decreased estimated GFR 19
Decreasing estimated GFR 30
Microalbuminuria 14
Macroalbuminuria  6
Blood pressure in relation to CKD 23
Unspecified 32
Metabolic complications,
27% (n = 55)
Bone and mineral metabolism 42
Hemoglobin 12
Acid-base homeostasis  1
Cardiovascular risk management,
4% (n = 9)
Diabetes  5
Cholesterol  4
Comorbidity in relation to CKD,
8% (n = 16)
Gout  1
Urinary tract infection  1
Patients condition  3
Drugs that interact with impaired 
kidney function
11
Other,
1% (n = 3)
Cardiomyopathy  2
Urinary tract infection  1
CKD = Chronic Kidney Disease; GFR = glomerular filtration rate.
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disCussion
Our data provide support for the introduction of telenephrology in primary care. The 
intended referral rate by the primary care clinicians was far higher than that advised by 
the nephrologist. Receiving advice from a nephrologist through telenephrology could 
result in more convenient care at lower health care costs.
Telenephrology and Other Electronic Consultation Systems
Several other studies have described the use of electronic consultation technology in 
the management of patients with chronic kidney disease. In Hawaii, nephrologists 
proactively intervened in primary care by using data from Kaiser Permanente’s electronic 
medical system and by providing unsolicited advice to family physicians.12 Their interven-
tion lead to an increase in timely referrals and a reduction in low-risk referrals. This 
initiative was nephrologist driven and was possible only because nephrologists had entry 
to all electronic health records, which meant that they had access to irrelevant data. 
Such access is not desirable from the perspective of efficiency and privacy.
In the United Kingdom, Stoves et al set up an e-mail referral system for patients 
with chronic kidney disease: if the general practitioner referred the patient by e-mail, 
the patient was asked to provide consent for the nephrologist to look in the electronic 
health record.13 Based on the information read, the nephrologist advised referral or gave 
management advice to be carried out in the primary care setting. This effort lead to a 
reduction in referrals from 30 to 8 patients (73% reduction), similar to our primary out-
come. The mean response time was 7 days and mean time needed for the consultation 
was 15.5 minutes. The time required in our study was less, which is probably because 
only relevant preformatted information was displayed.
Patient Benefits
Depending on the extent to which family physicians pose questions by telenephrology, 
patients might receive more adequate care in relation to blood pressure, hyperparathy-
roidism, anemia, and medication safety. This increased care will most probably affect 
patient survival and morbidity.14–16 Furthermore, patients can be referred for more timely 
predialysis care if family physicians and nephrologists monitor the progress of chronic 
kidney disease as a team.17 The convenience for patients lies in specialist responses that 
are faster than with a usual referral, prevention of time-consuming hospital visits, and 
not needing to see another doctor. Although we did not study patient satisfaction, we 
expect greater satisfaction if treatment can be given in a patient’s own environment, as 
was found in a study on joint teleconference consultations.18
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Economic Benefits
Telenephrology has the potential to reduce referrals and so could contribute to a cost 
reduction. A usual referral costs €600. Our telenephrology consultation cost €107, 
including a nephrology tariff and the online facilities. Each prevented referral meant a 
saving of €493. Additional costs in primary care should be evaluated. Pan et al examined 
telehealth models in a simulation study and found that physician-to-physician consulta-
tion systems can contribute to a substantial cost reduction.19
As indicated by our data, the introduction of telenephrology may also lead to referrals 
that, although not initially intended by the family physician, were deemed necessary by 
a nephrologist. In these cases, the higher costs of referrals are likely to be balanced by 
lower costs related to earlier detection and treatment of kidney disease.
Broadening the Concept
We think that e-consultation offers the ability to break down walls between primary and 
specialist care. It facilitates shared care for patients with chronic disease conditions, and 
it might enable effective use of expensive secondary care facilities. Joint teleconference 
medical consultation is a promising development as well, but it has the disadvantage 
that both the family physician and specialist must be available at the same time. 
Furthermore, a joint consultation does not provide documentation in the electronic 
health record. Where interprofessional consultation relies mainly on measurable and 
preformulated data, Web-based consultation seems more practical and effective than a 
referral or teleconferencing.
Limitations
We must consider some limitations of this study. The Web-based consultation aimed 
to lead to more appropriate referrals to the nephrologist, and the primary outcome 
measure was whether the intended referral rate in primary care decreased. It will be 
important to assess how robust this initial outcome is, or whether at a later date patients 
are referred despite the nephrologist’s recommendation not to refer. On the subject of 
referrals we merely analyzed the intention to refer. There were no data available on 
the actual number of referrals following this advice. These data will be generated in a 
cluster randomized controlled trial on the influence of telenephrology on the actual rate 
of referrals: the CONTACT study (Consultation Of Nephrology by Telenephrology Allows 
optimal Chronic kidney disease Treatment in primary care, Netherlands Trial Registration 
code 2368). In this trial the effect of telenephrology on the actual referral rate and the 
quality of care will be evaluated. This study will enable a direct comparison between re-
ferrals in practices using and not using telenephrology and will provide better evidence 
than the current study, which used an internal reference standard.
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Data on professional behavior (for example referral) are subject to clustering within 
professionals, for which we did not correct in this usability study.
The generalizability of the telenephrology technique depends on local settings. At the 
very least, the primary care physician must use an electronic health record that allows 
automatic data extraction. Although it might be possible to create a similar system that 
allows direct data entry by the family physicians, such data entry is prone to errors and 
certainly not time efficient.
We did not evaluate patient satisfaction, which is a limitation. The satisfaction of the 
professionals was measured in an early stage of the study, so only included 5 practices. 
The data are too few to interpret, but the opinion tended to be positive. In the imple-
mentation of telehealth, the applicability in daily work proved to be very important.20,21 
With that in mind, it is likely that the telenephrology system fit in well during the daily 
work routine; most clinicians and physicians used the system during office hours, spend-
ing less than 10 minutes on a consultation and nephrologists responded quickly.
In conclusion, a Web-based consultation system might reduce the number of referrals 
by enabling family physicians to receive suitable advice from nephrologists. The system 
is usable for both nephrologist and family physicians and allows efficient care of patients 
with chronic kidney disease in primary care.
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supplemental appendix 2: Dutch interdisciplinary CKD-guideline for primary care and nephrology: 
recommendations for the care of patients with CKD
normo / microalbuminuria macroalbuminuria
Patients > 65 years of age
eGFR > 60 ml/min/1.73m2
eGFR 45 – 60 ml/min/1.73m2
eGFR 30 – 44 ml/min/1.73m2
eGFR < 30 ml/min/1.73m2
Patients < 65 years of age
eGFR > 60 ml/min/1.73m2
eGFR 45 – 60 ml/min/1.73m2
eGFR 30 – 44 ml/min/1.73m2
eGFR < 30 ml/min/1.73m2
Green: evaluation and treatment in primary care. Yellow: consultation of a nephrologist (without refer-
ral). Red: referral to secondary care.
Adapted from Grauw de W, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard C, et al. Landelijke 
Transmurale Afspraak Chronische nierschade, http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_
samenwerking/k_ltas.htm (with permission of the Dutch College of General Practitioners).
supplemental appendix 3: the family physician’s intention to refer compared to the nephrologist’s 
referral advice plotted against the Dutch interdisciplinary CKD-guideline for primary care and nephrology
Dutch CKD-guideline
(could only be applied to patients with 
urine assessment)
Family physician Nephrologist
referral to secondary care
n = 23
Refer n=12 Refer n = 6
Consultation of a nephrologist
n = 43
Refer n = 15 Refer n =7
treatment in primary care
n = 33
Refer n = 10 Refer n =0
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absTraCT
background: Consultation of a nephrologist is important in aligning care for patients 
with chronic kidney disease (CKD) at the primary–secondary care interface. However, 
current consultation methods come with practical difficulties that can lead to postponed 
consultation or patient referral instead.
objective: This study aimed to investigate whether a web-based consultation platform, 
telenephrology, led to a lower referral rate of indicated patients. Furthermore, we 
assessed consultation rate, quality of care, costs and general practitioner (GPs’) experi-
ences with telenephrology.
Methods: Cluster randomized controlled trial with 47 general practices in the Nether-
lands was randomized to access to telenephrology or to enhanced usual care. A total of 
3004 CKD patients aged 18 years or older who were under primary care were included 
(intervention group n = 1277, control group n = 1727) and 2693 completed the trial. 
All practices participated in a CKD management course and were given an overview of 
their CKD patients.
results: The referral rates amounted to 2.3% (n = 29) in the intervention group and 
3.0% (n = 52) in the control group, which was a non-significant difference, OR 0.61; 
95% CI 0.31 to 1.23. The intervention group’s consultation rate was 6.3% (n = 81) 
against 5.0% (n = 87) (OR 2.00; 95% CI 0.75–5.33). We found no difference in quality 
of care or costs. The majority of GPs had a positive opinion about telenephrology.
Conclusion: The data in our study do not allow for conclusions on the effect of telene-
phrology on the rate of patient referrals and provider-to-provider consultations, com-
pared to conventional methods. It was positively evaluated by GPs and was non-inferior 
in terms of quality of care and costs.
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4
inTroduCTion
Care for patients with chronic kidney disease (CKD) poses a challenge for GPs due to 
the complexity of the disease and related comorbidity. Besides the risk of end-stage 
renal failure, CKD increases the risk of premature development of cardiovascular disease 
(1). To attenuate these risks, structured care including alignment between primary and 
secondary care is necessary (2). Management of CKD requires patient-centred care that 
should be provided in a primary care setting where possible and in a secondary care 
setting where necessary. In the UK, the National Institute for Health and Care Excellence 
(NICE) guidelines on CKD provide GPs with tools to decide which healthcare setting is 
best suited for providing patient’s the required care (3). In the Netherlands, the interdis-
ciplinary CKD guideline for primary care and nephrology serves the same purpose (4).
Within the Dutch healthcare system, consultation between GPs and specialists by 
phone is common practice and the existence of multiple interdisciplinary guidelines 
strengthens this approach. Consultation can be applied when the GP seeks expert 
knowledge or advice on for example an uncommon medical condition or test result, but 
also in situations where the patient’s illness is too complex or serious to solely manage in 
primary care, but does not require referral to a specialist. The advice of a nephrologist by 
means of consultation may increase quality of care (QoC) in a primary care setting and 
could limit referrals to only those that need an in-person referral. However, the consulta-
tion process is not always straightforward and can lead to postponed consultation or 
patient referrals instead (5).
Recently, in the Netherlands, the Radboud University Medical Center (RUMC) De-
partments of Primary and Community Care and of Nephrology devised a web-based 
consultation system: telenephrology. This system is an alternative to consultation by 
telephone or e-mail and has potential benefits: it is more time efficient, GPs and ne-
phrologists can use it independently of each other at a time convenient to them, there 
is a digital report of the consultation and data is securely transferred (6,7). This approach 
shares many similarities with teledermatology, the first teleconsultation application to 
be widely embedded in Dutch general practice and an approach that decreased patient 
referrals and healthcare costs (8).
We assumed that when the consultation process is low barrier and the nephrologist’s 
advice and knowledge become available to the GP, the need for in-person referral may 
be reduced. The primary aim was to investigate whether the use of telenephrology 
led to a lower in-person referral rate. Secondarily, we assessed the consultation rate 
between GPs and nephrologists, analyzed whether use of telenephrology was associ-
ated with higher QoC and performed a basic cost analysis. Tertiary aims were to report 
the number of newly diagnosed CKD patients during the trial, and their referral and 
consultation rates. Finally, we evaluated GPs’ opinion on telenephrology.
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subjeCTs and MeThods
The CONTACT study (‘Consultation Of Nephrology by Telenephrology Allows optimal 
Chronic kidney disease Treatment in primary care’) is a cluster randomized controlled 
trial (Netherlands Trial Registration code 2368).
Selection criteria
We recruited general practices during a CKD management course for GPs in the Neth-
erlands. The practices did not have access to telenephrology before.
We defined the CKD population as all patients 18 years or older who met the CKD 
criteria [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 and/or albu-
minuria] based on data between 2008 and 2011 from the practices’ electronic medical 
records (EMRs) (3,9). From there we included those patients who according to the 
Dutch interdisciplinary CKD guideline for primary care and nephrology would qualify for 
consultation or referral based on eGFR, albuminuria and age (4).
The guideline criteria for recommended consultation were (a) patients aged ≥ 65 
with an eGFR 30–45 ml/min/1.73 m2 and no severe albuminuria and (b) patients aged 
< 65 with an eGFR 45–60 ml/min/1.73 m2 and no severe albuminuria. The criteria for 
recommended referral were (a) patients aged ≥ 65 with an eGFR <30 ml/min/1.73 m2 
regardless of albuminuria status; (b) patients aged < 65 with an eGFR <45 ml/min/1.73 
m2 regardless of albuminuria status and (c) patients with severe albuminuria.
All participating practices were given overviews stating which of their patients met 
the consultation and referral criteria. Practices were free to follow up on these rec-
ommendations. The GPs reported which patients were already under secondary renal 
care. These patients were excluded from analysis. The intervention group had access to 
telenephrology between March 2011 and June 2012.
Consultation
In the intervention group, the GP could use the telenephrology application from the 
EMR. It functions as an add-on to the existing electronic referral system. Essential pa-
tient data on medical history, medication, laboratory results and blood pressure were 
automatically extracted. Telenephrology accessed individual patient data from the EMR 
only after the GP opened the consultation module for that specific patient. If the GP 
judged information from the medical history as not applicable, e.g. privacy-sensitive in-
formation, this could be removed. The nephrologist was notified about the consultation 
by e-mail or text message and consequently advised the GP on how to treat the patient 
in primary care, to refer directly, or to refer later if additional diagnostic information 
met conditions specified by the nephrologist. Subsequently, the GP was informed when 
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a reply had arrived. Requested additional information could be given in a follow-up 
consultation. Moreover, the GP could ask for clarification or pose additional questions.
GPs in the control practices used conventional consultation methods. Consultations 
were not reimbursed for GPs.
Data security
The data connection between the EMR and the telenephrology application is similar to 
what is used for electronic referral or teledermatology. GPs log on to their EMR system 
with their credentials and have a direct single sign-on (SSO) which is secure sockets layer 
(SSL) encrypted to access telenephrology. The connection can only be activated by the 
GP from the EMR of a specific patient after informed consent by the patient. The data 
shared through telenephrology is SSL encrypted and only retrievable for the approached 
specialist who logs on using a two-factor authentication. The telenephrology service 
provider is certified to ISO 27001-2013 and NEN 7510 standards and complies with 
Dutch privacy legislation regarding patient data (Wet Bescherming Persoonsgegevens). 
The service provider employs a security officer and has a privacy officer on call.
Data sources
All referrals were reported by both the GPs and the nephrologists in an online survey 
system. Consultations in the control group were reported in a similar way. Telenephrol-
ogy consultations were automatically logged by the facilitating company. Data for QoC 
and cost analysis were retrieved from the EMRs. A total of five different General Practice 
Information Systems were used across the practices to serve as EMR.
Outcomes
The primary outcome was the difference in referral rate between the telenephrology 
and control group, defined as the number of patients referred to secondary renal care 
as a fraction of total number of included patients.
Our secondary outcomes were the difference in consultation rates by telephone or telene-
phrology as a fraction of total number of included patients and QoC defined as adherence 
to the advised monitoring criteria from the Dutch interdisciplinary CKD guideline (Supple-
mentary Table S1). Included process indicators were (i) disease progression (assessment 
of eGFR or serum creatinine, albuminuria, glucose and blood pressure) and (ii) metabolic 
parameters [assessment of haemoglobin, calcium, phosphate, parathyroid hormone (PTH), 
serum albumin and potassium]. As a measure of GPs’ awareness of CKD, we evaluated 
compliance with coding renal impairment as a separate entity on the EMR episode list with 
International Classification of Primary Care (ICPC) code U99.1 in case of an eGFR <60 ml/
min/1.73 m2. Furthermore, we analyzed achievement of blood pressure targets <140/90 
and <130/80 mmHg, judged by the mean of the two latest measurements.
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For the main related medical costs, we included the number of contacts between 
patient and primary care, the number of blood samples taken per patient, erythropoi-
etin prescribed, referrals to secondary renal care and telenephrology and telephone 
consultations during the trial period.
Tertiary outcomes were to report the incidence of CKD during the trial (i.e. patients 
that did not meet the CKD criteria at T0, but did at T1), and their referral and consulta-
tion rates.
All general practices that participated in the intervention group were sent an online 
questionnaire about their experience with telenephrology. Included topics were content, 
feasibility and ease of use (Supplementary Table S2).
Sample size
Based on 50 pre-trial telenephrology consultations, we expected a 40% difference 
in referral rate (10). We expected that per group practice the guideline would advice 
consultation in 94–140 patients and referral in 17–23 patients (11). However, data on 
renal function or proteinuria is not known for every patient. English data showed that in 
the general population, a renal function was available in 27% of patients (12).
Therefore, we assumed consultation or referral would occur in 36 patients per group 
practice. Based on other studies and considering the fact that some patients had been 
referred earlier, we expected seven referrals per control practice (referral rate 19.4%) 
and four referrals (referral rate 11.1%) per intervention practice (13).
We assumed an intracluster correlation coefficient of 0.04. Based on a P-value of 0.05 
and a power of 80%, at least 38 practices had to be included.
Randomization
Randomization took place in blocks of two practices and was stratified according to 
the number of CKD patients allocated to the consultation group per practice. Based 
on the baseline study results, we regarded practices with less than 14 patients in the 
consultation group as low volume and the others were considered high volume (14). 
The randomization was performed by an independent statistician unaware of practice 
characteristics.
Analyses
We used descriptive statistics to assess patient baseline characteristics, referral and 
consultation rates, adherence to QoC indicators and results from the questionnaire. 
Because of the hierarchical structure of the data (patients nested within practices) the 
analyses were based on multilevel logistic regression models (PROC GLIMMIX in SAS). 
The type of General Practice Information System was considered a confounder for the 
outcomes referral/consultation rate and QoC, as these could be affected by the quality 
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of data recording. We performed models with a random intercept keeping the indepen-
dent variable (General Practice Information System) fixed for both outcomes. For QoC 
outcomes, we applied per protocol analysis and excluded the patients that were referred 
to secondary renal care during the study period as their monitoring was left at the dis-
cretion of the nephrologist and corrected for baseline QoC. The difference in mean costs 
per patient was analysed with a multilevel analysis with a cluster-corrected robustness 
test (details are provided in Supplementary Table S3). Descriptive analysis was conducted 
using SPSS version 20.0 (IBM PASW statistics 20), multilevel logistic regression analysis 
was conducted using SAS V9.2 and cost analysis was conducted using STATA 13.
resulTs
Forty-seven general practices signed up, with 23 intervention practices with 58 GPs and 
24 control practices with 70 GPs after randomization.
The 47 practices served a population of 207469 people, of whom 3004 patients 
fulfilled the inclusion criteria (Figure 1). Baseline characteristics were comparable be-
tween patients in the intervention (n = 1277) and control group (n = 1727) (Table 1). 
Twenty-nine patients were referred in the intervention group against 52 in the control 
group (referral rates of 2.3% and 3.0%, respectively), resulting in an odds ratio (OR) of 
0.61 (95% CI 0.31–1.23).
The difference in consultation rate was also non-significant, 6.3% (n = 81) in the in-
tervention group against 5.0% (n = 87) in the control group (Tables 2 and 4). Regarding 
QoC there was no difference on any of the process or outcome variables (Tables 3 and 
4). In comparison to the baseline results, registration of eGFR <60 ml/min/1.73 m2 on 
the EMR episode list increased by an absolute 14.9% in the intervention group and by 
16.4% in the control group. In total, 232 patients were lost to follow-up, mostly due to 
passing away and moving (Supplementary Table S4). The mean costs per patient during 
the trial in the intervention group were € 453.86; 95% CI 392.98–514.74 against € 
433.74; 95% CI 387.64–479.84 in the control group (P = 0.60).
Patients newly diagnosed with CKD stage 3 or worse during the trial amounted 
338/89659 in the intervention group and 469/117810 in the control group.
We received 38 completely filled out user evaluation questionnaires from 19/23 
intervention practices. Twenty-seven GPs felt that the content of information sent via 
telenephrology was good. Ease of use was deemed good by 15 respondents, reasonable 
by 14 and insufficient by 3. Twenty-six GPs mentioned that telenephrology had added 
to their knowledge of kidney disease. Thirty respondents were pleased with the feasibil-
ity of telenephrology and twenty-nine would recommend telenephrology to colleagues. 
Six GPs did not make use of telenephrology.
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figure 1. Flowchart
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Table 1. Baseline characteristics of the study cohort: CKD patients who met the consultation or referral 
criteria (data from 2008 to 2011)
Patient characteristics
intervention group
(N = 1277)
Control group
(N = 1727)
Demographics (SD)
 Age in years 68.0 (13.6) 66.4 (13.2)
 Male sex 34.6% 34.8%
Comorbidity
 Diabetes 27.3% 27.0%
 Hypertension 52.2% 54.7%
 Cardiovascular diseasea 32.8% 34.7%
Laboratory (SD) [n]
 Creatinine in µmol/l 119.8 (31.5) [n = 1277] 118.1 (28.0) [n = 1726]
 eGFR in ml/min/1.73 m2 46.7 (10.0) [n = 1277] 47.9 (9.5) [n = 1727]
 Fasting glucose in mmol/l 6.3 (1.7) [n = 939] 6.2 (1.7) [n = 1258]
 Hemoglobin in g/dl 13.34 (1.64) [n = 985] 13.53 (1.57) [n = 1264]
 Calcium in mmol/l 2.33 (0.12) [n = 226] 2.34 (0.13) [n = 267]
 Phosphate in mmol/l 1.05 (0.19) [n = 152] 1.04 (0.18) [n = 221]
 PTH in pmol/l 6.55 (3.98) [n = 63] 8.06 (5.24) [n = 82]
 Albumin in g/l 39.3 (3.7) [n = 149] 38.2 (4.9) [n = 161]
 Potassium in mmol/l 4.3 (0.47) [n = 1079] 4.3 (0.46) [n = 1354]
Urine (first and third quartile) [n]
 Albumin urine in mg/l 7.7 (3.0–45.0) [n = 450] 6.5 (2.9–31.0) [n = 407]
 Albumin/creatinine ratio 1.2 (0.9–4.1) [n = 648] 1.1 (0.9–4.2) [n = 781]
Physical examination (SD) [n]
 Systolic blood pressure in mmHg 140.1 (18.1) [n = 993] 140.7 (18.0) [n = 1341]
 Diastolic blood pressure in mmHg 78.3 (10.5) [n = 993] 79.8 (9.8) [n = 1342]
Values are given as mean (SD), median (IQR) or percentages.
aComprised International Classification of Primary Care (ICPC) codes K74-K77, K89, K90, K92.
Table 2. Referrals and consultations for the intention-to-treat cohort
referred rate Consulted rate
Intervention group
 Consultation (n = 1149) 9 0.8% 70 6.1%
 Referral (n = 128) 20 15.6% 11 8.6%
 Total (n = 1277) 29 2.3% 81 6.3%
Control group
 Consultation (n = 1569) 21 1.3% 76 4.8%
 Referral (n = 158) 31 19.6% 11 7.0%
 Total (n = 1727) 52 3.0% 87 5.0%
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Table 4. Outcomes of multilevel analysis for intervention group compared to control group
Variable odds ratio (95% Ci)
Referral 0.61 (0.31–1.23)
Consultation 2.00 (0.75–5.33)
U99.01 0.56 (0.26–1.24)
Monitoring of disease progression
 eGFR 0.90 (0.68–1.20)
 Albuminuria 1.29 (0.90–1.86)
 Blood pressure 1.02 (0.78–1.32)
 Glucose 1.03 (0.77–1.38)
 Complete monitoring disease progression 1.23 (0.89–1.70)
Monitoring of metabolic parameters
 Calcium 0.85 (0.49–1.48)
 Potassium 1.11 (0.81–1.52)
 Haemoglobin 0.90 (0.72–1.12)
 Phosphate 0.80 (0.42–1.54)
 PTH 0.90 (0.36–2.25)
 Serum albumin 1.12 (0.59–2.13)
 Complete monitoring of metabolic parameters 0.61 (0.22–1.72)
Outcome variables
 Blood pressure <140/90 mmHg 0.85 (0.66–1.09)
 Blood pressure <130/80 mmHg 1.15 (0.78–1.70)
disCussion
Summary
There was no difference in referral rates between the intervention and the control group 
(OR 0.61).
We also found no significant differences in consultation rate, QoC and costs. The 
majority of GPs had a positive opinion on telenephrology.
The referral rates of only 2.3% (n = 29) in the intervention group and 3.0% (n = 52) 
in the control group were much lower than our expected referral rates of 11.1% and 
19.4%. This has resulted in a lower power of the study.
Strengths and limitations
A key strength of our trial is that we studied telenephrology in a routine general care 
setting without any further interventions during the trial, besides the overview of pa-
tients with CKD we provided. Offering both intervention and control practices, these 
overviews created the possibility to measure the effect of telenephrology and even out 
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the effect of feedback arising from the overviews. We provided a realistic view on the 
GPs’ QoC by concentrating on patients who receive their CKD care in primary care, 
excluding those already under specialist care.
Several limitations should be considered. We applied the guideline classification based 
on single creatinine and albuminuria assessments whereas at least two and three mea-
surements are advised. This might have led to less accurate classification. Also, there is a 
possibility of contamination bias as the control group received education and overviews 
of their CKD population as a result of our study design to accurately measure the effect 
of telenephrology.
QoC might be underestimated due to analysis of data routinely recorded in the EMR. 
For example, blood pressure was measured, but was not registered in the EMR. Fur-
thermore, GPs stated in the evaluation that telenephrology added to their knowledge 
of CKD, but we did not possess data on what areas of knowledge were enhanced. 
The initial tertiary aim to analyze referrals and consultations in CKD patients newly 
diagnosed during the trial was not completed because the follow-up was too short and 
variable. Also, we could not conclude from the data whether erythropoietin prescrip-
tions were initiated before or during the trial. Due to this limitation, erythropoietin was 
not included in the cost analysis.
Comparison with existing literature
In comparison with our results other studies on telenephrology or provider-to-provider 
electronic consultations also reported referral reductions in absolute numbers, but not 
on a statistical significant level. A study by Garcia Garcia et al. (15) showed a 15% 
reduction in referrals in patients with CKD stage 3 and hypertension, following a shared 
care model that also included monthly face-to-face consultations and education be-
tween GPs and nephrologists. A UK-based study reported a reduction in referrals from 
30 to 8 patients after introduction of a CKD e-consultation service (16). In Canada, 
Keely et al. implemented an e-consultation service for a wide range of subjects. They 
reported that in 43% of consultations a traditional referral was originally contemplated, 
but was now avoided. For consultations regarding nephrology (n = 16), just over 60% 
of referrals were avoided (17). In the field of dermatology, a Dutch clinical trial about 
teledermatology did show a significant rate of prevented referrals in the total popula-
tion of 68% after analysis of approximately 37000 consultations (8). The high number 
of consultations led to adequate power in this trial.
In general, it appears difficult to substantiate the benefits of e-health with high levels 
of evidence. A systematic review of 27 studies on provider-to-provider e-consultations 
showed good feasibility and high GP satisfaction, but researchers did mention that ef-
fects on referrals, costs and clinical outcomes remained unclear (18). Our study showed 
similar results compared with the systematic review. However, despite difficulties to 
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demonstrate direct benefits of telenephrology, outcomes of semi-structured interviews 
with GPs, nephrologists and patients with CKD 3–4 showed that patients and doctors 
preferred CKD management in a primary care setting wherein the GP had access to 
a nephrologist. Both GPs and nephrologists strongly supported the use of electronic 
consultation systems (19).
Implications for research and/or practice
We found a non-significant reduction in referral rate with an odds ratio of 0.61. The 
biggest difference in referral rate was to be expected in the consultation group, where 
hypothetically telenephrology-facilitated consultation would empower GPs to provide 
care for more complex patients with CKD. In this group, there was a 40% relative 
difference in referral rate. However, the observed referral rate was far lower than we 
had estimated in our sample size calculation (3% against an expected 19.4%) and limits 
the possibilities to draw firm conclusions.
With regard to the large difference between the expected and actual referral rate, it 
would be valuable to further explore the GPs’ considerations when it comes to referral 
and consultation. The total number of consultations was too small to conclude that te-
lenephrology is a more stimulating tool to facilitate interdoctor consultations compared 
to conventional consultations methods.
There was no difference in QoC between the GPs in the intervention and control 
groups (Supplementary Table S5). Another possible explanation for lack of a difference 
could be contamination bias. Arguably, because of the study design, the control group 
partly acted as if they were an intervention group due to their participation in the CKD 
management course, their intrinsic motivation to participate in the study, the provision 
of the overview of CKD patients and their active registration of consultations and refer-
rals (20).
Conclusion
The data in our study do not allow for conclusions on the effect of telenephrology 
on the rate of patient referrals and provider-to-provider consultations, compared to 
conventional methods. It was positively evaluated by GPs and was non-inferior in terms 
of quality of care and costs. In our opinion, telenephrology deserves further evaluation 
before definite recommendations can be made.
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supplementary data Table s2: Content of questionnaire about experiences with telenephrology.
1. I work as a
a. GP
b. practice nurse
c. GP trainee
2. Gender
a. Male
b. Female
3. Age
a. < 20 years
b. 20 – 25
c. 25 – 30
d. 30 – 35 etc.
4. Did you make use of telenephrology?
a. Yes
b. No. If no, why not?
5. How many times did you make use of telenephrology?
a. 1 to 5
b. 6 to 10
c. 11 to 15
d. > 15
6. I think the amount of information sent via telenephrology to the nephrologist:
a. Good
b. Too much (unnecessary is …..)
c. Too little (missing is ….)
7. I think the ease of use of telenephrology is
a. inadequate (please comment)
b. reasonable
c. good
8. The use of telenephrology in everyday practice is
a. easily integrated.
b. difficult to integrate. Helpful would be...
9. The content of the advice by the nephrologist did
a. not add to my knowledge.
b. add to my knowledge.
10. The advices by the nephrologists were
a. easy to implement in general practice.
b. impractical, difficult to execute in general practice.
11. Would you miss telenephrology i fit were not available anymore?
a. Yes
b. No
12. Would you recommend telenephrology to colleagues?
a. Yes
b. No
13. Your positive and negative feedback on telenephrology.
a. ………….
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supplementary data Table s3: Variables for cost analysis.
Costs of primary care contacts were estimated using the Dutch college of healthinsurers’ manual for 
cost-research.(21) A regular GP consultation cost € 28,00 in 2009. We adjusted the cost to € 29,73 with 
the consumerpriceindex (CPI) of 2012.(22) A regular practice assistant consultation was estimated at € 
8,23 based on 1/6 of the hourly wage plus 35% overhead assuming a 40-hour fulltime employment 
salary of € 76.066 in 2011.(23) The following ratio was applied: consultation 1.0; long consultation 2.0; 
phone/emailconsultation 0.5; visit 1.5; long visit 3.0. Cost per blood sample was € 14,00.(24) For refer-
rals we allocated fixed fees per Diagnosis Treatment Combination (Diagnose Behandeling Combinatie, 
DBC): patients with albuminuria > 1 gram DBC 31.11.301 € 865,05; CKD stage 3 (eGFR 30 – 60) DBC 
31.11.324 € 711,42; CKD stage 4 or 5 (eGFR <30) DBC 31.11.325 € 1790,06.(25) A telenephrology 
consultation costed € 37,00, a consultation by telephone costed € 30,00.
supplementary data Table s4: Baseline characteristics for patients with incomplete follow-up.
Patient characteristic intervention group Control group
N = 110 N = 122
Demographics (SD)
Age in years 81.1 (12.0) 79.2 (11.7)
Male sex 37.3% 40.2%
Co morbidity
Diabetes 32.7% 42.6%
Hypertension 44.5% 54.9%
Cardiovascular disease 56.4% 63.9%
Laboratory (SD) [n]
Creatinine in µmol/l 146.7 (55.5) [n=110] 139.0 (40.8) [n=122]
eGFR in ml/min/1.73m2 37.2 (10.0) [n=110] 39.7 (9.3) [n=122]
Fasting glucose in mmol/l 6.4 (2.0) [n=68] 6.5 (1.9) [n=88]
Hemoglobin in g/dl 12.3 (2.07) [n=101] 12.6 (1.80) [n=101]
Calcium in mmol/l 2.32 (0.13) [n=32] 2.28 (0.11) [n=31]
Phosphate in mmol/l 1.04 (0.17) [n=13] 1.07 (0.20) [n=30]
PTH in pmol/l 11.82 (6.04) [n=6] 16.38 (13.66) [n=4]
Values are given as mean (SD), median (IQR) or percentages. * Comprised International Classification of 
Primary Care (ICPC) codes K74-K77,K89,K90,K92.
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absTraCT
background: GPs insufficiently follow guidelines regarding consultation and referral for 
chronic kidney disease (CKD).
objective: To identify patient characteristics and quality of care (QoC) in CKD patients 
with whom consultation and referral recommendations were not followed.
Method: A 14 month prospective observational cohort study of primary care patients 
with CKD stage 3–5. 47 practices participated, serving 207469 people. 2547 CKD 
patients fulfilled consultation criteria, 225 fulfilled referral criteria. We compared 
characteristics of patients managed by GPs with patients receiving nephrologist co-
management. We assessed QoC as adherence to monitoring criteria, CKD recognition 
and achievement of blood pressure (BP) targets.
results: Patients treated in primary care despite a consultation recommendation (94%) 
had higher eGFR values (OR 1.07; 95% CI: 1.05–1.09), were less often monitored 
for renal function (OR 0.42; 95% CI: 0.24–0.74) and potassium (OR 0.56; 95% CI: 
0.35–0.92) and CKD was less frequently recognised (OR 0.46; 95% CI: 0.31–0.68) than 
in patients with nephrologist co-management. Patients treated in primary care despite 
referral recommendation (70%) were older (OR 1.03; 95% CI:1.01–1.06) and had less 
cardiovascular disease (OR 0.37; 95% CI: 0.19–0.73). Overall, in patients solely man-
aged by GPs, CKD recognition was 50%, monitoring disease progression in 36% and 
metabolic parameters in 3%, BP targets were achieved in 51%. Monitoring of renal 
function and BP was positively associated with diabetes (OR 3.10; 95% CI: 2.47–3.88 
and OR 7.78; 95% CI: 3.21–18.87) and hypertension (OR 3.19; 95% CI: 2.67–3.82 and 
OR 3.35; 95% CI: 1.45–7.77).
Conclusion: Patients remaining in primary care despite nephrologists’ co-management 
recommendations were inadequately monitored, and BP targets were insufficiently met. 
CKD patients without cardiovascular comorbidity or diabetes require extra attention to 
guarantee adequate monitoring of renal function and BP.
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inTroduCTion
Chronic kidney disease (CKD) is a major global health problem with an increasing 
prevalence, due to aging of the population and rising incidence of hypertension and 
diabetes (1). CKD is associated with a high risk of cardiovascular morbidity, mortality and 
deterioration to end-stage renal disease (ESRD) (2). Prevention of cardiovascular events 
and preservation of kidney function requires early detection and proactive management 
of patients at high risk (3). As a consequence, care for patients with CKD necessitates a 
tailored pathway between primary and secondary care.
A high level of primary care engagement helps to ensure patient-centered and acces-
sible care. This is especially important in advanced or complicated cases of CKD, where 
collaborative care with a nephrologist should be recommended (4). The NICE guideline 
provides general practitioners (GPs) and nephrologists with recommendations on CKD 
management (5). In the Netherlands, the Dutch interdisciplinary CKD-guideline (DIG-
CKD) for primary care and nephrology describes optimal shared care for CKD patients 
(6). However, both literature from other researchers and our own group have noted 
deficiencies in the quality of care (QoC) delivered (7,8). We found that in only 8.3% of 
the patients recommendations from CKD guidelines with respect to consultation and 
referral to specialist care were followed (8). It is not known to what extent this affects 
QoC.
There are a variety of barriers to guideline adherence, of which the doctor, patient and 
practice factors play an important role. To our knowledge, little is known about the role 
of the patient and practice factors in referral and consultation decisions of GPs in CKD 
patients. Studies that specifically evaluate the impact of non-adherence to consultation 
and referral guidelines on QoC are scarce (7). We need better understanding of why 
current recommendations with respect to consultation or referral are not followed, and 
what consequences this generates for QoC. To address this issue, the primary aim of 
this study was to assess what patient and practice characteristics in CKD patients are 
associated with non-adherence to guidelines, regarding referral and consultation. The 
secondary aim was to describe QoC in patients without nephrologists’ co-management, 
despite guideline advice, and to identify patient characteristics associated with adequate 
monitoring.
MeThods
Setting
In a prospective observational cohort study we performed a secondary analysis of data 
from the CONTACT cluster randomised controlled trial [Consultation Of Nephrology 
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by Telenephrology Allows optimal Chronic kidney disease Treatment in primary care 
(Netherlands Trial Registration code 2368)]. The trial evaluated the effect of web-based 
consultation between GPs and nephrologists on in-person referral rates of adult CKD 
patients from 47 general practices, during 14 months of follow-up (Figure 1). By using 
the DIG-CKD’s classification, we included patients who met the criteria for nephrolo-
gists’ consultation or referral, based on age, eGFR and albuminuria. Patients referred 
before the start of the trial were excluded. Data was derived from GPs’ electronic medi-
cal records (EMRs). Further details about this procedure and data sources are described 
elsewhere (8,9).
figure 1. Flowchart CONTACT study.
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Classification
We defined patients who were subject to consultation or referred to nephrologist care, 
as ‘Nephrologists co-Management (NcM)’. In absence of consultation or referral, pa-
tients were defined as ‘Principal Primary Care (PPC)’.
Patient and practice characteristics
We included patient demographics, clinical data, comorbidities defined by International 
Classification of Primary Care (ICPC) codes (10) i.e. a history of diabetes (T90), hyperten-
sion (K86, K87) and cardiovascular disease (K74-K77, K89, K90, K92), and polyphar-
macy defined as 5 or more prescriptions of different chronic medications at baseline. 
Practice characteristics included type (solo-, duo- or group-practice), involvement in the 
GP-specialty-training and level of urbanization. All characteristics were recorded prior to 
the study period.
Quality of care
To determine QoC we assessed adherence to indicators as mentioned in the DIG-CKD, 
prior and during 14 months of follow-up. Indicators were:
I. Recognition of CKD in patients with an eGFR <60 ml/min/1.73m2 (separate entity on 
the EMR episode list with ICPC code U99.1 for renal impairment);
II. Monitoring of disease progression (assessment of renal function, albuminuria, glu-
cose, and blood pressure);
III. Monitoring of metabolic parameters (assessment of hemoglobin, calcium, phos-
phate, parathyroid hormone (PTH), serum albumin, and potassium); and
IV. Achievement of blood pressure (BP) targets (mean of the two latest measurements 
<140/90 mmHg).
Data analysis
The consultation and referral group differed in CKD severity, therefore we analysed 
outcomes separately. Patients lost to follow-up were excluded. We performed a mul-
tilevel multivariate logistic regression model to identify associated patient and practice 
characteristics (PROC GLIMMIX in SAS) due to the hierarchical structure of our study 
(patients nested within practices). We did the multilevel multivariate logistic regression 
analysis with all variables from the univariate multilevel analysis with P values <0.20. 
Only variables with less than 20% missing values were included for analysis. In a back-
ward elimination procedure, we sequentially removed the associated characteristic with 
the highest P values until all remaining variables were significant at the P < 0.05 level. 
To determine associations with monitoring, we additionally analysed the monitoring of 
both renal function and blood pressure as one dependent variable. We used descriptive 
statistics to assess adherence to process and outcome indicators (SPSS version 20.0).
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resulTs
Study population
47 practices participated in the CONTACT study, serving a population of 207469 people. 
3084 patients were eligible for inclusion. 312 patients were excluded, mostly due to 
passing away and moving, which left 2772 patients for analysis (Fig. 1). Of these, 2547 
patients fulfilled the criteria for consultation, and 225 patients for referral.
Patient and practice characteristics associated with principal primary care
Where the guideline advised nephrologists’ consultation in 2547 patients, actual ne-
phrologists co-management occurred in 149 patients (5.9%) (NcM group), leaving 2398 
patients (94.1%) in the PPC group (Table 1). In the univariate analysis, PPC patients were 
younger, had less hypertension, higher eGFR values, lower creatinine levels and had a 
lower prevalence of polypharmacy. GPs registered CKD less in the PPC compared to 
the NcM group (35.2% versus 51.0%). In PPC patients, renal function (76.1% versus 
91.3%), albuminuria (36.1% versus 61.1%), fasting glucose (54.9% versus 74.5%), 
blood pressure (62.9% versus 87.2%), calcium (9.4% versus 16.8%), potassium 
(58.6% versus 81.2%) and overall disease progression (31.2% versus 54.4%) were 
less monitored than in patients with nephrologists’ co-management. In the multilevel 
logistic regression analysis eGFR was positively associated with PPC (OR 1.07; 95% 
CI: 1.05–1.09) (Table 3). This means patients with a higher eGFR were more likely to 
receive PPC only. PPC was negatively associated with monitoring of renal function (OR 
0.42; 95% CI: 0.24–0.74), monitoring potassium (OR 0.56; 95% CI: 0.35–0.92) and 
recognition of CKD (OR 0.46; 95% CI: 0.31–0.68). This means patients in PPC were less 
often monitored for renal function and potassium, and less CKD was recognised than in 
patients with nephrologist co-management.
Where the guideline advised nephrologists referral in 225 patients, actual nephrolo-
gists co-management occurred in 67 patients (29.8%), leaving 158 patients (70.2%) in 
the PPC group (Table 2). In the multilevel logistic regression analysis patients in PPC were 
more likely to be older (OR 1.03; 95%CI 1.01–1.06) and less likely to have cardiovascular 
disease (CVD; OR 0.37; 95%CI 0.19–0.73) (Table 3). None of the practice characteristics 
were significantly associated with PPC.
Quality of care in PPC patients despite consultation or referral 
recommendation
In those PPC patients where guideline recommendations should have led to a consulta-
tion, GPs recognised CKD in 50.1% (1201/2398), followed the guideline for monitor-
ing disease progression in 34.8% (834/2398) and for metabolic parameters in 3.2% 
(77/2398). BP targets (<140/90 mmHg) were achieved in 52.1% (Table 4). Monitoring 
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of renal function and BP was associated with a history of diabetes (OR 3.10; 95% CI: 
2.47–3.88) and hypertension (OR 3.19; 95% CI: 2.67–3.82) (Table 5).
In PPC patients where guideline recommendations should have led to a referral, GPs 
recognised CKD in 43.7% (69/158), followed the guideline for monitoring disease pro-
gression in 46.2% (73/158) and for monitoring metabolic parameters in 2.5% (4/158). 
BP targets (<140/90 mmHg) were achieved in 39.7% (Table 4). Monitoring of renal 
function and BP was positively associated with age (OR 1.03; 95% CI: 1.00–1.06), a 
history of diabetes (OR 7.78; 95% CI: 3.21–18.87) and hypertension (OR 3.35; 95% CI: 
1.45–7.77) (Table 5).
Table 1. Patient and practice characteristics at baseline of CKD patients with a consultation recommen-
dation (n = 2547) treated in primary care (PPC) and patients treated with nephrology co-management 
(NcM) between April 2011 and June 2012
baseline patient characteristics
Group: consultation of nephrologist according to the 
guideline
overall 
[n = 2547]
ncM 
[n = 149]*
PPC 
[n = 2398]*
Multilevel 
P value
Demographics
 Age in years, mean (SD) 65.6 (12.8) 69.6 (11.5) 65.3(12.8) <0.001
 Male sex, n (%) 844 (33.1%) 46 (30.9%) 798 (33.3%) 0.313
Co morbidity, n (%)
 Diabetes 606 (23.8%) 43 (28.9%) 563 (23.5%) 0.134
 Hypertension 1377 (54.1%) 101 (67.8%) 1276 (53.2%) 0.003
 Cardiovascular disease 765 (30.0%) 49 (32.9%) 716 (29.9%) 0.397
Laboratory, mean (SD) [n]
 Creatinine in µmol/l
116 (23) 
[n = 2546]
121(21) 
[n = 149]
115 (23) 
[n = 2397]
0.003
 eGFR in ml/min/1.73m2
48.4 (8.8) 
[n = 2547]
44.8 (7.7) 
[n = 149]
48.6 (8.8) 
[n = 2398]
<0.001
 Fasting glucose in mmol/l
6.2 (1.6) 
[n = 1851]
6.3 (1.6) 
[n = 127]
6.2 (1.6) 
[n = 1724]
0.063
 Potassium in mmol/l
4.3 (0.5) 
[n = 2029]
4.3 (0.4) 
n = 138]
4.3 (0.5) 
[n = 1891]
0.941
 Hemoglobin in g/dl
13.6 (1.5) 
[n = 1885]
13.4 (1.4) 
[n = 97]
13.6 (1.5) 
[n = 1788]
0.144
Urine, n (%) [n measured]
 Moderate albuminuria
216 (17.9%)
[n = 1206]
24 (22.9%)
[n = 101]
192 (17.4%)
[n = 1101]
0.071
Physical examination, mean (SD)
 Diastolic blood pressure in mm Hg
80 (10) 
[n = 1951]
79 (9) 
[n = 138]
80 (10) 
[n = 1813]
0.195
 Systolic blood pressure in mm Hg
140 (17) 
[n = 1950]
142 (17) 
[n = 138]
140 (17) 
[n = 1812]
0.144
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baseline patient characteristics
Group: consultation of nephrologist according to the 
guideline
overall 
[n = 2547]
ncM 
[n = 149]*
PPC 
[n = 2398]*
Multilevel 
P value
Polypharmacy
 Prescription of ≥5 drugs in 2010, n (%) 637 (25.0%) 48 (32.2%) 589 (24.6%) 0.046
Baseline practice characteristics
Practice type, n (%)
 Solo 182 (7.1%) 10 (6.7%) 172 (7.3%)
0.995 Duo 613 (24.1%) 46 (30.9%) 567 (23.6%)
 Group 1752 (68.8%) 93 (62.4%) 1659 (69.2%)
GP specialty training practice, n (%) 1668 (65.5%) 125 (83.9%) 1543 (64.3%) 0.760
Urban location practice, n (%) 1840 (72.2%) 90 (60.4%) 1750 (73.0%) 0.869
Baseline quality of care indicators
Recognition of CKD**n (%) [n measured]
Recognition of CKD 921 (36.2%) 76 (51.0%) 845 (35.2%) <0.001
Monitoring of disease progression n (%)***
 Complete 828 (32.5%) 81 (54.4%) 747 (31.2%) <0.001
   Renal function 1960 (77.0%) 136 (91.3%) 1824 (76.1%) <0.001
   Albuminuria 957 (37.6%) 91 (61.1%) 866 (36.1%) <0.001
   Fasting glucose 1428 (56.1%) 111 (74.5%) 1317 (54.9%) 0.000
   Blood pressure (syst and/or diast) 1638 (64.3%) 130 (87.2%) 1508 (62.9%) <0.001
Monitoring of metabolic parameters
 Complete 61 (2.4%) 4 (2.7%) 57 (2.4%) 0.443
   Hemoglobin 1188 (46.6%) 71 (47.7%) 1117 (46.6%) 0.465
   Calcium 250 (9.8%) 25 (16.8%) 225 (9.4%) 0.017
   Phosphate 204 (8.0%) 21 (14.1%) 183 (7.6%) 0.020
   PTH 96 (3.8%) 11 (7.4%) 85 (3.5%) 0.451
   Serum albumin 147 (5.8%) 13 (8.7%) 134 (5.6%) 0.372
   Potassium 1526 (59.9%) 121 (81.2%) 1405 (58.6%) <0.001
Blood pressure targets****
 <140/90 mmHg
793 (48.4%) 
[n = 1638]
56 (43.1%) 
[n = 130]
737 (48.9%) 
[n = 1508]
0.259
 <130/80 mmHg
293 (17.9%) 
[n = 1638]
20 (15.4%) 
[n = 130]
273 (18.1%) 
[n = 1508]
0.312
* NcM: Nephrologists Co-Management. PPC: Principal Primary Care. Measured after 14 months of fol-
low up.
** Percentage calculated with patients with eGFR <60 ml/min/1.73m2 as denominator.
*** Renal function: eGFR (ml/min/1.73m2) or serum creatinine. Albuminuria: albumin creatinine ratio 
or urine albumin.
**** The percentages show the achieved blood pressure targets divided by the number of blood pres-
sure measurements.
Process and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the preceding 14 months is shown.
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Table 2. Patient and practice characteristics at baseline of CKD patients with a referral recommendation 
(n = 225) treated in primary care (PPC) and patients treated with nephrology co-management (NcM) 
between April 2011 and June 2012
baseline patient characteristic
Group: referral to nephrologist according to the guideline
overall
[n = 225]
ncM
[n = 67]*
PPC
[n = 158]*
Multilevel
P value
Demographics
 Age in years (SD) 70.7 (14.0) 67.9 (12.0) 71.9 (14.6) 0.054
 Male sex, n (%) 109 (48.4%) 30 (44.8%) 79 (50.0%) 0.475
Co morbidity, n (%)
 Diabetes 120 (53.3%) 39 (58.2%) 81 (51.3%) 0.393
 Hypertension 118 (52.4%) 39 (58.2%) 79 (50.0%) 0.300
 Cardiovascular disease 114 (50.7%) 42 (62.7%) 72 (45.6%) 0.066
Laboratory, mean (SD)
 Creatinine in µmol/l
127 (50) 
[n = 225]
123 (40.0) 
[n = 67]
128 (53) 
[n = 158]
0.490
 eGFR in ml/min/1.73m2
45.2 (14.1) 
[n = 225]
45.3 (12.3) 
[n = 67]
45.2 (14.8) 
[n = 158]
0.993
 Fasting glucose in mmol/l
7.0 (2.4) 
[n = 190]
6.7 (1.8) [n = 60]
7.2 (2.6) 
[n = 130]
0.244
 Potassium in mmol/l
4.4 (0.5) 
[n = 197]
4.2(0.5) [n = 60]
4.4 (0.5) 
[n = 137]
0.120
 Hemoglobin in g/dl
13.1 (1.9) 
[n = 162]
13.1 (2.4) 
[n = 43]
13.0 (1.6) 
[n = 119]
0.885
Urine, n (%) [n measured]
 Moderate albuminuria
14 (8.4%) 
[n = 167]
6 (11.1%) [n 
= 54]
8 (7.1%) 
[n = 133]
0.359
 Severe albuminuria
123 (73.7%) 
[n = 167]
38 (70.4%) [n 
= 54]
85 (75.2%) 
[n = 133]
0.503
Physical examination, mean (SD)
 Diastolic blood pressure in mm Hg
79 (11) 
[n = 191]
81(12) [n = 61]
78 (10) 
[n = 130]
0.186
 Systolic blood pressure in mm Hg
145 (20) 
[n = 191]
146 (21) [n = 61]
145 (19) 
[n = 130]
0.769
Polypharmacy
 Prescription of ≥ 5 drugs in 2010, n (%) 97 (43.1%) 34 (50.8%) 63 (39.9%) 0.135
Baseline practice characteristics
Practice type, n (%)
 Solo 28 (12.4%) 4 (6.0%) 24 (15.2%)
0.817 Duo 68 (30.2%) 25 (37.3%) 43 (27.2%)
 Group 129 (57.3%) 38 (56.7%) 91 (57.6%)
GP specialty training practice, n (%) 152 (67.6%) 45 (67.2%) 107 (67.7%) 0.895
Urban location practice, n (%) 171 (76.0%) 53 (79.1%) 118 (74.7%) 0.548
Baseline quality of care indicators
Recognition of CKD**n (%) [n measured]
 Recognition of CKD
70 (45.5%) 
[n = 154]
24 (48%) 
[n = 50]
46 (44.2%) 
[n = 104]
0.976
Monitoring of disease progression n (%)***
 Complete 109 (48.4%) 35 (52.2%) 74 (46.8%) 0.496
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baseline patient characteristic
Group: referral to nephrologist according to the guideline
overall
[n = 225]
ncM
[n = 67]*
PPC
[n = 158]*
Multilevel
P value
   Renal function 188 (83.6%) 57 (85.1%) 131 (82.9%) 0.678
   Albuminuria 125 (55.6%) 42 (62.7%) 83 (52.5%) 0.177
   Fasting glucose 161 (71.6%) 52 (77.6%) 109 (69.0%) 0.206
   Blood pressure (syst and/or diast) 161 (71.6%) 50 (74.6%) 111 (70.3%) 0.591
Monitoring of metabolic parameters
 Complete 4 (1.8%) 2 (3.0%) 2 (1.3%) 0.388
   Hemoglobin 113 (50.2%) 28 (41.8%) 85 (53.8%) 0.125
   Calcium 37 (16.4%) 11 (16.4%) 26 (16.5%) 0.989
   Phosphate 22 (9.8%) 9 (13.4%) 13 (8.2%) 0.246
   PTH 6 (2.7%) 3 (4.5%) 3 (1.9%) 0.288
   Serum albumin 22 (9.8%) 8 (11.9%) 14 (8.9%) 0.479
   Potassium 160 (71.1%) 52 (77.6%) 108 (68.4%) 0.171
Blood pressure targets****
 <140/90 mmHg
60 (37.3%) 
[n = 161]
19 (38.0%) 
[n = 50]
41 (36.9%) 
[n = 111]
0.902
 <130/80 mmHg
28 (17.4%) 
[n = 161]
11 (22.0%) 
[n = 50]
17 (15.3%) 
[n = 111]
0.305
* NcM: Nephrologists Co-Management. PPC: Principal Primary Care. Measured after 14 months of fol-
low up.
** Percentage calculated with patients with eGFR <60 ml/min/1.73m2 as denominator.
*** Renal function: eGFR (ml/min/1.73m2) or serum creatinine. Albuminuria: albumin creatinine ratio 
or urine albumin.
**** The percentages show the achieved blood pressure targets divided by the number of blood pres-
sure measurements.
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care 
and nephrology. For each indicator, performance in the preceding 14 months is shown.
Table 3. Odds ratios of baseline patient and process characteristics for treatment of CKD in principal 
primary care; consultation (n = 2547) and referral group (n = 225)
Variable Consultation group or (95%Ci) referral group or (95%Ci)
Patient characteristics
 eGFR in ml/min/1.73m2 1.07 (1.05–1.09)
 Age in years 1.03 (1.01–1.06)
 Cardiovascular disease 0.37 (0.19–0.73)
Process characteristics
 Monitoring renal function* 0.42 (0.24–0.74)
 Monitoring potassium 0.56 (0.35–0.92)
 Recognition of CKD 0.46 (0.31–0.68)
* Renal function: eGFR (ml/min/1.73m2) or serum creatinine.
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Table 4. Quality of care in CKD patients treated in principal primary care
outcome quality of care indicators
overall Consultation group referral group
[n = 2556] PPC [n = 2398]* PPC [n = 158]*
Recognition of CKD**
 Recognition of CKD
1270 (49.7%) 
[n = 2556]
1201 (50.1%) 
[n = 2398]
69 (43.7%) 
[n = 158]
Monitoring of disease progression n (%)
 Complete 907 (35.5%) 834 (34.8%) 73 (46.2%)
   Renal function*** 1819 (71.2%) 1683 (70.2%) 136 (86.1%)
   Albuminuria 1040 (40.7%) 955 (39.8%) 85 (53.8%)
   Fasting glucose 1372 (53.7%) 1273 (53.1%) 99 (62.7%)
   Blood pressure (syst and/or diast) 1650 (64.5%) 1534 (64.0%) 116 (73.4%)
Monitoring of metabolic parameters n (%)
 Complete 81 (3.2%) 77 (3.2%) 4 (2.5%)
   Hemoglobin 1051 (41.1%) 975 (40.7%) 76 (48.1%)
   Calcium 309 (12.1%) 289 (12.1%) 20 (12.7%)
   Phosphate 259 (10.1%) 245 (10.2%) 14 (8.9%)
   PTH 130 (5.1%) 125 (5.2%) 5 (3.2%)
   Serum albumin 218 (8.5%) 206 (8.6%) 12 (7.6%)
   Potassium 1492 (58.4%) 1381 (57.6%) 111 (70.3%)
Blood pressure targets****
 <140/90 mmHg
845 (51.2%) 
[n = 1650]
799 (52.1%) 
[n = 1534]
46 (39.7%) 
[n = 116]
 <130/80 mmHg
332 (20.1%) 
[n = 1650]
319 (20.8%) 
[n = 1534]
13 (11.2%) 
[n = 116]
* PPC: Principal Primary Care: patients did not receive nephrologists consultation nor referral
** Percentage calculated with patients with eGFR <60 ml/min/1.73m2 as denominator
*** Renal function: eGFR (ml/min/1.73m2) or serum creatinine. Albuminuria: albumin creatinine ratio 
or urine albumin.
**** The percentages show the achieved blood pressure targets divided by the number of blood pres-
sure measurements.
Process and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the 14 months of the CONTACT trial is shown.
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Table 5. Relationship between patient characteristics and monitoring of renal function and systolic blood 
pressure in the principal primary care group (95% CI). Significant odds ratios, p < 0.05, n = 2398 (con-
sultation group) and n = 158 (referral group)
Variable
Consultation group referral group
PPC* PPC*
Monitoring of renal function** and 
blood pressure*** or (95%Ci)
Monitoring of renal function** and 
blood pressure*** or (95%Ci)
Patient characteristics
 Age 1.03 (1.00–1.06)
 Diabetes 3.10 (2.47–3.88) 7.78 (3.21–18.87)
 Hypertension 3.19 (2.67–3.82) 3.35 (1.45–7.77)
* PPC: Principal Primary Care: patients did not receive nephrologists consultation nor referral.
** Renal function: eGFR (ml/min/1.73m2) or serum creatinine.
*** Blood pressure: measurement of systolic and/or diastolic blood pressure.
disCussion
Major findings
Overall, adherence by GPs to the guideline recommendations regarding a consultation 
or referral was low. As a consequence, the vast majority of CKD patients were only 
managed in primary care, without nephrologists’ co-management. These patients were 
less frequently assigned with a CKD diagnosis in their EMR than patients who received 
nephrologists’ co-management. Factors related to management in primary care, despite 
a consultation recommendation, were higher eGFR values, lack of CKD recognition and 
absence of monitoring renal function and potassium. In the group of patients advised 
with a referral, patients managed in primary care were older and had less cardiovascular 
disease. Furthermore, GPs did not sufficiently monitor disease progression and meta-
bolic parameters. Monitoring of renal function and blood pressure occurred more often 
in patients with a history of diabetes or hypertension.
Strengths and limitations
To our knowledge, this study is one of the very few to investigate factors related to low 
levels of nephrologists co-management and to determine subsequent QoC.
The consultation and referral group differed in CKD severity. For that reason we 
analysed the groups separately. The distinction enabled targeted results of both groups. 
Furthermore, we performed a multilevel analysis taking possible differences between 
the general practices into account.
Several limitations should be considered. First, we included patients in the study based 
on a single creatinine and albumin assessment, whereas two measurements are advised. 
Thus, the approach used in this study may have overestimated the number of CKD 
patients. Second, we used data from practices participating in an RCT, which could have 
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led to selection bias of motivated GPs and overestimation of QoC. Also, the number of 
referrals and consultations could be underestimated, as patients who had been referred 
before start of the trial were not included. Furthermore, follow-up length and number 
of patients did not allow endpoints like mortality or progression to ESRD. It was not 
possible to compare QoC between patients in PPC and NcM as we did not have access 
to data from the latter.
Comparison with existing literature
Patient characteristics related to consultation or referral
A similar study design found predictors for active nephrologists co-management; 
younger age, presence of hypertension and male gender (7). In our study, age also 
played a role in the referral process. The effect of age varied between the consultation 
and referral group. In the consultation group, PPC patients were younger compared to 
patients who received nephrologists co-management. This is remarkable, since younger 
patients with impaired renal function are more likely to have kidney pathology than 
older patients. In the referral group, PPC patients were older and age was positively 
associated with PPC. Other studies also found associations between higher age and 
non-referral (11,12). Based on patients characteristics and treatments needs, Wonnacot 
et al. argued there is no evidence to assume that patients over 75 years old have less 
need for nephrologists care than younger patients (13).
The eGFR value indicates a need for GPs to ask for the advice of nephrologists. This 
is confirmed by a British study in which patients without a referral showed higher eGFR 
values (28.5 ml/min/1.732) than the total CKD population (23.4 ml/min/1.732) (12).
Patients with diabetes or hypertension often received nephrologists’ co-management. 
Other research shows inconsistencies about the association between comorbidity and 
nephrologists’ referral (11,14). Also, cardiovascular disease is related to nephrologists’ 
co-management. In our previous study (9) CKD-patients in primary care with cardio-
vascular disease received less monitoring than patients without cardiovascular disease, 
suggesting monitoring was left to the discretion of the cardiologists.
Quality of care in patients without nephrologists’ co-management.
CKD recognition in our study was low. This is in line with other studies where recogni-
tion varied between 27.1% and 48.1% (15,16). The ICPC code U99.1 for impaired renal 
function was more often applied to patients who received nephrologists co-management 
(7,16). It is unclear whether there is a causal relationship between the absence of CKD 
recognition by the GPs and not involving nephrologists, despite guideline advice. This 
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could be due to GPs recognising CKD but having reasons for not assigning a diagnosis 
and seeking collaboration with the nephrologist.
Another study yielded approximately the same degree of monitoring of disease 
progression and metabolic parameters (17). A US study supported that GPs do not 
sufficiently monitor metabolic parameters (7). Regarding blood pressure targets, Samal 
et al. demonstrated 71% of the patients had blood pressure below 140/90 mmHg and 
45% below 130/90 mmHg (17). These outcomes are better compared to ours.
Implications for research and/or practice
We assumed that GPs would provide adequate care for CKD patients managed in 
primary care, despite a referral or consultation recommendation in the interdisciplinary 
guideline. This study unfortunately shows more of the opposite. GPs often did not pro-
vide adequate care as recommended by the guideline. This raises the question ‘why?’. 
Future qualitative research could reveal GPs’ perspectives on CKD management and 
guideline recommendations. When GPs have good reasons for not seeking nephrolo-
gists involvement, they must still ask themselves whether QoC is sufficiently guaranteed, 
especially in case of higher age, higher eGFR or absence of diabetes or hypertension.
In the Netherlands, care for patients with chronic conditions is standardized in chronic 
care programs (18) wherein GPs have a leading role and a proactive approach. Much of 
the observed CKD management was most likely performed as part of care for regular 
cardiovascular disease or diabetes. In this approach there is a lacuna for CKD patients 
without comorbidity, as they are not included in current chronic care programs.
Embedding CKD care in a model comparable to that of diabetes or hypertension 
would be a good chance to improve monitoring and treatment of CKD patients. There 
is a risk in organizing a variety of pathways for patients with multi morbidity. In case 
of multiple comorbidities, care models should be integrated with each other to ensure 
patient centered chronic care (19).
CKD recognition may be regarded as a proxy for CKD awareness (20). Strategies to 
increase awareness may be sought after in education and in terms of financial sup-
port. Furthermore, electronic feedback from laboratory results in the electronic medical 
records could identify CKD patients. Also GPs could check periodically if they have 
overlooked CKD patients.
ConClusion
Despite the existence of an interdisciplinary guideline, in the Netherlands nephrologists’ 
co-management level is low. QoC for patients remaining in primary care, despite a 
consultation or referral recommendation, is exceedingly suboptimal. This is especially 
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the case in CKD patients not already embedded in a Chronic Care Model for diabetes or 
cardiovascular disease. We observed an alarming low rate of renal function and blood 
pressure monitoring. For this reason, primary care CKD patients without cardiovascular 
comorbidity or diabetes require extra efforts to guarantee adequate monitoring of renal 
function and blood pressure.
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absTraCT
Purpose: Most CKD patients are managed in primary care. Quality of care (QoC) is 
not optimal and should be improved to prevent further morbidity. Our objective was 
to assess whether a multi-faceted intervention of FP education coupled with practice 
feedback leads to higher QoC compared to usual care practices.
Methods: A nonrandomised controlled trial using data from patients with CKD stage 3 
in 24 intervention (n=1160) and 109 control practices (n=3559). QoC outcome measures 
were: CKD documentation, achievement of blood pressure targets <140/90 mmHg and 
<130/80 mmHg, change in albuminuria status, monitoring of CKD progression and 
monitoring of metabolic parameters.
results: CKD documentation increased in both groups: an absolute gain of 17.7% in 
the intervention practices and 1.5% in the controls, resulting in a significant difference 
in final CKD documentation of 57.5% against 51.3%, OR 17.49 (95% CI 8.81 – 34.72). 
Blood pressure targets were equally met, yet in the intervention group patients less fre-
quently progressed to severe albuminuria: 1.9% against 4.1%, OR 0.27 (0.09 – 0.85). 
Monitoring rates were significantly higher in the intervention group and the difference 
was most notable in monitoring for metabolic parameters: OR 4.20 (95% CI 2.07 – 
8.50).
Conclusions: The simple multi-faceted intervention of FP education coupled with prac-
tice feedback in our study increased monitoring in CKD patients Of greatest relevance 
was the increase in CKD documentation.
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inTroduCTion
Chronic kidney disease (CKD) is a serious medical condition with an estimated global 
prevalence of between 11 to 13%.(1) The majority of CKD management is carried out in 
primary care and FPs play a key role in providing care for this patient group.(2) However, 
research data shows that primary care CKD management may not be optimal, especially 
regarding CKD awareness among FPs, achievement of blood pressure targets and moni-
toring patients for albuminuria.(2, 3) Especially CKD awareness is of primary importance, 
since it is a trigger for monitoring and treatment.(3, 4) Hypertension and albuminuria 
are major and modifiable risk factors for CKD progression and cardiovascular complica-
tions. Controlling blood pressure and reducing urinary albumin excretion are essential 
to preserve renal function and reduce subsequent cardiovascular complications.(5, 6)
We recently performed a cluster randomized controlled trial to evaluate if an e-con-
sultation platform, that allowed low-barrier FP initiated consultation of a nephrologist, 
led to lower referral rates. In this trial all FPs were educated on CKD management and 
received a list of their CKD patients.(7) We found no significant difference in outcomes 
and considered the possibly of contamination bias, assumed to be a result of the mutual 
interventions. The aim of this study is to determine whether FP education and providing 
practices with a list of their CKD patients had a positive effect on quality of care (QoC) 
compared to routine usual care.
MeThods
Setting
In this secondary analysis of patient data from the CONTACT trial (Consultation Of 
Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in 
primary care, Netherlands Trial Registration code 2368) we selected the control arm 
which consisted of 24 non-academic family practices.(7) We will refer to this as the 
Education and Feedback (E&F) group. The FPs in this group were educated by a FP 
and a nephrologist on CKD management and on the content of the interdisciplinary 
CKD-guideline for primary care and nephrology during a two hour meeting.(8) The 
following subjects were addressed: CKD diagnosis, blood pressure treatment, metabolic 
complications, medication safety, and consultation and referral recommendations as 
stated in the guideline.
Next to the educational intervention, the practices in the E&F group also received 
individual feedback, consisting of a list of their patients who met the consultation and 
referral criteria. These patients were not necessarily on the practices’ CKD register, but 
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the population was selected based on laboratory data from the electronic medical record 
(EMR). The practices were free to follow-up on these recommendations.
We compared the E&F intervention to routine usual care. For this comparison we 
selected 109 family practices from the General Practitioner database from the depart-
ment of Primary and Community Care of the Radboud university medical center. These 
practices did not participate in the CONTACT trial nor received specific education or 
feedback. The practice characteristics are detailed in table 1.
Patient selection
The Dutch interdisciplinary CKD-guideline for primary care and nephrology provides FPs 
with advice to decide which healthcare setting is best suited for providing patients the 
required care based on age, estimated glomerular filtration rate (eGFR) and albuminuria 
status.(8) These settings are: treatment in primary care, consultation of a nephrologist 
without patient referral, and referral to secondary care. We included adult patients who 
met the criteria for consultation without referral during a 15 month baseline period: 
(a) patients aged ≥ 65 with an eGFR 30-45 ml/min/1.73m2 and no severe albuminuria; 
(b) patients aged < 65 with an eGFR 45-60 ml/min/1.73m2 and no severe albuminuria. 
This matches CKD stages G3a A1-2 and G3b A1-2 from the Kidney Disease: Improving 
Global Outcomes (KDIGO) CKD Work Group CKD guideline released in 2012.(9) We 
used a single laboratory reported creatinine value and estimated GFR with the Modifica-
tion of Diet in Renal Disease (MDRD) equation. Patient age was determined on the 
baseline eGFR date.(10) We used a single measurement to determine albuminuria status 
and in congruence with the guideline we defined moderate albuminuria as an urinary 
albumin to creatinine ratio (ACR) of 2.5–25 mg/mmol in men and 3.5–35 mg/mmol in 
women. Higher ratios reflected severe albuminuria. If an ACR was unavailable, we used 
urine albumin concentration with cut-off values >20–200 mg/l for moderate and >200 
mg/l for severe albuminuria. The follow-up period was 14 months, April 2011 to June 
2012. We excluded patients if follow-up data were not available.
Outcomes
The primary QoC outcome was recognition of CKD defined as documentation of de-
creased renal function as a separate diagnosis on the EMR episode list with International 
Classification of Primary Care (ICPC) code U99.1 for renal impairment.
Further QoC outcome indicators were achievement of blood pressure targets <140/90 
mmHg and <130/80 mmHg using the mean of the two latest measurements, and 
change in albuminuria prevalence.
QoC process indicators were CKD monitoring criteria which we derived from the 
interdisciplinary CKD-guideline for primary care and nephrology. Included indicators 
were: monitoring of disease progression (assessment of eGFR or serum creatinine, 
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albuminuria, glucose, and blood pressure) and monitoring of metabolic parameters 
(assessment of hemoglobin, calcium, phosphate, parathyroid hormone (PTH), serum 
albumin, and potassium).
Analysis
Annual monitoring is recommended, but in practice monitoring can take place outside 
this 12 month timeframe. Therefore, for both groups, we applied a 15 month timeframe 
for baseline results and used the entire follow-up duration of 14 months for the final 
outcomes. Because of the hierarchical structure of our data (patients nested within 
practices) the analysis were based on an univariate multilevel logistic model using SPSS 
version 22 (IBM PASW statistics 22). In the model we corrected for clustering at practice 
level and for baseline QoC outcomes. We used descriptive statistics for the comparison 
of baseline characteristics. We considered a p-value <0.05 statistically significant.
Ethical approval
Ethical approval was not required according to the accredited Medical Research Ethics 
Committee Arnhem/Nijmegen registration number 2010/187. This study complies with 
the Code of Conduct for Health Research, which was approved by the Dutch Data 
Protection Authorities (College Bescherming Persoonsgegevens, CBP) for conformity 
with the applicable Dutch privacy legislation.
resulTs
Study population and practices
We included 1160 patients in the E&F group and 3559 patients in the usual care control 
group (Figure 1). The study populations were comparable in terms of baseline charac-
teristics and CKD stages (Table 2).
Outcomes
CKD documentation in the EMR episode list increased in both groups: an absolute gain 
of 17.7% for the E&F practices and 1.5% for the controls. There was a significant differ-
ence in final CKD documentation in favour of the intervention group, 57.5% (95% CI 
54.7 - 60.4%) against 51.3% (95% CI 49.7 – 53.0%), OR 17.49 (95% CI 8.81 – 34.72).
Achievement of blood pressure targets also rose in both groups: for the target <140/90 
mmHg from 46.5% to 54.0% in the intervention practices and 46.8% to 52.2% in the 
control practices. This difference was not significant between the groups.
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The prevalence of moderate and severe albuminuria increased in both groups. How-
ever, the latter increased less in the E&F group: 1.9% compared to 4.1%, OR 0.27 
(0.09 – 0.85).
Of all disease progression parameters, renal function and blood pressure had the 
highest monitoring rates in both groups: 78.8% and 71.9% in the E&F group against 
74.2% and 62.7% in the control group. The overall rate of monitoring disease progres-
sion was significantly higher in the E&F group, 41.6% (95% CI 38.7 - 44.4%) against 
31.1% (95% CI 29.6 - 32.6%) in the control group, OR 1.58 (95% CI 1.15 – 2.18).
For metabolic parameters monitoring rates for calcium, phosphate and PTH doubled 
or nearly doubled in the E&F group. This resulted in a significant difference in final 
outcomes compared with the control group. Complete monitoring of metabolic pa-
rameters amounted to 7.1% (95% CI 5.6 – 8.6%) in the E&F group and 1.5% (95% CI 
1.1 - 1.9%) in the control group, OR 4.20 (95% CI 2.07 – 8.50).
Further details on quality of care are presented in table 3.
figure 1. Flowchart
Low risk: age < 65 and CKD stage 1-2, age ≥ 65 and CKD stage 1-3a .
Moderate risk: age < 65 and CKD stage 3a, age ≥ 65 and CKD stage 3b.
High risk: age < 65 and CKD stage 3b-5, age ≥ 65 and CKD stage 4-5, severe albuminuria.
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Table 1. Practice characteristics
Education & Feedback Group (n=24) Usual Care control Group (n=109)
Practice population 4908 4046
Practice type
Solo 2 9
Duo 9 47
Group 13 53
Vocational training practice 17 59
Practice location
Urban 18 52
Rural 6 57
Table 2. Baseline patient characteristics
Education & Feedback 
group [n=1160]
Usual Care control group 
[n=3559]
p-value
Demographics (SD)
Age in years 65.8 (12.7) 67.3 (13.1) 0.001*
Male sex 32.5% 33.4% 0.590**
CKD stage 3a 58.6% [n=680] 53.4% [n=1902] 0.002**
CKD stage 3b 41.4% [n=480] 46.6% [n=1657] 0.002**
Co morbidity
Diabetes 26.9% 27.8% 0.545**
Hypertension 59.4% 60.9% 0.369**
Cardiovascular disease 32.4% 36.2% 0.020**
Laboratory (SD)
Creatinine in µmol/l 116 (23) [n=1159] 118 (23) [n=3555] 0.053*
eGFR in ml/min/1.73m2 48 (9) [n=1160] 47 (9) [n=3559] 0.001*
Fasting glucose in mmol/l 6.2 (1.5) [n=803] 6.2 (1.6) [n=2476] 0.683*
Hemoglobin in g/dl 13.5 (1.5) [n=663] 13.4 (1.5) [n=2090] 0.064*
Calcium in mmol/l 2.36 (0.14) [n=135] 2.33 (0.11) [n=348] 0.015*
Phosphate in mmol/l 1.0 (0.2) [n=114] 1.0 (0.2) [n=270] 0.916*
PTH in pmol/l 7.6 (4.4) [n=61] 7.4 (4.7) [n=117] 0.723*
Potassium in mmol/l 4.2 (0.4) [n=858] 4.3 (0.5) [n=2733] < 0.001*
Albumin in g/l 39.0 (4.6) [n=83] 39.3 (6.0) [n=246] 0.663*
Urine (first and third quartile)
Albumin urine in mg/l 17 (3 – 13) [n=280] 20 (4 – 17) [n=825] < 0.001***
Albumin/creatinine ratio 2.6 (0.9 – 2.2) [n=477] 2.9 (0.9 – 2.5) [n=1484] 0.005***
Physical examination (SD)
Systolic blood pressure in mmHg 140.3 (17.3) [n=860] 140.0 (17.6) [n=2374] 0.694*
Diastolic blood pressure in mmHg 79.9 (9.6) [n=861] 78.8 (10.0) [n=2377] 0.005*
* unpaired t-test. ** Fisher’s exact test. *** Mann-Whitney U test.
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Table 3. Quality of care in Education & Feedback practices and Usual Care control practices at T0 and T1
Quality of Care Education & Feedback 
Group
(n=1160)
Usual Care control Group
(n=3559)
p-value* Odds ratio*
(95% CI)
T0 difference T1 T0 difference T1
Ckd 
documentation
in eMr
39.8% 
(462)
+ 17.7% 57.5% 
(667)
49.8% 
(1774)
+ 1.5% 51.3% 
(1827)
0.000 17.49 (8.81 – 
34.72)
blood pressure targets**
< 140/90 mmHg 46.5% 
(400)
+ 7.5% 54.0% 
(450)
46.8% 
(1112)
+ 5.4% 52.2% 
(1164)
0.648 1.05 (0.85 – 1.30)
< 130/80 mmHg 16.6% 
(143)
+ 3.4% 20.0% 
(167)
18.3% 
(436)
+ 3.3% 21.6% 
(481)
0.917 0.99 (0.76 – 1.27)
albuminuria status***
No albuminuria 84.0% 
(458)
- 3.6% 80.4% 
(434)
77.9% 
(1163)
- 5.5% 72.4% 
(996)
Moderate 
albuminuria
16.0% 
(87)
+ 1.8% 17.8% 
(96)
22.1% 
(329)
+ 1.3% 23.4% 
(322)
0.546 0.89 (0.62 – 1.29)
Severe albuminuria 0.0% (0)+ 1.9% 1.9% 
(10)
0 + 4.1% 4.1% 
(57)
0.025 0.27 (0.09 – 0.85)
Monitoring disease progression
Renal function 100.0% 
(1160)
- 21.2% 78.8% 
(914)
100.0% 
(3359)
- 25.8% 74.2% 
(2640)
0.010 1.39 (1.08 – 1.79)
Fasting glucose 69.2% 
(803)
- 8.3% 60.9% 
(706)
69.6% 
(2476)
- 12.8% 56.8% 
(2022)
0.017 1.33 (1.05 – 1.68)
Albuminuria 47.0% 
(545)
- 0.4% 46.6% 
(540)
41.9% 
(1492)
- 2.3% 38.6% 
(1375)
0.021 1.40 (1.05 – 1.87)
Blood pressure 74.2% 
(861)
- 2.3% 71.9% 
(834)
66.8% 
(2377)
- 4.1% 62.7% 
(2232)
0.012 1.50 (1.09 – 2.07)
Complete 41.0% 
(476)
+ 0.6% 41.6% 
(482)
33.1% 
(1179)
-2.0% 31.1% 
(1107)
0.005 1.58 (1.15 – 2.18)
Monitoring metabolic parameters
Hemoglobin 57.2% 
(663)
- 11.7% 45.5% 
(528)
58.7% 
(2090)
- 18.9% 39.8% 
(1415)
0.009 1.30 (1.07 – 1.59)
Calcium 11.6% 
(135)
+ 6.7% 18.3% 
(212)
9.8% 
(348)
-1.1% 8.7% 
(308)
0.000 2.47 (1.62 – 3.78)
Phosphate 9.8% 
(114)
+ 7.0% 16.8% 
(195)
7.6% 
(270)
- 0.8% 6.8% 
(242)
0.000 3.08 (1.89 – 5.04)
PTH 5.3% 
(61)
+ 6.3% 11.6% 
(134)
3.3% 
(117)
- 0.9% 2.4% 
(87)
0.000 4.42 (2.30 – 8.50)
Serum albumin 7.2% 
(83)
+ 5.5% 12.7% 
(147)
6.9% 
(246)
- 0.6% 6.3% 
(224)
0.006 1.98 (1.22 – 3.22)
Potassium 74.0% 
(858)
- 9.7% 64.3% 
(746)
76.8% 
(2733)
- 14.3% 62.5% 
(2224)
0.161 1.21 (0.93 – 1.57)
Complete 3.3% 
(38)
+3.8% 7.1% 
(82)
2.4% 
(85)
- 0.9% 1.5% 
(54)
0.000 4.20 (2.07 – 8.50)
(Renal function: eGFR or serum creatinine; Albuminuria: albumin creatinine ratio or urine albumin). * 
univariate multilevel logistic analysis at T1 corrected for QoC at T0 and clustering at practice level. ** 
the percentages show the achieved blood pressure targets divided by the number of blood pressure 
measurements. *** p-value and odds ratios compared to no albuminuria.
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disCussion
Summary
FPs’ CKD recognition in the form of CKD documentation improved considerably in the 
E&F group, from 40% to 58%, and much more than in the control group which changed 
from 50% to 51%. We found no difference in reaching blood pressure targets. Patients 
in the E&F group less frequently progressed to severe albuminuria. The E&F group also 
had significantly higher monitoring rates on nearly all parameters except for potassium.
Strengths and limitations
A strength of our study is the inclusion of a large number of control practices that can 
be considered routine usual care, limiting attention and selection bias.(11) Furthermore 
we deliberately selected patients < 65 years with CKD stage 3a and patients ≥ 65 years 
with CKD stage 3b as they represent a group that is at moderate risk for CKD related 
complications and progression to end-stage renal disease, but is still largely managed 
in primary care. Also, the multi-faceted intervention was simple and therefore easy to 
implement in practice.
Several limitations should be considered. Firstly, practices in the E&F group voluntarily 
participated in a RCT which suggests their research interest. This interest together with 
the non-randomized design of this study adds to selection bias. However, the groups 
were comparable at baseline regarding patient characteristics. The control group 
included eight academic practices whereas the E&F group did not. Analysis with the 
academic practices excluded did not alter our results (Appendix 1).
The higher rate of baseline CKD documentation in the control group likely led to 
overestimation of the results in the analysis as the control group had less room for im-
provement to begin with. Possibly, this was caused by the fact that all control practices 
previously participated in general documentation improvement projects not specifically 
targeted at CKD compared to 54% (13/24) of the E&F practices. Despite likely overes-
timating the absolute OR value, the significance of the result remains valid. Prevalence 
of albuminuria could be overestimated, as it was based on a single measurement. The 
reported QoC may have been influenced by the impossibility to exclude patients under 
secondary renal care, as information on referrals was unavailable in the control group. 
Patients under secondary care may receive adequate renal care which is not presented 
in the EMR data.
Comparison with existing literature
CKD recognition was generally high in our study, as observational studies reported elec-
tronic documentation of CKD between 4-43%.(3, 4, 12-14) However, an interventional 
study on laboratory reported eGFR coupled with an educational program by Akbari 
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et al. in Canadian academic family practices increased FPs’ recognition from 22% of 
patients with CKD to 85%.(15) Their wider definition of CKD recognition, namely as any 
written evidence in the EMR that a physician had recognized CKD, partly explains the 
difference with our study. In a quality improvement study by Fox et al. CKD recognition 
improved from 21% to 79% following a more extensive intervention that included 
practice enhancement assistants, computer decision-making support, and monthly site 
visits.(16) Compared to this study our less laborious E&F intervention improved CKD 
documentation in practices with a near double baseline documentation rate, although 
the absolute gain in documentation was lower.
Achievement of blood pressure targets was lower compared to two cluster RCTs, one 
by Drawz et al. on providing a CKD registry coupled with FP education on guideline 
adherence, and one by Scherpbier et al. on a shared care model in family practice. 
Both RCTs reported blood pressure targets <130/80 mmHg in 44% of CKD patients.
(17, 18) In the study by Drawz et al. intervention practices were actively guided to 
construct their CKD registry, whereas in our study the documentation was left to the 
practices themselves. A cluster RCT by de Lusignan et al. reported that audit-based 
education led to a significant 2.4 mmHg reduction in systolic blood pressure and an 
increase in achievement of blood pressures at target <140/90 mmHg from 49% to 
61%.(19) Only providing practices with information on CKD management did not alter 
systolic blood pressure. Our intervention would be less labour intensive, but we did not 
find a difference in systolic blood pressure. Our results were comparable with results 
from observational studies where patients with CKD stage 3-4 reached blood pressure 
targets <140/90 mmHg in 45% to 71% and <130/80 mmHg in 13% to 54%.(3, 4, 13)
The lower incidence of severe albuminuria in the E&F group compares with results 
from a Mexican non-randomized study on the effect of FP education on kidney function 
outcomes in patients with CKD and diabetes type 2.(20) Patients in whom their FP 
improved his or her clinical competence saw a decrease in urinary albumin excretion, 
whereas excretion levels increased when FPs did not improve their clinical competence.
Renal function was monitored at a lower rate compared with the 86% from an 
American study by Allen et al. among multi-specialty practices housing both FPs and 
nephrologists.(3) Albuminuria was monitored above average as observational studies 
that included patients with CKD stages 3 and 4 reported rates between 26% and 
30%.(3, 13) However, results from the QOF show an 82% monitoring rate.(21) A 
non-randomized study by Mendu et al. reported a 73% albuminuria monitoring rate 
in patients with CKD stage 1-4 following a CKD checklist incorporated in the EMR 
combined with FP education regarding CKD guidelines.(22) Drawz et al. reported an 
increase in monitoring albuminuria from 56% to 63%.(17)
Compliance with monitoring of metabolic parameters was low in our study. Obser-
vational data showed monitoring of calcium in 45% and PTH in 13%.(3) Mendu et al. 
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reported an increase in monitoring for calcium from 29% to 97%, for phosphate from 
15% to 66% and for PTH from 11% to 61%.(22) Drawz et al. also noted increases: 
for phosphate monitoring from 59% to 75% and for PTH from 13% to 28%.(17) In 
the study by Fox et al. monitoring of PTH, phosphate or vitamin D went up from 14 to 
37%.(16) However, there is debate about whether patients with CKD stage 3 should 
be periodically screened for mineral and bone disorders. The NICE CKD guideline does 
not recommend routine measurements in patients with CKD stage G3 in contrast to the 
KDIGO guideline on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
(23, 24)
Other studies showed FPs may experience conflict between the guideline recom-
mendations and their own perspective on CKD management.(25, 26) In a qualitative 
study by Simmonds et al. FPs expressed their concern regarding CKD monitoring due to 
different interpretations of the CKD concept and different approaches to healthcare and 
moral decision-making.(27) This was especially the case in patients with CKD stage G3 
and probably contributes to the low guideline adherence seen in most studies.
In a broader perspective our results match the positive findings of two Cochrane re-
views. Forsetlund et al. reported educational meetings can improve professional practice 
by an average absolute risk difference (RD) of 6%.(28) Ivers et al. reported audit and 
feedback interventions can improve practice performance by an average RD of 4.3%.
(29) We found an RD of 2.6% for complete monitoring disease progression and 4.7% 
for complete monitoring of metabolic parameters.
Implications for research and practice
A key benefit resulting from the education and feedback intervention in our study is 
the high increase in the number of patients that have CKD documented on the episode 
list of their EMR. This documentation can be a notification for FPs to monitor patients 
and can be regarded as an indicator for awareness of CKD on the side of the FP.(3) In 
addition, registration can trigger medication safety notifications.(30, 31) In the relatively 
short follow-up period in our study, the interventions did not contribute to higher rates 
of achieving blood pressure targets.
In conclusion, the simple intervention of educating FPs on CKD management coupled 
with practice feedback in the form of a list of their CKD patients increased CKD recogni-
tion and monitoring.
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appendix 1. Quality of care in Education & Feedback practices and Usual Care control practices at T0 
and T1 with the eight academic control practices excluded.
Quality of Care Education & Feedback Group
(n=1160)
Usual Care control Group
(n=3080)
p-value* Odds ratio*
(95% CI)
T0 difference T1 T0 difference T1
Ckd 
documentation
in eMr
39.8% 
(462)
+ 17.7% 57.5% 
(667)
49.1% 
(1513)
+ 0.9% 50.0% 
(1540)
0.000 23.92
(11.78 – 48.59)
blood pressure targets**
< 140/90 mmHg 46.5% 
(400)
+ 7.5% 54.0% 
(450)
46.2% 
(915)
+ 5.8% 52.0% 
(961)
0.689 1.05 (0.84 – 1.31)
< 130/80 mmHg 16.6% 
(143)
+ 3.4% 20.0% 
(167)
18.5% 
(367)
+ 3.1% 21.6% 
(399)
0.880 0.98 (0.75 – 1.28)
albuminuria status***
No albuminuria 84.0% 
(458)
- 3.6% 80.4% 
(434)
77.3% 
(930)
- 5.8% 71.5% 
(812)
Moderate 
albuminuria
16.0% 
(87)
+ 1.8% 17.8% 
(96)
22.7% 
(273)
+ 1.4% 24.1% 
(273)
0.493 0.88 (0.61 – 1.27)
Severe 
albuminuria
0.0% (0) + 1.9% 1.9% 
(10)
0.0% (0) + 4.4% 4.4% 
(50)
0.021 0.26 (0.08 – 0.81)
Monitoring disease progression
Renal function 100.0% 
(1160)
- 21.2% 78.8% 
(914)
100.0% 
(3080)
- 26.9% 73.1% 
(2250)
0.004 1.44 (1.13 – 1.85)
Fasting glucose 69.2% 
(803)
- 8.3% 60.9% 
(706)
67.6% 
(2083)
- 12.4% 55.2% 
(1699)
0.011 1.34 (1.07 – 1.69)
Albuminuria 47.0% 
(545)
- 0.4% 46.6% 
(540)
39.1% 
(1203)
- 2.1% 36.9% 
(1135)
0.025 1.39 (1.04 – 1.84)
Blood pressure 74.2% 
(861)
- 2.3% 71.9% 
(834)
64.3% 
(1979)
- 4.3% 60.0% 
(1847)
0.004 1.59 (1.16 – 2.18)
Complete 41.0% 
(476)
+ 0.6% 41.6% 
(482)
29.5% 
(910)
- 0.6% 28.9% 
(891)
0.007 1.56 (1.13 – 2.15)
Monitoring metabolic parameters
Hemoglobin 57.2% 
(663)
- 11.7% 45.5% 
(528)
59.9% 
(1844)
- 19.8% 40.1% 
(1236)
0.014 1.29 (1.05 – 1.58)
Calcium 11.6% 
(135)
+ 6.7% 18.3% 
(212)
8.5% 
(263)
- 0.3% 8.2% 
(252)
0.000 2.48 (1.62 – 3.80)
Phosphate 9.8% 
(114)
+ 7.0% 16.8% 
(195)
6.5% 
(200)
- 0.1% 6.4% 
(198)
0.000 3.08 (1.88 – 5.06)
PTH 5.3% 
(61)
+ 6.3% 11.6% 
(134)
2.3% 
(71)
- 0.1% 2.2% 
(68)
0.000 4.50 (2.29 – 8.86)
Serum albumin 7.2% 
(83)
+ 5.5% 12.7% 
(147)
6.2% 
(190)
- 0.3% 5.9% 
(181)
0.005 2.04 (1.24 – 3.38)
Potassium 74.0% 
(858)
- 9.7% 64.3% 
(746)
75.1% 
(2313)
- 14.5% 60.6% 
(1867)
0.088 1.26 (0.97 – 1.63)
Complete 3.3% 
(38)
+3.8% 7.1% 
(82)
1.6% 
(49)
- 0.2% 1.4% 
(44)
0.000 4.25 (2.06 – 8.74)
(Renal function: eGFR or serum creatinine; Albuminuria: albumin creatinine ratio or urine albumin). * 
univariate multilevel logistic analysis at T1 corrected for QoC at T0 and clustering at practice level. ** 
the percentages show the achieved blood pressure targets divided by the number of blood pressure 
measurements. *** p-value and odds ratios compared to no albuminuria.
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absTraCT
objective: To assess the impact on cardiovascular risk factor management in primary 
care by the introduction of chronic kidney disease epidemiological collaboration (CKD-
EPI) for estimated-glomerular filtration rate (eGFR) reporting.
design and setting: Cross-sectional study of routine healthcare provision in 47 primary 
care practices in The Netherlands with Modification of Diet and Renal Disease Study 
eGFR reporting.
Methods: eGFR values were recalculated using CKD-EPI in patients with available 
creatine tests. Patients reclassified from CKD stage 3a to CKD stage 2 eGFR range were 
compared to those who remained in stage 3a for differences in demographic variables, 
blood pressure, comorbidity, medication usage and laboratory results.
results: Among the 60 673 adult patients (37% of adult population) with creatine 
values, applying the CKD-EPI equation resulted in a 16% net reduction in patients with 
CKD stage 3 or worse. Patients reclassified from stage 3a to 2 had lower systolic blood 
pressure (139.7 vs 143.3 mm Hg p<0.0001), higher diastolic blood pressure (81.5 vs 
78.4 mm Hg p<0.0001) and higher cholesterol (5.4 vs 5.1 mmol/L p<0.0001) compared 
to those who remained in stage 3a. Of those reclassified out of a CKD diagnosis 463 
(32%) had no comorbidities that would qualify for annual CVD risk factor assessment 
and 20 (12% of those with sufficient data) had a EuroSCORE CVD risk >20% within 
10 years.
Conclusions: Use of the CKD-EPI equation will result in many patients being removed 
from CKD registers and the associated follow-up. Current risk factor assessment in this 
group may be lacking from routine data and some patients within this group are at an 
increased risk for cardiovascular events.
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inTroduCTion
Chronic kidney disease (CKD) is common and causes substantial morbidity, mortality and 
healthcare expenditure because it is associated with an increased risk of cardiovascular 
events as well as progression to end-stage renal failure.1–3 Estimated glomerular filtra-
tion rate (eGFRs) are routinely calculated from measured serum creatine values to assess 
renal function.4 The eGFR is central to the classification of CKD into different stages and 
is used alongside other evidence of kidney disease, such as structural abnormalities on 
imaging or albuminuria. A key consequence of this staging of CKD is that it is used to 
guide the management of cardiovascular risk markers, the frequency of follow-up and 
the need for referral.4 In The Netherlands there is guidance for primary care on how to 
assess and manage cardiovascular risk.5
Globally, the standard equation used by healthcare laboratories to calculate eGFR 
is the four variable Modification of Diet and Renal Disease (MDRD) study equation.6 
Using pooled data from diagnostic accuracy studies, a newer more accurate equation 
was developed—the chronic kidney disease epidemiological collaboration (CKD-EPI) 
equation.7–10 Several studies have shown that use of the CKD-EPI equation to calculate 
eGFR leads to a reduction in CKD diagnoses in younger patients, but an increase in CKD 
diagnoses in elderly patients.11,12 Data from cohort studies and the US health insurance 
schemes have shown that CKD stage derived from the CKD-EPI formula better predicts 
cardiovascular events and cardiovascular risk than does CKD stage derived from the 
MDRD equation.13–15
The impact on cardiovascular risk follow-up and management in primary care arising 
from the introduction of the CKD-EPI formula for routine eGFR reporting has not been 
assessed. We do know that the CKD-EPI formula will change the CKD stage of many 
patients.11 This has important implications as current guideline-driven care pathways 
emphasise different intensities of monitoring and drug prescribing according to CKD 
stage. For patients who have their CKD diagnosis removed entirely (by a shift from 
an MDRD-derived eGFR of <60 to a CKD-EPI-derived eGFR of >60 mL/min/1.73 m2 in 
the absence of known albuminuria or other evidence of kidney disease) this will lead 
to a less intensive treatment of cardiovascular risk factors unless there are comorbid 
diagnoses such as diabetes mellitus that necessitate enrolment in a cardiovascular risk 
management programme.
In The Netherlands, all routine chronic disease management is undertaken by primary 
care physicians in community-based practices, and national guidance on monitoring is 
available.4 Reporting of eGFR with serum creatine in The Netherlands began in 2006 
and the EuroSCORE model for cardiovascular risk assessment is currently recommended 
for use in primary care.5 The aim of the study was to determine the cardiovascular risk 
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profile of patients who no longer fulfilled CKD stage 3 criteria when using the CKD-EPI 
formula for eGFR reporting.
MeThod
Recruitment of patients
This study used patient data from general practices that participated in a cluster ran-
domised controlled trial on the effect of web-consultation between a general practitio-
ner (GP) and nephrologist on face-to-face referrals—the CONTACT study (Consultation 
of Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in 
primary care, Netherlands Trial Registration code 2368). The CONTACT study recruited 
practices during a CKD management course for GPs in the eastern Netherlands. Forty-
seven non-academic general practices participated and in the current study the lat-
est data were analysed from their registered populations’ electronic medical records 
between 1 January 2008 and 30 June 2011.
Estimation of renal function
eGFRs were calculated for patients aged 18 years or older using both the MDRD and 
CKD-EPI equations.6,7 The most recent serum creatine values were selected and were 
either standardised to isotope dilution mass spectrometry (IDMS) or subject to the ap-
propriate correction factor for laboratories using the Jaffé technique.16
Patient characteristics
Demographic and clinical data including age, sex, albuminuria, comorbidities, medi-
cation, blood pressure and lipid levels were extracted from electronic medical records 
(table 3). Albuminuria was divided into microalbuminuria and macroalbuminuria. Mi-
croalbuminuria was defined as a urinary albumin to creatine ratio (ACR) of 2.5–25 mg/
mmol in men and 3.5–35 mg/mmol in women. Higher ratios were considered to reflect 
macroalbuminuria. If the ACR was not available we used a urine albumin concentration 
>20–200 mg/L for microalbuminuria and >200 mg/L for macroalbuminuria.17 Comor-
bidities were classified using the International Classification of Primary Care (ICPC) codes 
as a history of the following diseases: cardiovascular disease (CVD) (K74-K77, K89, K90, 
K92), diabetes mellitus (T90) and hypertension (K86, K87). Anatomical therapeutic 
chemical (ATC) codes were used to select prescriptions from 2010, and included ACE 
inhibitors and angiotensin receptor blockers (C09), diuretics (C03) and statins (C10). 
Blood pressure was reported as the mean of the two most recent measurements. In 
order to reduce potential under ascertainment bias for chronic disease, if patients were 
prescribed medications for chronic disease management without an appropriate code, 
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for example, antihypertensive medication without hypertension coded in the medical 
record, we assumed that the relevant chronic disease was present, even if not coded.
Analysis
The prevalence of CKD stages derived from the use of the MDRD and CKD-EPI equa-
tions was calculated using the size of the registered population aged 18 years and over 
as the denominator. Demographic and clinical features of patients reclassified from 
CKD stage 3a to stage 2 by using the CKD-EPI equation were compared with patients 
who remained in stage 3a. Next, we specifically described characteristics and cardio-
vascular risk profile of patients whose CKD stage 3a was changed to stage 2 who had 
no diagnosed comorbidity that would otherwise have necessitated their participation 
in a cardiovascular risk management programme. To assess cardiovascular risk profile 
we applied the EuroSCORE 10 year risk for CVD.5 To ensure conservative estimation 
we assumed negative smoking status when lacking. Continuous data were compared 
using t tests and categorical data were analysed using chi-squared tests. Analysis was 
conducted using SPSS V.20.0 (IBM PASW statistics 20).
resulTs
Practice population
The 47 study practices serve a population of 207 469 people of whom 162 562 were 
over 18 years of age. Between 2008 and 2011, 37% of all adults registered with these 
practices (n=60 673) had their serum creatine measured. In the over 65 age group this 
figure rose to 71% (20 959 out of 29 591).
Study population
The use of the CKD-EPI equation changed the CKD stage for 20% of patients (n=12 278) 
with a measured serum creatine value. This reclassification resulted in a 16% net reduc-
tion in the total number of individuals with CKD stage 3 or worse: 1428 patients were 
reclassified from stage 3a to stage 2, whereas 195 patients were reclassified from stage 
2 to stage 3a (table 1). As a consequence the prevalence of detected CKD stages 3–5 
declined from 4.8% to 4.0% in the total adult population.
Thirty-two per cent (n=19 235) of those who had a serum creatine measurement 
also had a urine assessment to evaluate albuminuria, and the numbers of patients with 
different levels of albuminuria are shown in table 2, stratified by eGFR category using 
both MDRD and CKD-EPI eGFRs. Overall in those tested, the prevalence of microal-
buminuria was 12.1% (n=2322) and of macroalbuminuria was 1% (n=284). Of the 
patients reclassified from CKD stage 3a to stage 2 eGFR range, albuminuria was tested 
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for in 43% (n=617) and the prevalence of microalbuminuria was 8.6% (n=53) and of 
macroalbuminuria was 1.5% (n=9).
Patients reclassified out of CKD compared to patients remaining in stage 
3a
Compared to patients whose CKD stage remained 3a, those who were reclassified to 
stage 2 range eGFR using the CKD-EPI equation were younger, more were female, with 
less microalbuminuria, a comparable prevalence of macroalbuminuria, fewer comor-
bidities and were prescribed fewer antihypertensive and lipid-lowering drugs (table 3). 
Systolic blood pressure was significantly lower and diastolic blood pressure significantly 
higher in patients reclassified out of CKD. Total cholesterol and low-density lipoprotein 
(LDL)-cholesterol were significantly higher in this group.
Patients reclassified out of CKD without other diagnosed comorbidities
A total of 463 patients (32% of those reclassified out of CKD) would be removed from 
a cardiovascular risk management programme as they were not diagnosed with other 
comorbidities (table 4). Cholesterol measurement was performed in 64% of patients. 
The majority of patients had not had an albuminuria assessment. Blood pressure was 
measured in 218 patients and 111 (51%) of them had elevated values ≥140/90 mm Hg 
requiring further monitoring. Similarly, 20 of 172 patients (12%) with sufficient data to 
complete cardiovascular risk assessment had a EuroSCORE 10 year CVD risk of >20%.
Patients reclassified into a CKD diagnosis
A total of 195 patients were reclassified from stage 2 to stage 3a CKD, and of these, 166 
(85%) had existing comorbidities that would already have identified them for cardio-
vascular risk assessment. Among the 29 patients who had no identifiable comorbidity, 
their mean age was 85.4 years (SD 5.1, youngest 76 years) and in the 11 patients with 
recorded BP, mean values were 137.5 mm Hg (SD 13.7)/71.4 mm Hg (5.4). Of the eight 
patients with sufficient data for CVD risk scoring, six patients were >20%, although all 
were outside the age range for accurate scoring and may qualify for high-risk status on 
age alone.
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Table 1. Reclassification of primary care patients when using CKD-EPI instead of MDRD
eGfr categories with Mdrd (ml/
min/1.73 m2)
eGfr categories with Ckd-ePi (ml/min/1.73m2)
Total
>90 60–89 45–59 30–44 15–29 <15
>90 15 195 741 0 0 0 0 15 936
60–89 9580 27 184 195 0 0 0 36 959
45–59 0 1428 4338 146 0 0 5912
30–44 0 0 106 1345 63 0 1514
15–29 0 0 0 9 290 7 306
<15 0 0 0 0 3 43 46
Total 24 775 29 353 4639 1500 356 50 60 673
CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration 
rate; MDRD, Modification of Diet and Renal Disease Study.
Table 2. Numbers of patients with proteinuria according to estimated eGFR category with either MDRD 
or CKD-EPI in 19235 primary care patients with available results of urine analysis
eGfr categories (ml/min/1.73 m2
>90 60–89 45–59 30–44 15–29 <15
MDRD eGFR
 Macroalbuminuria 37 97 67 55 21 7
 Microalbuminuria 437 1140 489 219 35 2
 No albuminuria 3016 10768 2297 496 51 1
CKD-EPI eGFR
 Macroalbuminuria 43 98 61 53 21 8
 Microalbuminuria 516 1089 442 226 47 2
 No albuminuria 4678 9617 1783 490 58 3
CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration 
rate; MDRD, Modification of Diet and Renal Disease Study.
Table 3. Characteristics of patients reclassified out of CKD compared to those who remained in stage 3a
Variable
remained 
in stage 3a 
(n=4338)
no of 
available 
data
reclassified 
out of Ckd 
(n=1428)
no of 
available 
data
P for 
comparison
Age 74.0 (9.5) 4338 60.3 (9.5) 1428 <0.0001
Female 61% N=2654 4338
76% 
N=1087
1428 <0.0001
Cardiovascular disease 36% N=1566 4338 18% N=250 1428 <0.0001
Hypertension 57% N=2463 4338 47% N=666 1428 <0.0001
Diabetes 26% N=1134 4338 17% N=243 1428 <0.0001
None (also excluding albuminuria) 21% N=924 4338 39% N=557 1428 <0.0001
Statins 46% N=2000 4338 33% N=475 1428 <0.0001
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Variable
remained 
in stage 3a 
(n=4338)
no of 
available 
data
reclassified 
out of Ckd 
(n=1428)
no of 
available 
data
P for 
comparison
ACE inhibitors and/or Angiotensin 
II receptor antagonists
54% N=2349 4338 37% N=533 1428 <0.0001
Diuretics 43% N=1862 4338 26% N=367 1428 <0.0001
Creatine in µmol/L 102 (14.3) 4338 93 (11.4) 1428 <0.0001
Cholesterol/HDL ratio 4.2 (1.4) 3338 4.3 (1.6) 1118 0.020
Total cholesterol in mmol/L 5.1 (1.2) 3498 5.4 (1.1) 1157 <0.0001
HDL in mmol/L 1.31 (0.40) 3454 1.36 (0.41) 1150 <0.0001
LDL in mmol/L 3.05 (1.02) 3451 3.31 (1.01) 1150 <0.0001
Triglycerides in mmol/L 1.65 (0.83) 3458 1.64 (1.05) 1156 0.616
Albumin/creatine ratio* 1.0 (0.9–2.5) 2092 0.9 (0.7–1.2) 583 <0.0001
Albumin urine in mg/L* 6.0 (2.9–17.0) 1174 3.0 (2.0–8.0) 348 <0.0001
Microalbuminuria 410 2161 53 617 <0.0001
Macroalbuminuria 55 2161 6 617 0.113
Diastolic blood pressure in mm Hg 78.4 (9.4) 3540 81.5 (9.0) 1043 <0.0001
Systolic blood pressure in mm Hg 143.3 (17.5) 3540 139.7 (15.8) 1042 <0.0001
*Values are mean (SD) or median (first, third quartile). Percentages of prevalence are calculated with the 
denominator of available data.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 4. Characteristics of patients reclassified out of CKD without diagnosed comorbidity
Mean (sd)
no of patients with 
available data
Age 56.6 (10.0) 463
Female 79% 463
Creatine in µmol/L 97 (11.9) 463
Chol/HDL ratio 4.4 (1.6) 285
Total cholesterol in mmol/L 5.8 (1.0) 295
HDL in mmol/L 1.44 (0.43) 290
LDL in mmol/L 3.78 (0.89) 289
Triglycerides in mmol/L 1.42 (0.76) 289
Albumin/creatine ratio 0.9 (0.5–0.9) 65
Albumin urine in mg/L 2.9 (2.0–5.25) 38
Diastolic blood pressure in mm Hg 81.8 (9.1) 218
Systolic blood pressure in mm Hg 138.0 (16.7) 218
Either systolic or diastolic blood pressure ≥140/90 mm Hg 111 218
EuroSCORE 10 year cardiovascular disease risk ≥20% 20 172
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disCussion
Principal findings
Application of the CKD-EPI equation to our study population resulted in a net 16% 
decrease (prevalence from 4.8% to 4.0%) in the total number of individuals with 
CKD stage 3 or worse based on eGFR criteria. Patients reclassified from stage 3a to 
stage 2 were younger, more were female with lower prevalence of comorbidities and 
a differential effect was seen on blood pressure with lower systolic but higher diastolic 
mean values. Although 32% of patients reclassified out of stage 3a had no documented 
comorbidity that would entail annual CVD risk factor assessment as part of a chronic 
disease management programme, an estimated 12% of these patients did indeed have 
elevated CVD risk. Not all reclassified patients had an adequate CVD risk factor assess-
ment so our results may underestimate the scale of this problem, although it is still likely 
that CKD-EPI reclassification has reduced the number of low-risk patients in stage 3.
Differences in prevalence of prescribed lipid lowering therapy may explain why higher 
total cholesterol and LDL levels were seen in patients who were reclassified to a higher 
eGFR value, above the 60 mL/min/1.73 m2 cut-off. Higher prevalence of comorbidities, 
in patients in CKD stage 3 using CKD-EPI estimation, are indications for improved risk 
factor control for primary and secondary prevention are likely to explain the greater 
statin prescribing and lower lipid levels in patients retaining a stage 3 CKD diagnosis. 
However, the differences in blood pressure are not explained by differences in antihyper-
tensive prescribing, due to the differential effect on systolic and diastolic blood pressure.
Strengths and limitations of this study
One of the strengths of our study is the use of routine general practice data from a 
large population which enhances the generalisability of our results. In the absence of a 
screening programme, existing CKD diagnoses are made from clinician-directed testing 
and so cannot provide true population prevalence. However, we were able to include 
a large proportion of the (potential) CKD population as creatine results were known in 
71% of patients over 65 years of age. A strength of the analysis of patients reclassified 
from stage 3 CKD to stage 2 eGFR range is that we made the conservative assumption 
that patients prescribed medication used to treat comorbidities did indeed have that 
comorbidity, even if it was not coded in the medical record. This will have the effect of 
reducing the number of patients in the subgroup without comorbidity reclassified out 
of a CKD diagnosis, and the impact that we did find is likely to underestimate the effect 
of reclassification. Furthermore, our study accurately reflects the changes in CKD stage 
and status that will arise from use of the CKP-EPI formula in current clinical practice with 
clinician-directed testing.
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A limitation of this study is that our classification of patients was based on a single 
creatine result, whereas guidelines recommend two measurements ≥3 months apart 
before making a diagnosis. However, this is unlikely to affect the proportional changes 
seen to a great extent given the size of our dataset and is in line with the approach used 
in most CKD studies.11,12,18–20 Albuminuria and cardiovascular risk factor assessment 
were incomplete and this highlight an area for quality improvement in general practice. 
However, despite the low usage of albuminuria assessment, our estimates of the gains 
and losses in CKD diagnoses are likely to be reliable. We did not have ethnicity data and 
assumed our population to be Caucasian. This assumption was based on ethnicity data 
from the Statistics Netherlands that shows 92% of the population is Caucasian in the 
eastern Netherlands.21 Both MDRD and CKD-EPI equations estimate true GFR and are 
therefore prone to some degree of error.
Comparison with existing literature
In other studies, a similar decrease in CKD prevalence was found: from 4.2% to 3.9% 
and 4.9% to 4.4% in two large adult UK population-based studies,18 and from 5.41% 
to 4.80% in the Quality Improvement in CKD trial.22 Also, CKD stage alteration in one-
fifth of all patients with a creatine measurement by use of the CKD-EPI equation is a 
figure consistent with previous estimates.11
Cohort studies stratifying patients at baseline with reclassified CKD stages using CKD-
EPI eGFRs report lower cardiovascular events in these patient groups during follow-
up,13–15 suggesting that overall, risk prediction is improved. Two studies that analysed 
the characteristics of patients reclassified out of a CKD diagnosis using CKD EPI are in 
agreement with our results, finding that these patients were predominantly women, 
of younger age and with less diabetes compared to those whose CKD stage remained 
unchanged.19 ,23 White et al19 did not report diastolic blood pressure or LDL-cholesterol 
levels, but found that those reclassified out of CKD had lower systolic blood pressure, 
similar total cholesterol levels and lower triglycerides levels and a lower 10-year CVD 
risk. Although we also found lower systolic blood pressure levels, we found higher total 
(and LDL) cholesterol and no reduction in triglyceride levels. The differential effect on 
systolic and diastolic blood pressure may be explained by the fact that the reclassified 
patients in our study had a younger mean age. Diastolic blood pressure has been shown 
to be high in early middle age and then fall in older age as systolic blood pressure 
increases.24 Patients with a CKD-EPI eGFR sufficiently higher than their MDRD eGFR to 
lose their CKD diagnosis are young enough to exhibit this effect.
Korhonen et al20 found no significant differences in cardiovascular risk factors be-
tween those reclassified and those remaining in the same CKD stage when the CKD-EPI 
formula was used, but the study size (n=1747)was probably too small to detect the 
differences we identified. No previous study has examined medication use.
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Meaning of the study
Introduction of CKD-EPI to calculate eGFR can be expected to lower primary care work-
load and reduce treatment and costs in patients who overall have low cardiovascular 
risk. While the CKD-EPI equation shows greater calibration than the MDRD equation in 
that it more accurately stratifies patients in terms of their cardiovascular risk, we have 
found that by using routinely collected data in primary care, patients reclassified out 
of CKD had a more favourable cardiovascular profile in terms of age and comorbidity 
compared to patients who remained in stage 3a. However, there is a small group of 
patients with elevated cardiovascular risk who will no longer be detected and managed.
Unanswered questions and future research
Uncertainty remains about the impact on patient cardiovascular follow-up in those who 
lose their CKD diagnosis with use of the CKD-EPI formula. Although fewer cardiovascular 
events are seen in patients reclassified from retrospective observational data,13–15 their 
care would have been guided by MDRD staging rather than the less severe CKD stage 
seen with CKD-EPI. Prospective follow-up studies are therefore required to appropriately 
determine the impact of CKD-EPI GFR estimation on cardiovascular events.
Current guidelines apply a fixed eGFR threshold to define CKD with the result that 
some patients will not be diagnosed with CKD in the presence of reduced renal function 
for their age group. This effect may be particularly relevant in younger patients, who may 
for example, have a ‘normal’ eGFR of 80 mL/min/1.73 m2 which is ‘normal’ according to 
Dutch guidelines4 yet it is significantly lower than the average GFR in people of a similar 
age.25 It may be more appropriate to report the statistical deviation of eGFR values from 
age-matched population mean and to highlight those that lie below a given percentile 
for further assessment and cardiovascular risk assessment. The CKD-EPI equation would 
make such an approach more feasible since it can be used to accurately report on eGFR 
>60 mL/min/1.73 m2.8 Further research is therefore needed to determine the feasibility 
of age-matched eGFR reporting to guide patient management.
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Approximately twelve percent of the general population has chronic kidney disease 
(CKD).(1) They are at risk for cardiovascular events and progression to end-stage renal 
disease (ESRD).(2, 3) The majority of CKD patients is managed in the general practice 
setting. International studies noted deficiencies in the quality of primary care CKD man-
agement, but the quality of care (QoC) provided for CKD patients in the Netherlands is 
unknown. The estimated glomerular filtration rate (eGFR) is generally calculated through 
application of the Modification of Diet in Renal Disease study (MDRD) equation.(4) In 
2009 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 
developed to succeed the MDRD equation.(5)
One of the features of primary care CKD management is the possibility for GPs to 
consult a nephrologist for expert advice without having to refer the patient. This consul-
tation is traditionally done by phone or e-mail, but this has several limitations. Therefore, 
we developed an e-consultation platform, telenephrology, as an alternative consultation 
method that has potential benefits: time efficiency, independent use, digital report of 
the consultation and secure data transfer.
In short, this thesis aimed to:
• Assess QoC for patients with CKD managed in Dutch primary care.
• Describe the effect of the e- consultation platform telenephrology on referral rate, 
consultation rate and QoC.
• Describe QoC in patients without nephrologists co-management despite guideline 
advice.
• Study the effect of a multi-faceted intervention of GP education coupled with prac-
tice feedback on QoC.
• Describe the cardiovascular risk profile of patients reclassified out of CKD when 
using the CKD-EPI equation instead of the MDRD equation for eGFR reporting.
Main findinGs
Quality of CKD care in routine general practice in the Netherlands
The Dutch interdisciplinary CKD guideline provides recommendations on how to moni-
tor and treat patients with CKD in primary care. The study in chapter 2 assessed QoC 
in routine general practice expressed as guideline adherence. Blood pressure targets 
<140/90 mmHg were reached in 43% of patients and were positively associated with a 
history of cardiovascular disease. CKD was documented in the electronic medical record 
(EMR) in only 31% of potentially identifiable patients and was positively associated with 
a history of hypertension or cardiovascular disease. Monitoring of disease progression 
was complete in 42% of CKD patients. However, higher monitoring rates were seen 
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in patients with diabetes or hypertension, which was most likely performed as part 
of regular diabetes care or cardiovascular risk monitoring programmes. We concluded 
that there seemed room for improvement across all aspects of Dutch primary care CKD 
management. Systematic documentation of CKD in the EMR and monitoring of renal 
function and albuminuria deserve attention, and most clinical relevance lies in the 
achievement of blood pressure targets.
Telenephrology’s feasibility
In addition to monitoring and treatment recommendations, the Dutch interdisciplin-
ary CKD guideline also advises on which health care setting best suits the patients 
needs: management in primary care, management in primary care with input from a 
nephrologist through consultation, or referral to secondary care. We developed the 
e-consultation platform telenephrology to overcome several barriers that are present in 
conventional consultation methods. We hypothesised that telenephrology would lead 
to more consultations and an increase in the number of patients managed in primary 
care with the help of advice by the nephrologist. We ultimately expected a decrease in 
referral rate as referrals would be limited to only those patients where circumstances 
require referral to secondary care. In the pilot study in chapter 3 we evaluated 122 
e-consultations from 28 general practices and five nephrology departments and found 
telenephrology to potentially reduce referrals by 60.5%. The service was feasible, as 
most GPs and nephrologists used the platform during office hours, spending less than 
ten minutes on a consultation and nephrologists responded within two days.
Telenephrology’s effect on referral and consultation rates, QoC, and costs
Next we performed the cluster randomised controlled trial described in chapter 4. We 
recruited 47 general practices during a CKD management course. All practices received 
lists stating which of their patients met the guideline consultation and referral criteria: 
3004 patients in total. The intervention group had access to telenephrology and the 
control group could use traditional consultation methods. The results of the trial did not 
confirm the potential reduction of referrals as suggested by the pilot study. We found 
a non-significant difference in referral rate, 2.3% in the intervention group against 
3.0% in the control group. The consultation rate in both groups was much lower 
than expected, 6.3% in the intervention group against 5.0% in the control group. We 
could not conclude that telenephrology led to a significantly higher consultation rate 
compared to conventional consultation methods. There were no significant differences 
in QoC and average costs per patient between the groups. In the evaluation GPs ac-
knowledged telenephrology’s feasibility and added that using the platform contributed 
to their knowledge of kidney disease. Surprisingly, the observed referral rate in the 
control group was far lower than we had estimated for our sample size calculation: 
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3.0% against an expected 19.4%. Together with the possibly of contamination bias, as-
sumed to be a result of the mutual interventions of GP education and practice feedback 
in the form of patient lists, no definite conclusions can be made.
Quality of care in patients without nephrologist co-management despite 
guideline advice
We defined ‘guideline advice for nephrologists co-management’ as situations when 
the recommended health care setting was: (a) management in primary care with input 
from a nephrologist through consultation, or (b) referral to secondary care. Chapter 5 
showed that GPs did not follow this consultation or referral advice in respectively 94% 
and in 70% of patients with CKD stages 3-5. The vast majority of patients with CKD 
stage 3-5 was therefore cared for by their GP and not in co-management with the ne-
phrologist, as recommended by the guideline. Not following the consultation or referral 
advice was most strongly associated with: (a) lack of renal function monitoring, (b) no 
CKD documentation in the EMR, and (c) lower prevalence of cardiovascular disease. The 
quality of care outcomes for this patient group showed CKD documentation in 50%, 
monitoring of disease progression in 36% and achievement of blood pressure targets 
<140/90 mmHg in 51% of patients. Patients with a history of diabetes or hypertension 
were more likely to have their renal function and blood pressure measured.
Effect of GP education and providing practices with a list of their CKD 
patients on QoC
Our assumption of contamination bias in the telenephrology trial as described in chapter 
4 led to a further exploration of the multi-faceted intervention of GP education on CKD 
management coupled with providing practices with an overview of their CKD popula-
tion in chapter 6. For this we selected the control arm of the trial, which consisted of 
24 practices. We will refer to this now as the Education and Feedback (E&F) group. We 
compared this group to 109 control practices selected from an existing big-data set of 
general practices. We found a significant increase in patients that had CKD documented 
on the episode list of their EMR: an absolute gain of 17.7% in the E&F group against 
1.5% in the control group. Also, the overall rate of monitoring disease progression and 
metabolic parameters was significantly higher in the E&F group. During the relatively 
short follow-up period of 14 months the multi-faceted intervention did not contribute 
to higher rates of achieving blood pressure targets <140/90 mmHg. We concluded that 
this relatively simple multi-faceted intervention of educating GPs on CKD management 
coupled with practice feedback in the form of a list of their CKD patients had a positive 
influence on CKD recognition and monitoring.
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Cardiovascular risk profile of patients reclassified out of CKD when using 
the CKD-EPI equation
Efforts to increase the accuracy of GFR estimation led to the development of the CKD-
EPI equation. Literature reported the CKD-EPI equation provides greater calibration in 
eGFR as well as cardiovascular risk stratification. The findings of our study in 47 general 
practices in chapter 7 showed that the CKD-EPI equation in our cohort of 60673 adult 
patients with a creatinine measurement also more accurately stratifies patients in terms 
of their cardiovascular risk compared to the MDRD equation. We found that, when 
using the CKD-EPI equation instead of the MDRD equation, patients reclassified out of 
CKD had a more favourable cardiovascular profile in terms of age (60.3 against 74.0 
years) and comorbidity compared to patients who remained in CKD stage 3a. Of those 
reclassified out of a CKD diagnosis 32% had no comorbidities that would necessitate 
annual CVD risk factor assessment. However, within this group 12% of patients had 
a EuroSCORE CVD risk >20% within 10 years, but would no longer be detected and 
managed.
sTrenGThs and liMiTaTions
The main strengths of the studies in this thesis were the utilisation of general practice 
data from a large population and the focus on patients who received their CKD care in 
primary care.
Several limitations should also be addressed. The judgement of QoC through assess-
ment of guideline adherence from EMR data had the underlying assumption that higher 
guideline adherence reflected higher QoC. However, sometimes non-adherence to a 
guideline is justified. Unfortunately, in our studies it was not possible to distinguish situ-
ations in which the GP provided high QoC by not adhering to guideline recommenda-
tions based on the individual patient’s context. Also, QoC has many other dimensions, 
such as quality of life and patient’s values and satisfaction, which were no part of our 
studies.
The lack of effect in the telenephrology trial, especially on referral rate, may in retro-
spect well be related to the trial design and the very low referral rates. In our attempt 
to purely measure the effect of telenephrology, the control group partly acted as if they 
were an intervention group due to their participation in the CKD education program 
and the provision of the overview of CKD patients, as shown in chapter 6.
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disCussion
CKD documentation
The baseline QoC study described in chapter 2 showed a 31% CKD documentation 
rate in the EMR with the highest rates in patients with the lowest eGFR. Eighty-eight 
percent of the expected CKD stage 3-5 population could have been ascertained by 
screening of routine laboratory results. The lack of CKD documentation is also found 
in studies across different nations. Australian primary care research showed 18% CKD 
registration and a Swedish cohort study reported 12% CKD registration.(6, 7) Similar to 
our findings CKD is generally better registered when comorbidity is present. A US cohort 
study by Guessous et al. reported higher registration rates in patients with diabetes and 
hypertension.(8) A UK study similarly reported that CKD documentation was positively 
associated with hypertension, diabetes and cardiovascular disease.(9)
A possible explanation for the low registration rates could be a lack of CKD knowledge 
and awareness among GPs.(10, 11) An American survey reported 51% of primary care 
physicians were unfamiliar with CKD guidelines.(12) In a UK survey GPs self-reported 
they were not confident in treating CKD and the study showed that they were less likely 
to achieve outcome targets on areas where their confidence was low.(13) In qualitative 
studies GPs acknowledged struggling with the definition of CKD and its management 
and expressed their willingness for education.(14-16)
The outcomes may also reflect the concerns that GPs have when it comes to the 
clinical consequences of CKD. Literature notes that GPs have reservations about as-
signing a CKD diagnosis and are concerned about the implications of such a diagnosis: 
especially in elderly where CKD prevalence is estimated at 34% for patients in their 70s, 
and where the clinical consequences of a mild reduction in renal function appear small.
(1, 15, 17-21) This may explain our result of lower documentation rates in patients 
with higher eGFR. Researchers have also voiced their concern of potentially overstating 
the extent of CKD, with the CKD classification system leading to over diagnosis in the 
elderly and under diagnosis in the young, and plea for an age-adjusted approach to 
CKD.(22-26) The Dutch interdisciplinary CKD guideline already differentiates between 
patients younger and older than 65 years of age, and the European Renal Best Practice 
(ERBP) guideline development group recently released a clinical practice guideline on 
CKD management in patients above 65 years of age.(27) Yet, other researchers reject 
the suggestion of such an age-adjusted approach.(28, 29)
The low registration rates are unfortunate since CKD documentation is associated with 
higher QoC such as better monitoring of albuminuria and metabolic parameters.(9, 30) 
The earlier mentioned study by Guessous et al. found that patients with documented 
CKD were 61% more likely to use an ACE inhibitor, 27% more likely to use a statin and 
37% less likely to use an NSAID compared to patients without CKD documentation.(8) 
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A UK cohort study reported coded CKD patients were more likely to achieve blood pres-
sure targets <140/85 mmHg (55% against 47%) or have their albumin-creatinine ratio 
(ACR) recorded (20% against 12%).(31) Perhaps GPs have a better overview of their 
documented CKD population and can provide care accordingly. Also, CKD documenta-
tion can help to automatically trigger medication safety notifications in the EMR.(32, 33)
The International Classification of Primary Care (ICPC) code U99.1 for impaired renal 
function is currently a dichotomous code that differentiates between an eGFR higher or 
lower than 60 ml/min/1.73m2. Consequently, it does not reflect the patient’s severity of 
renal function impairment and it does not incorporate albuminuria status. With regard 
to medication safety notifications and drug dose adjustments the eGFR threshold of 60 
ml/min/1.73m2 may be too high for most drug prescriptions, as dose adjustments based 
on renal function generally start at an eGFR of < 50 ml/min/1.73m2.(34)
We found an increase in CKD documentation following the multifaceted interven-
tion of GP education coupled with individual practice patient overviews described in 
chapter 6. It not only sparked an increase in CKD documentation in the EMR, but also 
increased GP commitment to guideline adherence. A literature overview by de Lusignan 
et al. showed that feedback is a useful tool to raise the quality of EMRs in primary care, 
especially when feedback is provided in an educational context within a peer group.
(35) The QICKD trial showed that general practices that received audit-based education 
providing feedback about their performance were more likely to achieve low systolic 
blood pressures in their patients with CKD compared to usual care practices.(36)
Guideline adherence
Our results in chapter 2 showed all aspects of CKD monitoring leave room for im-
provement, but guideline recommendations were better adhered to in the presence 
of diabetes. We assumed that part of the CKD care was carried out as a component 
of diabetes care. An Israeli study involving CKD patients with diabetes also showed 
good performance in areas that overlap with diabetes care, but not for specific kidney 
disease-focused activities.(37) Interestingly, in chapter 5, even when the GP deferred 
from consultation and referral advice and was expected to perform the monitoring in 
the primary care practice, the monitoring rates were suboptimal.
Perhaps, along the lines of the explanation in the previous paragraph, GPs struggle 
to identify their CKD patients and as a consequence under perform on guideline adher-
ence. Also, there could have been difficulties regarding the guideline content and its 
implementation. In congruence with the concerns described above GPs may experience 
conflict between the guideline recommendations and their own perspective on CKD 
management. Simmonds et al. reported clinician dissonance around guidelines for 
CKD monitoring due to different interpretations of CKD and different approaches to 
healthcare and moral decision-making.(17) In addition, implementation of the guideline 
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may be difficult as Vest et al. showed in semi-structured interviews. They reported bar-
riers such as lack of knowledge and understanding around CKD, difficulties engaging 
providers and patients in CKD management, limited time and competing demands and 
challenges obtaining and using data to monitor progress.(10)
The concerns voiced by GPs about the implications of a CKD diagnosis are relevant 
and deserve attention. It is important to provide high quality care and efficiently use 
healthcare resources for those patients in whom it will matter most. This requires the 
ability to effectively discern between patients at low and high risk of progression to ESRD 
and development of cardiovascular disease. Several research groups have developed and 
validated risk equations to determine who are at high risk for ESRD and cardiovascular 
events.(38-43) In addition, our results in chapter 7 showed that the introduction of the 
CKD-EPI equation to replace the MDRD equation for estimation of GFR results in a better 
correlation between CKD stage and cardiovascular risk profile. New literature underlines 
these results, as Choi et al. showed that the CKD-EPI-based eGFR demonstrated better 
predictive values for clinical outcomes than MDRD based eGFR in a cohort of patients 
with myocardial infarction.(44) The CKD-EPI equation is already actively used in several 
regions in the Netherlands. A consequence would be that more elderly and less young 
people will be diagnosed with CKD, even though studies show a stronger association 
of eGFR with mortality, ESRD and premature cardiovascular disease in younger age 
groups than in the elderly.(20, 22, 23) However, the accuracy of CKD-EPI could allow 
for reporting of eGFR values up to 90 ml/min/1.73m2 and help identify young individuals 
whose eGFR values are below a given percentile (e.g. 5th percentile or lower) compared 
to an age-matched population mean in order to identify impaired renal function at an 
earlier moment and help discriminate which young patients might benefit from further 
renal and cardiovascular risk assessment.(45) Feedback on laboratory results that are 
automatically compared to age and gender standardised population means could help 
inform the GP when a patients meets these pre-specified conditions.
Also, it is important to maintain a critical view on guideline recommendations. Mul-
tiple research groups have critically appraised CKD guidelines. Mendu et al. found that 
in the initial CKD workup by nephrologists frequently many tests are obtained, despite 
low rates of actual impact (<5%) on diagnosis and management.(46) The Canadian 
Society of Nephrology commented on the 2012 KDIGO guideline for CKD evaluation 
and management. In their comments they suggest a more conservative approach to 
monitoring renal function, screening for metabolic bone disease and setting blood 
pressure targets.(47) A systematic literature review by Smits et al. noted quality indica-
tors (QIs) that were considered content, face and operational valid in patients with 
CKD focused on monitoring eGFR, ACR, lipid levels and blood pressure, the use of 
NSAIDs, nitrofurantoin and biphosphonates. Additional QIs in patients with CKD and 
comorbidities focused on monitoring haemoglobin and treatment with angiotensin-
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converting-enzyme-inhibitors/angiotensin-receptor-II-blockers in patients with CKD and 
comorbidities.(48)
Other studies tried to enhance guideline implementation through clinical decision 
support systems (CDSS) that integrate with the practice information system. The ear-
lier mentioned automatic feedback on eGFR values and risk calculation for ESRD and 
cardiovascular events could be coupled to decision support suggestions. Drawz et al. 
provide a coherent overview of possibilities to use the EMR and CDSSs to support CKD 
care.(49) Studies by Mendu et al. and Litvin et al. showed that a CDSS that integrated 
CKD guideline advice into the EMR resulted in significantly improved adherence to CKD 
management guidelines.(50, 51) However, Abdel-Kader et al. found no difference in 
adherence to guideline referral recommendations, CKD documentation, albuminuria 
assessments, blood pressure targets or use of renoprotective medication.(52) Pefanis 
et al. performed a pilot study on electronic diagnosis and management assistance 
for CKD in Australian primary care. The software integrated with the EMR and led to 
improved CKD risk factor identification, albuminuria monitoring, CKD documentation, 
and achievement of blood pressure targets.(53) In a systematic review by Jia et al. CDSSs 
on drug prescription were effective in reducing medication errors.(54) This literature 
shows CDSSs are promising approach to guideline implementation. In the Netherlands 
NHGDoc is the best known primary care CDSS. It was developed in 2006 and is based 
on guidelines by the Dutch College of General Practitioners. The effect of NHGDoc on 
the quality of primary care will be examined in a cluster RCT.(55) In a process evaluation 
alongside the trial and in a focus group study users appreciated NHGDoc. The most 
frequently perceived barriers regarding NHGDoc were: insufficient knowledge about 
the system, irrelevant or too many alerts or suggestions, and difficulty integrating the 
systems into daily practice.(56, 57)
Telenephrology and the future of e-consultation
In the pilot study in chapter 3 telenephrology was feasible and in the trial´s evaluation in 
chapter 4 GPs acknowledged its feasibility and added that telenephrology contributed 
to their knowledge of kidney disease. The promising pilot result that telenephrology 
could potentially reduce referrals was not confirmed in the cluster RCT described in 
chapter 4 where we found no significant differences in referral rate or in other outcome 
measures.
E-consultation services similar to telenephrology already exist or are being developed 
for other specialties (e.g. teledermatology and telepulmonology).(58, 59) In a review of 
36 e-consultation studies, largely on dermatology, GPs were satisfied with the timely 
advice from specialists, confirmation of diagnoses and educational benefits. No clinical 
outcomes were reported. Patients had a generally positive experience with quick spe-
cialist response times (ranging from 4.6 hours to 3.9 days), avoided referrals (12–84%) 
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and satisfaction ranging from 78% to 93%. The impact on costs remained inconclusive.
(60) A recent pilot study on e-consultation between GPs and nephrologists in the USA 
also showed high feasibility, user satisfaction and potential to reduce referrals. In 55% 
of consultations the GP would have referred the patient had the e-consult not existed, 
but nephrologists deemed in-person referral necessary in 13% of consultations.(61)
The generic Canadian Champlain BASE eConsult service is very similar to our telene-
phrology in its approach to facilitate consultation. Just like our intervention, the Cham-
plain BASE eConsult service is an asynchronous, web-based system that allows GPs to 
submit a patient-specific question to a specialist. This system has led to several scientific 
publications, one of which suggests potential costs savings from a societal perspective.
(62) Another study reported GPs participating in the Champlain BASE study appreciated 
the service and perceived benefits for the quality of patient care through their own 
educational benefits, improved access to specialist knowledge, and an increased ability 
to reassure patients in their treatments and reduce the burden these treatments placed 
on their daily lives.(63) In a US study on e-consultations within the Veterans Affairs 
healthcare system, GPs reported high utility and usability. Specialists recognised the 
value of e-consults, but expressed concerns about additional workload.(64) The field 
of e-consultation is very much in development and in general the feasibility and user 
satisfaction of these platforms seems to be established. However, it remains difficult 
to substantiate positive pilot results and provide evidence on clinical end-points and 
cost-effectiveness.
For the successful development and implementation of e-consultation platforms 
there are conditions that need to be met. In a qualitative study on electronic referral 
and consultation systems in the US Tuot et al. reported that elements of successful 
e-consultation system implementation included executive and clinician leadership, 
established funding models for specialist clinician reimbursement, and a commitment 
to optimising clinician workflows.(65) A review by Eden et al. assessed facilitators and 
barriers in health information exchange and reported similar findings.(66) In a survey 
Cohen et al. showed that primary care providers expect health information exchange to 
benefit QoC. However, the biggest perceived barriers were lack of effective exchange 
capabilities, sending and receiving patient information electronically, lack of provider 
and staff time, and complex workflow changes required.(67)
The literature above highlights aspects that deserve attention in order to enhance the 
chance of successful implementation of e-consultation services. The following technical 
and legislative conditions should also be addressed: secure transfer and storage of data, 
appreciating the privacy aspect of data sharing (e.g. the data are only visible to the 
applicable doctor and patient), and determining who is accountable for the data.
In a wider perspective e-consultation can be applied to any situation in which the 
specialist can advice the GP without the need to meet with the patient face-to-face. 
Chapter 8
138
Thinking ahead ten years from now, we might see more patients receiving their required 
care in a general practice setting, in which GPs and practice nurses stay up-to-date in 
managing the patient´s conditions by sharing patient information through e-consulta-
tion services with the applicable specialists and providing patients with opportunities 
to be actively involved in this process and share their preferences. Sharing patient data 
among healthcare professionals will become increasingly mainstream and consultation 
methods that do not allow for direct sharing of data could become the less favourable 
option. A recent British interview study states that patients, GPs and specialists prefer 
a ‘GP with access to a specialist’ setting. Both GPs and specialists strongly supported 
sharing patients’ medical records via electronic consultation systems.(68) The role of 
the patient in sharing and controlling their own data is steadily being determined. In 
October 2016 the Dutch government passed a bill that guides how exchange of medical 
data between healthcare providers should be arranged.(69) The bill also arranges for 
patients to decide what data from their EMR they want to share and whom they want 
to share it with. In addition, patients have the right to view the content of their EMR 
as well as being able to see which healthcare providers viewed their EMR. In 2019 the 
healthcare infrastructure should be able to provide these options.
Recommendations for practice
Ckd documentation: When a CKD diagnosis is made based on decreased eGFR, every 
patient should be assigned the ICPC code U99.1 for impaired renal function for the sake 
of better monitoring and medication safety. The education and feedback intervention 
described in chapter 6 is an easy approach to improve CKD documentation. Possibly, 
CKD documentation could be assisted by automatic feedback on laboratory results. 
For example, the GP would receive a notification to add the U99.1 code in the EMR 
when the patient meets pre-specified laboratory results. Such feedback could also sup-
port case finding based on routine laboratory data. The ICPC group could consider to 
add more meaning to CKD documentation by adopting the KDIGO CKD classification. 
This aligns the ICPC code with the CKD classification and provides a way to factor in 
albuminuria status. Medication safety notifications could be enabled per individual drug 
by automatically comparing the drug´s specific eGFR threshold for dose adjustment with 
the patient’s current eGFR registered in the EMR.
Ckd awareness: CKD should be acknowledged as a chronic condition with signifi-
cant adverse effects on life expectancy and with heightened risks cardiovascular disease 
and ESRD. Studies reported that the significance of CKD is better understood by GPs 
when the concept is placed in the context of cardiovascular disease and diabetes.(70)
 In addition to the Dutch interdisciplinary CKD guideline that already exists, the current 
development of an independent CKD guideline for Dutch primary care is a welcome 
way to spread CKD knowledge amongst GPs. It can help to clearly define the theoretical 
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framework of CKD. Also, an update to the secondary care CKD guideline is being made, 
together with a revision of the interdisciplinary guideline to align CKD management 
between primary and secondary care providers.
Ckd risk assessment: GPs should be encouraged to determine albuminuria status 
in patients with an eGFR <60 ml/min/1.73m2 in order to estimate the risk of ESRD and 
cardiovascular disease. The EMR could be adjusted to facilitate automatic risk estimation 
in the individual patient.(53)
Ckd guideline content: The risk assessments mentioned above can be integrated 
in the CKD guideline in order to provide more tailored advice. Assessment of eGFR 
and albuminuria status are essential to monitoring CKD progression, but perhaps in 
patients with steady outcomes over the years the frequency of routine monitoring can 
be reduced. The current CKD group in which screening for metabolic complications is 
indicated might be too large given the low adherence rates and literature that suggests 
low impact rates. With regard to more efficient use of healthcare resources in patients in 
whom it will matter most it might be possible to construct a number needed to test to 
find an abnormal outcome for each metabolic parameter across the CKD classification. 
With such a construct we can discuss what number needed to test we find acceptable 
and adjust guideline recommendations accordingly.
Ckd management: The increased risk of cardiovascular events in patients with CKD 
should be reflected more explicitly in cardiovascular risk management. Perhaps in a way 
similar to diabetes as the increase in cardiovascular risk is comparable.(71) For example 
the European Society of Cardiology’s guideline on cardiovascular disease prevention 
considers the patient’s eGFR in its risk assessment. However, they do not include the 
patient’s albuminuria status despite it is regarded an independent risk factor for cardio-
vascular disease.(72)
Telenephrology: The e-consultation platform telenephrology deserves a place in ev-
eryday practice. Its practical advantages and the positive evaluation by GPs and practice 
nurses make telenephrology a valuable alternative to traditional consultation methods.
Recommendations for research
Ckd management and Cdss: A CDSS for CKD management in Dutch general prac-
tice may help GPs in their care for patients with CKD. Ideally, the system incorporates 
individual patient context factors that are available in the EMR in order to personalise 
recommendations as much as possible. This would result in sensible support suggestions 
that the GP can consider in light of his/her personal knowledge about the patient, and 
further individualise care together with the patient. Development of such a system may 
be worth exploring.
further evaluation of telenephrology: In the Dutch healthcare setting the wide-
spread availability of telenephrology nowadays makes it logistically difficult to perform 
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another randomised controlled trial. Data from the telehealth provider facilitating 
telenephrology show that in 2016 35 nephrology departments were connected to the 
platform compared to five during the trial period. In the same year there were 1300 par-
ticipating GPs. The number of e-consultations per year were 550 in 2012, 1230 in 2013, 
1650 in 2014, 2200 in 2015 and 2900 in 2016. Alternatively, an observational study 
could evaluate the content and number of telenephrology consultations within a cohort 
of general practices. Analysis of the variation between practices and departments in 
quantity and content of e-consultations further explores the potential of telenephrology, 
since it reveals ‘best practices’ and on the other hand highlights the advantages to be 
gained in those who hardly use the service. However, this design would be limited by 
contamination bias and confounding by indication. An additional user survey could 
explore a possible educational effect through telenephrology. This may be especially 
evaluated in practices with a crescendo decrescendo number of consultations.
expanding the e-consultation service: In our study the e-consultation was GP-
initiated and consequently concerned a patient in primary care. It is possible to adjust 
the platform for a specialist-initiated contact to refer a patient in secondary care back 
to primary care. This process potentially enables patients to receive their care in general 
practice with specialist monitoring in the background, whereas otherwise the patient 
would stay in secondary care for follow-up. We are preparing a pilot study to test the 
feasibility of such an adjusted e-consultation platform in which patients with CKD are 
referred back to primary care. Another important aspect of this pilot is the possibility for 
patients to be actively involved in the e-consultation. Patients can view the consultation 
content and can provide input.
Final conclusions
GPs need to be more aware of the clinical relevance of CKD as a risk factor for cardiovas-
cular disease and for ESRD and should be further encouraged to document CKD in the 
EMR. CKD also deserves a more prominent place in cardiovascular risk management.
GPs’ concerns regarding clinical consequences of CKD deserve attention. Efforts to 
improve risk estimation and critical evaluation of guideline content could help to better 
tailor recommendations for the individual patient . In addition, providing GPs with au-
tomatic feedback on laboratory results, CKD documentation and risk estimations could 
improve quality of care. CKD management support through a CDSS with individualised 
recommendations based on EMR data and risk estimations is worth exploring in the 
Dutch primary care setting.
Telenephrology, and e-consultation in general, should have a place in everyday prac-
tice, as it is a very accessible means of specialist consultation. The telenephrology service 
should be further developed to allow patient referral from secondary to primary care 
with specialist monitoring and active involvement of patients in their e-consultation.
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Naar schatting voldoet ongeveer twaalf procent van de bevolking aan de criteria voor 
chronische nierschade (CNS). De belangrijkste criteria zijn het bestaan van tenminste 3 
maanden van:
- verminderde nierfunctie uitgedrukt als geschatte glomerulaire filtratiesnelheid 
(eGFR)
- verhoogd eiwitverlies in de urine uitgedrukt als albuminecreatinine ratio (ACR)
De eGFR wordt doorgaans berekend door toepassing van de Modification of Diet in Renal 
Disease study (MDRD) formule. In 2009 werd de Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formule gepresenteerd als opvolger van de MDRD formule. 
Globaal heeft de helft van de patiënten een verminderde eGFR en de andere helft een 
verhoogd eiwitverlies in de urine. Patiënten met CNS hebben een verhoogd risico op 
hart- en vaatziekten en progressie naar eindstadium nierfalen. De meeste patiënten 
met CNS worden door de huisarts in de eerste lijn behandeld. Internationale studies 
hebben tekortkomingen geconstateerd in de kwaliteit van de eerstelijns zorg voor deze 
patiëntengroep, maar de kwaliteit van zorg in de Nederlandse situatie is onbekend. 
Voor de zorg is soms overleg met of verwijzing naar de nierspecialist nodig. De Landelijk 
Transmurale Afspraak (LTA) chronische nierschade geeft adviezen met betrekking tot 
overleg en verwijzing. Binnen de eerstelijnszorg heeft de huisarts de mogelijkheid om de 
nierspecialist te raadplegen voor aanvullend advies zonder de patiënt direct te moeten 
verwijzen. Dit overleg vindt vaak plaats via telefoon of e-mail, maar dat heeft meerdere 
beperkingen. Daarom ontwikkelden wij een e-consultatieplatform, telenefrologie, als 
alternatieve overlegmethode die potentiële voordelen biedt: tijdsefficiëntie, gebruik 
onafhankelijk van elkaar op een zelf gekozen moment, digitale verslaglegging van het 
overleg in het dossier van de patiënt en veilige dataoverdracht.
Samengevat richt dit proefschrift zich op:
• Beoordeling van kwaliteit van zorg voor patiënten met CNS in de Nederlandse huis-
artspraktijk.
• Beschrijving van het effect van het e-consultatieplatform telenefrologie op verwij-
zingspercentage, overlegpercentage en kwaliteit van zorg.
• Beschrijving van kwaliteit van zorg bij patiënten met CNS zonder mede-management 
door de nierspecialist ondanks het advies uit de LTA CNS dit wel te doen.
• Bestudering van het effect van nascholing voor huisartsen in combinatie met praktijk 
feedback in de vorm van overzichtslijsten van de eigen CNS populatie op de kwaliteit 
van zorg.
• Beschrijving van het cardiovasculaire risicoprofiel van patiënten die bij herclassificatie 
niet langer voldoen aan de definitie van CNS bij gebruik van de CKD-EPI formule in 
plaats van de MDRD formule.
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belanGrijksTe beVindinGen
Kwaliteit van CNS zorg in de Nederlandse huisartspraktijk
De Landelijk Transmurale Afspraak (LTA) chronische nierschade geeft aanbevelingen 
over hoe patiënten met CNS in de eerstelijnszorg kunnen worden gecontroleerd en 
behandeld. In het onderzoek in hoofdstuk 2 wordt de kwaliteit van zorg van patiënten 
met CNS beoordeeld in de algemene huisartspraktijk, uitgedrukt in mate waarin deze 
LTA wordt nageleefd. De bloeddrukstreefwaarden (<140/90 mmHg) werden bereikt bij 
43% van de patiënten en werden vaker bereikt bij patiënten met een voorgeschie-
denis van hart- en vaatziekten. CNS werd bij slechts 31% van de potentieel identifi-
ceerbare patiënten gedocumenteerd in het elektronisch patiëntdossier (EPD) en werd 
beter gedocumenteerd bij patiënten met een voorgeschiedenis van hoge bloeddruk 
of hart- en vaatziekten. Monitoring van ziekteprogressie was volledig bij 42% van de 
patiënten, waarbij hogere monitoring cijfers werden gezien bij patiënten met diabetes 
of hoge bloeddruk. Deze patiënten werden waarschijnlijk systematisch vervolgd als 
onderdeel van de diabeteszorg- of cardiovasculaire risico-monitoringprogramma’s. We 
concludeerden dat er veel ruimte was voor verbetering in alle aspecten van CNS zorg 
in de Nederlandse huisartspraktijk. Systematische documentatie van CNS in het EPD en 
monitoring van nierfunctie en eiwitverlies in de urine verdienen aandacht. De grootste 
klinische relevantie ligt in het vaker behalen van bloeddrukstreefwaarden.
Toepasbaarheid van telenefrologie
Naast de monitoring- en behandelingsaanbevelingen adviseert de LTA chronische nier-
schade welke zorgsetting het beste past bij het stadium van CNS: behandeling in de 
eerste lijn, behandeling in de eerste lijn met advies van een nierspecialist door middel 
van overleg, of verwijzing naar de nierspecialist. We ontwikkelden het e-consultatieplat-
form ‘Telenefrologie’ om de verschillende nadelen van conventionele overlegmethoden 
te ondervangen. We veronderstelden dat telenefrologie zou leiden tot meer overleg 
en een toename van het aantal patiënten dat in de eerste lijn wordt behandeld met 
behulp van advies van de nierspecialist. We verwachtten uiteindelijk een afname van 
het verwijspercentage, aangezien verwijzingen zouden worden beperkt tot alleen die 
patiënten waarbij een verwijzing naar de tweede lijn noodzakelijk is ondanks de moge-
lijkheid van consultatie. In de pilotstudie in hoofdstuk 3 hebben we 122 e-consultaties 
geëvalueerd afkomstig van 28 huisartspraktijken en vijf deelnemende ziekenhuizen en 
vonden een potentiele verwijsreductie van 60,5%. Telenefrologie was toepasbaar in 
de dagelijkse routine, aangezien de meeste huisartsen en nierspecialisten het platform 
tijdens kantooruren gebruikten, minder dan tien minuten besteedden aan een consult 
en nierspecialisten binnen twee dagen reageerden.
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Effect van telenefrologie op het aantal verwijzingen en consultaties, 
kwaliteit van zorg en kosten
Vervolgens hebben we telenefrologie getoetst in een cluster gerandomiseerde trial (RCT) 
zoals beschreven in hoofdstuk 4. Zevenenveertig huisartspraktijken werden geworven 
tijdens een nascholing over chronische nierschade. Alle ontvingen patiëntlijsten met 
daarop alle patiënten uit hun praktijk die voldeden aan de richtlijncriteria voor overleg 
met of verwijzing naar de nierspecialist: in totaal 3004 patiënten. De interventiegroep 
had toegang tot telenefrologie en de controlegroep kon conventionele overlegmetho-
den gebruiken. De resultaten gaven geen bevestiging van de potentiële verwijsreductie 
zoals vermoed op basis van de pilotstudie. We vonden een niet-significant verschil in 
verwijzingspercentage, 2,3% in de interventiegroep tegen 3,0% in de controlegroep. 
Dit percentage was veel lager dan verwacht (circa 20%). Het overlegpercentage in beide 
groepen verschilde niet, 6,3% in de interventiegroep tegen 5,0% in de controlegroep. 
Er waren geen significante verschillen in kwaliteit van zorg en in gemiddelde kosten 
per patiënt tussen de groepen. In de evaluatie onderschreven de huisartsen de toepas-
baarheid van telenefrologie en voegden eraan toe dat het gebruik ervan bijdroeg aan 
hun kennis over nierschade. Uiteindelijk kunnen we niet concluderen dat telenefrologie 
leidde tot een significant hoger overlegpercentage in vergelijking met conventionele 
overlegmethoden. Doordat er dermate weinig verwijzing en consultatie plaatsvond 
heeft de trial achteraf gezien een te klein aantal patiënten bestudeerd. Daarnaast is 
er mogelijk sprake geweest van zogenoemde contaminatie bias, waarbij ook de zorg 
in de controlegroep is veranderd. Dat komt mogelijk doordat ook de praktijken in de 
controlegroep de huisartsennascholing en praktijkfeedback in de vorm van patiëntlijs-
ten ontvingen. Het lager dan verwachtte verwijzingspercentage in combinatie met de 
mogelijke contaminatie bias leidt ertoe dat er geen harde conclusies uit de RCT kunnen 
worden getrokken.
Kwaliteit van zorg bij patiënten zonder mede-management door de 
nierspecialist ondanks het advies van de richtlijn
We definieerden het advies van de richtlijn ‘mede-management door de nierspeci-
alist’ als situaties waarin de aanbeveling was: (a) management in de eerste lijn met 
inbreng van een nierspecialist door overleg, of (b) verwijzing naar de nierspecialist in de 
tweede lijn. hoofdstuk 5 laat zien dat huisartsen dit overlegadvies of verwijsadvies in 
respectievelijk 94% en 70% van de patiënten met chronische nierschade stadium 3-5 
niet volgden. De overgrote meerderheid van de patiënten met chronische nierschade 
stadium 3-5 werd daarom door de eigen huisarts behandeld en niet in medebehan-
deling met de nierspecialist, zoals aanbevolen door de richtlijn. Het niet volgen van 
overleg of verwijsadvies kwam vaker voor bij: (a) gebrek aan nierfunctiemonitoring, (b) 
ontbrekende CNS-documentatie in het EPD en (c) patiënten zonder voorgeschiedenis 
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van hart- en vaatziekten. De kwaliteit van zorg voor deze patiëntengroep toonde CNS-
documentatie bij 50%, monitoring van ziekteprogressie bij 36% en het bereiken van 
bloeddrukstreefwaarden (<140/90 mmHg) bij 51% van de patiënten. Patiënten met een 
voorgeschiedenis van diabetes of hoge bloeddruk hadden meer kans op meting van 
hun nierfunctie en bloeddruk.
Effect van nascholing voor huisartsen en het verstrekken van 
overzichtslijsten van de eigen CNS populatie op kwaliteit van zorg
Onze aanname van contaminatie bias in de telenefrologie trial in hoofdstuk 4 leidde 
tot verdere verkenning van de meervoudige interventie bestaande uit nascholing voor 
huisartsen over chronische nierschade in combinatie met het verstrekken van over-
zichtslijsten van de eigen CNS populatie. In hoofdstuk 6 selecteerden we hiervoor de 
controlegroep van de trial, die bestond uit 24 huisartspraktijken. Deze controlegroep 
uit de RCT werd in dit hoofdstuk beschouwd als ‘interventiegroep’, in de zin dat zij 
nascholing en feedback hadden gekregen. We refereren aan deze groep als de Educatie 
en Feedback (E&F) groep. Deze E&F groep werd vergeleken met 109 controlepraktijken 
geselecteerd uit een bestaande data set van huisartspraktijken die geen nascholing of 
feedback hadden ontvangen. We vonden een significante toename van CNS documen-
tatie in het EPD binnen de E&F groep: een absolute toename van 17,7% in de E&F groep 
tegen 1,5% in de controlegroep. Ook was de volledige monitoring van ziekteprogressie 
en metabole parameters significant hoger in de E&F groep. Tijdens de relatief korte 
follow-up periode van 14 maanden droeg onze meervoudige interventie niet bij aan het 
frequenter bereiken van bloeddrukstreefwaarden (<140/90 mmHg). We concluderen 
dat deze relatief simpele meervoudige interventie van het nascholen van huisartsen op 
het gebied van chronische nierschade in combinatie met praktijkfeedback in de vorm 
van overzichtslijsten van de eigen CNS populatie een positieve invloed had op herken-
ning en monitoring van CNS.
Cardiovasculaire risicoprofiel van patiënten die bij gebruik van de CKD-EPI 
formule niet langer voldoen aan de definitie van CNS
Het schatten van de nierfunctie in de dagelijkse praktijk is gebaseerd op wiskundige 
rekenmodellen (formules) waarin leeftijd, geslacht en hoogte van het serum creatinine 
zijn opgenomen. Tot recent werd hierbij de Modification of Diet and Renal Disease 
(MDRD) formule toegepast. Pogingen om de nauwkeurigheid van nierfunctieschat-
tingen te verhogen hebben geleid tot de ontwikkeling van de chronic kidney disease 
epidemiological collaboration (CKD-EPI) formule. De literatuur toont aan dat de CKD-EPI 
formule een nauwkeuriger schatting van de glomerulaire filtratiesnelheid geeft, evenals 
een nauwkeuriger cardiovasculaire risicostratificatie. We hebben dat getoetst in een 
eerstelijnspopulatie. De bevindingen in hoofdstuk 7 laten zien dat de CKD-EPI formule 
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in ons cohort van 60673 volwassen patiënten met een creatinine-meting uit 47 huisarts-
praktijken nauwkeuriger het cardiovasculaire risico stratificeert dan de MDRD formule. 
Patiënten die niet langer voldeden aan de definitie van CNS bij gebruik van de CKD-EPI 
formule in plaats van de MDRD formule hadden een gunstiger cardiovasculair profiel 
wat betreft leeftijd (60,3 tegen 74,0 jaar) en comorbiditeit in vergelijking met patiënten 
die wel bleven voldoend aan de definitie van CNS. Van de groep die niet langer voldeed 
aan de CNS criteria had 32% geen comorbiditeit die alsnog een jaarlijkse inschatting 
van het cardiovasculaire risico vereist en die met het vervallen van de diagnose CNS 
dus niet langer specifiek hiervoor gevolgd zouden worden. Van deze groep had 12% 
van de patiënten echter een 10- jaars EuroSCORE cardiovasculair risico > 20% waarbij 
follow-up wel degelijk relevant is.
aanbeVelinGen Voor de PrakTijk
CNS-documentatie: Telkens wanneer de diagnose chronische nierschade wordt gesteld 
op basis van verminderde eGFR, dient in het dossier van de patiënt de International 
Classification of Primary Care (ICPC) code U99.1 voor verminderde nierfunctie te 
worden toegekend met als doel een betere monitoring en medicatieveiligheid. De in 
hoofdstuk 6 beschreven educatie en feedback-interventie is een eenvoudige aanpak 
om CNS-documentatie te verbeteren. Eventueel kan CNS-documentatie worden gehol-
pen door middel van automatische feedback op laboratoriumresultaten. De huisarts zou 
bijvoorbeeld een melding kunnen ontvangen om de ICPC code U99.1 voor verminderde 
nierfunctie toe te voegen aan het EPD wanneer de patiënt voldoet aan vooraf vastge-
stelde laboratoriumresultaten. Dergelijke feedback kan ook case-finding ondersteunen 
op basis van routinematige bepaalde laboratoriumgegevens. De ICPC werkgroep zou 
kunnen overwegen om meer verdieping aan CNS-documentatie te geven door de Kidney 
Disease: Improving Global Outcomes (KDIGO) classificatie van chronische nierschade in 
te passen. Dit zou de ICPC-code gelijktrekken met de CNS-classificatie en biedt een 
manier om eiwitverlies in de urine als factor mee te wegen. Medicatieveiligheidsmel-
dingen kunnen per afzonderlijk medicament worden ingeschakeld door automatisch de 
specifieke eGFR-drempel voor dosisaanpassing van het geneesmiddel te vergelijken met 
de huidige eGFR van de patiënt die staat geregistreerd in het EPD.
CNS bewustzijn: CNS zou beter erkend moeten worden als een chronische aandoening 
met significante nadelige effecten op de levensverwachting en met verhoogde risico’s 
op hart- en vaatziekten en eindstadium nierfalen. Uit studies blijkt dat de betekenis van 
CNS beter door de huisartsen wordt begrepen wanneer het concept in het kader van 
hart- en vaatziekten en diabetes wordt geplaatst. Naast de LTA chronische nierschade 
uit 2009, is de huidige ontwikkeling van de Standaard chronische nierschade van het 
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Nederlands Huisartsen Genootschap (NHG) een welkome manier om CNS kennis onder 
huisarts te verspreiden. Het kan helpen om het theoretische kader van CNS duidelijker 
te definiëren. Ook wordt de CNS richtlijn van de nierspecialisten herzien, samen met 
een transitie van de LTA naar een multidisciplinaire richtlijn om CNS management te 
stroomlijnen tussen de eerste en tweede lijn.
CNS risico inschatting: huisartsen moeten worden aangemoedigd om het eiwitverlies 
in de urine te bepalen bij patiënten met een eGFR <60 ml/min/1,73m2 om het risico 
op eindstadium nierfalen en hart- en vaatziekten te schatten. Het EPD kan worden 
aangepast om automatische risicoschattingen voor de individuele patiënt te faciliteren.
CNS richtlijninhoud: De hierboven genoemde risico inschattingen kunnen in de NHG 
standaard worden geïntegreerd om meer advies op maat te geven. Evaluatie van de 
eGFR en de mate van eiwitverlies in de urine is essentieel voor het monitoren van 
ziekteprogressie, maar misschien kan bij patiënten met stabiele uitslagen de frequentie 
van routinematige monitoring worden verminderd. De groep patiënten met chronische 
nierschade waarbij momenteel screening naar metabole complicaties is geïndiceerd kan 
wellicht te groot zijn, aangezien de literatuur suggereert dat er vaak geen consequenties 
zijn en de screeningsadviezen in de praktijk zeer weinig naleving vinden. Met betrekking 
tot efficiënter gebruik van middelen in de gezondheidszorg gericht op patiënten die 
er het meest bij gebaat zijn, is het wellicht mogelijk om een number-needed-to-test 
om een  abnormale uitkomst te vinden op te stellen voor elke metabole parameter 
verdeeld over de CNS-classificatie. Met een dergelijke constructie kunnen we bespreken 
welk number-needed-to-test we acceptabel vinden en richtlijnaanbevelingen daar op 
aanpassen.
CNS management: Het verhoogde risico op cardiovasculaire aandoeningen bij 
patiënten met CNS moet explicieter worden weergegeven binnen het cardiovasulair 
risicomanagement. Misschien op een manier die vergelijkbaar is met diabetes, aange-
zien de toename van het cardiovasculaire risico vergelijkbaar is. De richtlijn preventie 
van hart- en vaatziekten van de European Society of Cardiology weegt bijvoorbeeld de 
eGFR mee in haar risico schatting. Daarentegen wordt het eiwitverlies in de urine niet 
meegewogen, hoewel het als een onafhankelijke risicofactor voor hart- en vaatziekten 
wordt beschouwd.
Telenefrologie: Het e-consultatieplatform Telenefrologie verdient een plek in de 
dagelijkse praktijk. De praktische voordelen en de positieve evaluatie door huisartsen 
en praktijkondersteuners maken telenefrologie een waardevol alternatief voor conven-
tionele overlegmethoden.
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aanbeVelinGen Voor onderzoek
CNS management en Clinical Decision Support Systems (CDSS): Een CDSS voor manage-
ment van chronische nierschade in de Nederlandse huisartspraktijk kan de huisartsen 
helpen in hun zorg voor patiënten met CNS. Idealiter bevat het systeem individuele 
patiëntcontextfactoren die beschikbaar zijn in het EPD om de aanbevelingen zo veel 
mogelijk te personaliseren. Dit zou resulteren in zinvolle ondersteuningsvoorstellen 
die de huisarts in het licht van zijn of haar persoonlijke kennis over de patiënt kan 
overwegen en de zorg verder met de patiënt kan individualiseren. Het verkennen van 
ontwikkelingsmogelijken voor een dergelijk systeem kan de moeite waard zijn.
Verdere evaluatie van telenefrologie: In de Nederlandse gezondheidszorg maakt de 
wijdverspreide beschikbaarheid van telenefrologie het logistiek moeilijk om een  nieuwe 
gerandomiseerde trial uit te voeren. Gegevens van de telenefrologie provider laten zien 
dat in 2016 35 nierziekten-afdelingen verbonden waren met het platform in vergelijking 
met vijf tijdens de trialperiode. In hetzelfde jaar waren er 1300 deelnemende huisartsen. 
Het aantal e-consultaties per jaar was 550 in 2012, 1230 in 2013, 1650 in 2014, 2200 
in 2015 en 2900 in 2016. Als alternatief voor een nieuwe RCT kan observationeel 
onderzoek plaatsvinden naar de inhoud en het aantal telenefrologie consulten binnen 
een cohort van huisartspraktijken. Analyse van de variatie tussen praktijken en afdelin-
gen in kwantiteit en inhoud van e-consultaties kan het potentieel van telenefrologie 
verder blootleggen, aangezien het ‘best practices’ aan het licht brengt en anderzijds de 
mogelijke voordelen voor praktijken die het platform nauwelijks gebruiken benadrukt. 
Een aanvullend gebruikersonderzoek kan een mogelijk educatief effect uitgaand van 
Telenefrologie onderzoeken. Dit kan vooral geëvalueerd worden in praktijken met een 
oplopend-aflopend aantal consultaties.
Uitbreiding van het e-consultatieplatform: In onze studie is het de huisarts die de 
e-consultatie initieert en betreft daarmee een  patiënt in de eerste lijn. Het is mogelijk 
om het platform aan te passen voor specialistisch geïnitieerd contact om een  patiënt 
in de tweede lijn terug te verwijzen naar de eerste lijn. In potentie ontvangen pati-
enten daarmee hun zorg in de huisartspraktijk met monitoring door de specialist op 
de achtergrond, terwijl ze anders binnen de tweede lijn blijven voor follow-up. Onze 
onderzoeksgroep bereidt een pilotstudie voor om de haalbaarheid van een dergelijk 
aangepast e-consultatieplatform te testen, waarbij patiënten met CNS ondersteund 
door het platform worden terugverwezen naar de huisarts. Een ander belangrijk aspect 
van deze pilot is de mogelijkheid patiënten actief te betrekken bij de e-consultatie. 
Patiënten zullen bijvoorbeeld de inhoud van de consultatie kunnen bekijken en zelf 
input leveren.
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eindConClusies
Huisartsen moeten zich meer bewust worden van de klinische relevantie van chronische 
nierschade als risicofactor voor hart- en vaatziekten en voor eindstadium nierfalen. Deze 
bewustwording zal huisartsen stimuleren om CNS beter te documenteren in het EPD. 
CNS verdient een prominente plek binnen het cardiovasculaire risicomanagement.
De inhoudelijke zorgen van huisartsen over de klinische consequenties van CNS verdie-
nen aandacht. Pogingen om risicoschattingen te verbeteren en kritische herziening van 
de richtlijn uit 2009, kunnen bijdragen aan aanbevelingen die meer op maat zijn voor de 
individuele patiënt. Daarnaast kan automatische feedback op laboratoriumresultaten, 
op CNS documentatie en op risico schattingen de kwaliteit van zorg verbeteren. Onder-
steuning van CNS management via een CDSS met geïndividualiseerde aanbevelingen 
op basis van EPD data en risico schattingen is de moeite waard om te verkennen in de 
Nederlandse eerstelijns setting.
Telenefrologie en e-consultatie in het algemeen zouden een grotere plaats moeten 
hebben in de dagelijkse praktijk. De techniek biedt een toegankelijke manier voor de 
huisarts om de expertise van de specialist te benutten en past bij de visie om laagdrem-
pelige zorg dichtbij de patiënt te bieden.
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Het laatste hoofdstuk alweer van mijn proefschrift, wellicht het best gelezen en ze-
ker een belangrijk hoofdstuk. Belangrijk voor mij om iedereen die direct en indirect 
heeft bijgedragen aan dit proefschrift te kunnen bedanken. Ten eerste alle nefrologen, 
huisartsen, praktijkondersteuners en assistenten van alle deelnemende praktijken en 
ziekenhuizen. Dankzij jullie inzet heeft het project kunnen groeien tot iets moois. Graag 
wil ik een aantal mensen in het bijzonder noemen.
In 2011 had ik het geluk om als student geneeskunde bij mijn wetenschappelijke 
stage bij de afdeling Eerstelijnsgeneeskunde kennis te maken met Wim en Nynke. Nynke 
destijds als promovendus en Wim als begeleider op het Telenefrologieproject. Toen het 
project zo groot werd dat er een volgende promovendus werd gezocht heb ik niet 
getwijfeld en mij meteen aangemeld. Wim en Nynke, ik ben jullie ontzettend dankbaar 
voor het geschonken vertrouwen en ik ben heel trots op wat we samen hebben bereikt!
Beste Wim, wat ben je een schitterend voorbeeld voor mij. Je bent open, bevlogen, 
vol van ideeën en staat altijd klaar om te helpen of mee te denken. Ik stel onze samen-
werking bijzonder op prijs en heb er veel plezier aan beleefd.
Beste Nynke, ook jij bent natuurlijk onmisbaar voor mij geweest. Ik heb ontzettend 
veel respect voor de manier waarop je als een duizendpoot al je taken combineert. Je 
bent zelfs met al deze taken altijd snel bereikbaar voor vragen en met jouw prettige 
analytische blik vanuit eerstelijnsperspectief is de betekenis van onze bevindingen voor 
de huisarts steeds goed in beeld gebleven.
Beste Jack, ik ken niemand die meer parate kennis bezit dan jij. Je bent voor mij dan 
ook van onschatbare waarde geweest tijdens mijn promotietraject. De snelheid en het 
ogenschijnlijk gemak waarmee je treffende feedback gaf op mijn artikelen, met vaak 
een Aha-Erlebnis mijnerzijds, heeft het proefschrift zeker naar een hoger plan getild. 
Heel veel dank daarvoor.
Beste Pim, ook jou wil ik natuurlijk graag bedanken voor al je steun. Ik ben onder de 
indruk van de manier waarop je de methodologische voordelen en nadelen overziet en 
dankzij jouw sterke inbreng op dat gebied is het onderzoek zeker robuuster geworden. 
Veel dank!
Beste Chris, het was erg prettig om onder jouw hoede mijn eerste stappen in de 
onderzoekswereld te zetten. Veel dank voor je betrokkenheid en je blijvende interesse 
in het verdere verloop van mijn promotietraject.
Beste leden van de manuscriptcommissie, prof. dr. Cees Tack, prof. dr. Ron Ganse-
voort en dr. Tijn Kool, bedankt voor de tijd en moeite die jullie hebben genomen om het 
proefschrift te beoordelen.
Beste Lea, dankzij jouw inzet en kwaliteiten liep het contact met de ziekenhuizen en 
praktijken op rolletjes. Bedankt voor al je ondersteuning.
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Beste Reinier, waar zouden mijn analyses toe hebben geleid zonder jouw hulp? Waar-
schijnlijk tot enkele curieuze uitkomsten. Bedankt voor al je begrijpelijke uitleg over 
statistiek en je behendigheid op het gebied van de wondere warboel van opties in SPSS.
Beste Marion, je was een als een soort extra lid van de promotiecommissie betrokken 
bij veel artikelen. Bedankt voor alles wat je hebt bijgedragen.
Dear Dan and Chris, it has been a privilege and pleasure to work with you.
Beste Jozé, Eddy, Gerald, Bianca en Nicole, heel erg bedankt voor jullie bijdrage aan 
de artikelen.
Beste Frank en Carola, wat ben ik ontzettend blij dat jullie mij willen bijstaan tijdens de 
promotie. Heel erg bedankt! Carola, ik had geen betere kamergenoot kunnen treffen 
dan jij. Ik heb echt fijn met je kunnen sparren over ons onderzoek en over allerlei zaken 
daarbuiten. Ik vond het een feest om met je te mogen samenwerken!
Beste Saskia, jouw scherpte en organisatie zijn de kwaliteit van de onderzoeksgege-
vens enorm ten goede gekomen. Dank je wel!
Beste José en Hans, veel dank voor al jullie werk omtrent de dataextracties.
Beste Juul, Simone, Tim, Peter, Lea, Elza, Annette, Kees en alle andere collega’s, 
bedankt voor alle gezelligheid, wijsheid en goede koffie! Met jullie als collega’s heb ik 
steeds met veel plezier op de afdeling gewerkt.
Beste Inge, ontzettend bedankt voor al je inzet en je uitstekende bijdrage aan het 
onderzoek. Ik waardeer het enorm dat je zelfs lang na je stage vanuit Tanzania no hebt 
meegedacht en meegeschreven.
Beste Wouter, Charissa, Wilco, Esther, Jeroen, Gerard, Nayomi, Thomas en Samantha 
bedankt voor al vele jaren vriendschap! Ook al is het vanwege de afstand vaak even 
plannen om af te spreken, het is altijd weer super gezellig om met jullie te zijn.
Beste Leonieke, Maurice, Frank, Karin en alle andere vrienden, dank jullie wel voor de 
gezelligheid hier in Nijmegen en op de skivakantie!
Lieve pa en ma, ontzettend bedankt voor al jullie steun, liefde en vertrouwen! Door 
jullie hulp heb ik me kunnen ontwikkelen tot waar ik nu ben. Bedankt dat jullie altijd 
klaar staan!
Nadine en Nicole, lieve zusjes, bedankt dat jullie zo hebben meegeleefd met de 
vorderingen in mijn traject. Met jullie kan ik lekker flauwekullen en is een halve droge 
opmerking of blik al genoeg. Thanks!
Lieve Chris en Carolien, Marleen en Joost, bedankt voor jullie steun en interesse tijdens 
mijn onderzoeksperiode, maar vooral voor alle gezelligheid en warmte die er altijd is.
Lieve Els en Emma, ik hou van jullie! En Emma ook jij nu al bedankt voor al je wijsheid. 
Met jullie wil ik nog heel veel moois meemaken.
161
Curriculum Vitae
CurriCuluM ViTae
Vincent van Gelder werd geboren op 7 januari 1987 in Rhenen en groeide op in Veen-
endaal. Hij behaalde in 2005 zijn tweetalig VWO diploma aan het Marnix College in 
Ede. Dat jaar begon hij aan de studie geneeskunde aan de Radboud Universiteit in 
Nijmegen. Tijdens de co-schappen werd zijn interesse voor de huisartsgeneeskunde 
gewekt. Na het afronden van zijn studie in 2012 begon Vincent als arts in opleiding 
tot huisarts-onderzoeker aan de huisartsopleiding in Nijmegen. Hij hoopt in 2018 zijn 
huisartsopleiding af te ronden.
Vincent is getrouwd met Els en samen hebben ze een dochtertje Emma.
